INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190501, 'Edrophonium', 'Quinidine', 'Moderate', 'Anticholinergic agents and other agents with significant anticholinergic activity (e.g., clozapine, class IA antiarrhythmics especially disopyramide) may antagonize the effects of cholinergic skeletal muscle stimulants (e.g., ambenonium, edrophonium, guanidine, neostigmine, pyridostigmine). Although this interaction may be desirable in some situations, such as when atropine is used to treat excessive muscarinic side effects and cholinergic crisis induced by anticholinesterase overdose, unintentional or indiscriminate use of anticholinergic agents in the treatment of myasthenia gravis may exacerbate symptoms.', NULL, 'Agents with potent anticholinergic activity should preferably be avoided in patients receiving cholinergic skeletal muscle stimulants.', NULL, 'Agents with potent anticholinergic activity should preferably be avoided in patients receiving cholinergic skeletal muscle stimulants. If concurrent use is necessary, patients treated for myasthenia gravis should be monitored for potential exacerbation of symptoms.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190729/', '[1] "Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190502, 'Epinephrine (topical)', 'Carteolol', 'Moderate', 'Coadministration of non-cardioselective beta-blockers, such as propranolol, with topical solutions containing epinephrine may enhance the hypertensive effect of epinephrine, which may increase the risk of cardiac arrest and hypertensive stroke. The mechanism of this interaction involves beta-blocker antagonism of epinephrine''s beta-agonist effects which results in unopposed alpha-stimulated vasoconstriction and reflexive decreases in heart rate.', NULL, 'Caution and close monitoring of cardiovascular status (i.', NULL, 'Caution and close monitoring of cardiovascular status (i.e., blood pressure, heart rate) are recommended when topical solutions containing epinephrine are administered to patients treated with non-cardioselective beta-blockers. Some authorities recommend avoiding treatment with topical solutions containing epinephrine (AU; Laceraine Topical Wound Anaesthetic(R)) in patients receiving a non-cardioselective beta-blocker.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190730/', '[1] Houben H, Thien TH, De Boo TH, et al "Influence of selective and non-selective beta-adrenoceptor blockade on the haemodynamic effect of adrenaline during combined antihypertensive drug therapy." Clin Sci 57 (1979): s397-9[2] Gandy W "Severe epinephrine-propanolol interaction." Ann Emerg Med 18 (1989): 98-9[3] Houben H, Thien T, De Boo T, Lemmens W, Van Herwaarden CL, Fennis JF, Van ''t Laar A "Influence of selective and non-selective beta-adrenoreceptor blockade on the haemodynamic effect of adrenaline during combined antihypertensive drug therapy." Clin Sci 57 (1979): s397-9[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Foster CA, Aston SJ "Propranolol-epinephrine interaction: a potential disaster." Plast Reconstr Surg 72 (1983): 74-8[6] van Herwaarden CL, Binkhorst RA, Fennis JF, van ''t Laar A "Effects of adrenaline during treatment with propranolol and metoprolol." Br Med J 2 (1977): 1029[7] Ichinohe T, Igarashi O, Kaneko Y "The influence of propranolol on the cardiovascular effects and plasma clearance of epinephrine." Anesth Prog 38 (1991): 217-20', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190503, 'Epinephrine (topical)', 'Ergometrine', 'Major', 'Additive or synergistic increases in blood pressure and/or ischemic response may occur when ergot alkaloids are combined with peripheral or central vasoconstrictors. Ergot alkaloids produce arterial vasoconstriction by stimulating alpha-adrenergic and serotonin receptors and inhibiting endothelial-derived relaxation factor release.', NULL, 'Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.', NULL, 'Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents. If concomitant use is required, patients should be monitored for excessive vasoconstriction and have vital signs measured regularly. Patients should also be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190731/', '[1] "Product Information. ProAmatine (midodrine)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[2] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[3] Barthel W, Glusa E, Koth W "Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ." Int J Clin Pharmacol Ther Toxicol 25 (1987): 63-9[4] Buchanan N, Cane RD, Miller M "Symmetrical gangrene of the extremities associated with the use of dopamine subsequent to ergometrine administration." Intensive Care Med 3 (1977): 55-6[5] "Product Information. Bellergal-S (ergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[6] Chuang SS "Finger ischemia secondary to the synergistic agonist effect of norepinephrine and ergonovine and in a burn patient." Burns 29 (2003): 92-4[7] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[8] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[9] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[10] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[11] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[12] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[13] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[14] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[15] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[16] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[17] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[18] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[19] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[20] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[21] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[22] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[23] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[24] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[25] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[26] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[27] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[28] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[29] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[30] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[31] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[32] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[33] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[34] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[35] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[36] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[37] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[38] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190504, 'Isoetharine', 'Epinephrine (topical)', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190732/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190505, 'Epinephrine (topical)', 'Ketamine', 'Moderate', 'Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index. Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.', NULL, 'Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.', NULL, 'Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190733/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Ketalar (ketamine)." JHP Pharmaceuticals, Saddle River, NJ.[4] Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Neuvonen PJ, Olkkola KT "S-ketamine concentrations are greatly increased by grapefruit juice." Eur J Clin Pharmacol 68 (2012): 979-86[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] "Product Information. Ketalar (ketamine)." JHP Pharmaceuticals, Saddle River, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190506, 'Epinephrine (topical)', 'Methysergide', 'Major', 'Additive or synergistic increases in blood pressure and/or ischemic response may occur when ergot alkaloids are combined with peripheral or central vasoconstrictors. Ergot alkaloids produce arterial vasoconstriction by stimulating alpha-adrenergic and serotonin receptors and inhibiting endothelial-derived relaxation factor release.', NULL, 'Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.', NULL, 'Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents. If concomitant use is required, patients should be monitored for excessive vasoconstriction and have vital signs measured regularly. Patients should also be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190734/', '[1] "Product Information. ProAmatine (midodrine)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[2] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[3] Barthel W, Glusa E, Koth W "Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ." Int J Clin Pharmacol Ther Toxicol 25 (1987): 63-9[4] Buchanan N, Cane RD, Miller M "Symmetrical gangrene of the extremities associated with the use of dopamine subsequent to ergometrine administration." Intensive Care Med 3 (1977): 55-6[5] "Product Information. Bellergal-S (ergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[6] Chuang SS "Finger ischemia secondary to the synergistic agonist effect of norepinephrine and ergonovine and in a burn patient." Burns 29 (2003): 92-4[7] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[8] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[9] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[10] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[11] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[12] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[13] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[14] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[15] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[16] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[17] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[18] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[19] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[20] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[21] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[22] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[23] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[24] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[25] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[26] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[27] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[28] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[29] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[30] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[31] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[32] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[33] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[34] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[35] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[36] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[37] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[38] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190507, 'Epinephrine (topical)', 'Penbutolol', 'Moderate', 'Coadministration of non-cardioselective beta-blockers, such as propranolol, with topical solutions containing epinephrine may enhance the hypertensive effect of epinephrine, which may increase the risk of cardiac arrest and hypertensive stroke. The mechanism of this interaction involves beta-blocker antagonism of epinephrine''s beta-agonist effects which results in unopposed alpha-stimulated vasoconstriction and reflexive decreases in heart rate.', NULL, 'Caution and close monitoring of cardiovascular status (i.', NULL, 'Caution and close monitoring of cardiovascular status (i.e., blood pressure, heart rate) are recommended when topical solutions containing epinephrine are administered to patients treated with non-cardioselective beta-blockers. Some authorities recommend avoiding treatment with topical solutions containing epinephrine (AU; Laceraine Topical Wound Anaesthetic(R)) in patients receiving a non-cardioselective beta-blocker.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190735/', '[1] Houben H, Thien TH, De Boo TH, et al "Influence of selective and non-selective beta-adrenoceptor blockade on the haemodynamic effect of adrenaline during combined antihypertensive drug therapy." Clin Sci 57 (1979): s397-9[2] Gandy W "Severe epinephrine-propanolol interaction." Ann Emerg Med 18 (1989): 98-9[3] Houben H, Thien T, De Boo T, Lemmens W, Van Herwaarden CL, Fennis JF, Van ''t Laar A "Influence of selective and non-selective beta-adrenoreceptor blockade on the haemodynamic effect of adrenaline during combined antihypertensive drug therapy." Clin Sci 57 (1979): s397-9[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Foster CA, Aston SJ "Propranolol-epinephrine interaction: a potential disaster." Plast Reconstr Surg 72 (1983): 74-8[6] van Herwaarden CL, Binkhorst RA, Fennis JF, van ''t Laar A "Effects of adrenaline during treatment with propranolol and metoprolol." Br Med J 2 (1977): 1029[7] Ichinohe T, Igarashi O, Kaneko Y "The influence of propranolol on the cardiovascular effects and plasma clearance of epinephrine." Anesth Prog 38 (1991): 217-20', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190508, 'Epinephrine (topical)', 'Racepinephrine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190736/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190509, 'Epinephrine (topical)', 'Ritodrine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190737/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190510, 'Epinephrine (topical)', 'Sibutramine', 'Moderate', 'Additive or synergistic effects on blood pressure and heart rate may occur when sibutramine is combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors. Sibutramine is a potent inhibitor of norepinephrine and serotonin reuptake, and a less potent inhibitor of dopamine reuptake.', NULL, 'Caution is advised if sibutramine is coadministered with other drugs that can increase blood pressure and/or heart rate.', NULL, 'Caution is advised if sibutramine is coadministered with other drugs that can increase blood pressure and/or heart rate. Blood pressure and pulse should be measured prior to initiating therapy with sibutramine and monitored at regular intervals thereafter. Dose reduction or discontinuation of sibutramine should be considered in patients who experience a sustained increase in blood pressure or pulse rate.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190738/', '[1] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[2] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[3] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[4] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190511, 'Epinephrine (topical)', 'Terbutaline', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190739/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190512, 'Sulfisoxazole', 'Acetohexamide', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190740/', '[1] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[2] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[3] Field JB, Ohta M, Boyle C, Remer A "Potentiation of acetohexamide hypoglycemia by phenylbutazone." N Engl J Med 277 (1967): 889-94[4] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[5] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[6] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J "Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole." Diabet Med 4 (1987): 245-7[7] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[8] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT "Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride." Clin Pharmacol Ther 69 (2001): 194-200[9] Ravic M, Johnston A, Turner P "Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs." Postgrad Med J 66 (1990): s30-4[10] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[11] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[12] Tran PO, Gleason CE, Robertson RP "Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function." Diabetes 51 (2002): 1772-8[13] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[14] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[15] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[16] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[17] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[18] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[19] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[20] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[21] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA "Effect of pirprofen on glibenclamide kinetics and response." Br J Clin Pharmacol 14 (1982): 123-6[22] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[23] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[24] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[25] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[26] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[28] Sawka AM, Burgart V, Zimmerman D "Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors." Diabetes Care 24 (2001): 1845-6[29] Wing LM, Miners JO "Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition." Br J Clin Pharmacol 20 (1985): 482-5[30] Tremaine LM, Wilner KD, Preskorn SH "A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide." Clin Pharmacokinet 32(Suppl 1) (1997): 31-36[31] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Tannenbaum H, Anderson LG, Soeldner JS "Phenylbutazone-tolbutamide drug interaction." N Engl J Med 290 (1974): 344[33] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[34] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[35] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB "Aspirin-induced hypoglycaemia in a patient on haemodialysis." Lancet 2 (1971): 1092-3[36] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[37] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[38] Kradjan WA, Witt DM, Opheim KE, Wood FC "Lack of interaction between glipizide and co-trimoxazole." J Clin Pharmacol 34 (1994): 997-1002[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[41] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[42] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[43] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[44] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[45] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[46] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[47] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[48] Lozada A, Dujovne CA "Drug interactions with fibric acids." Pharmacol Ther 63 (1994): 163-76[49] Shah SJ, Bhandarkar SD, Satoskar RS "Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone." Int J Clin Pharmacol Ther Toxicol 22 (1984): 470-2[50] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[51] Nikkila EA, Ylikahri R, Huttunen JK "Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia." Proc R Soc Med 69 (1976): 58-63[52] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[53] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[54] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[55] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[56] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[57] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[58] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[59] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[60] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[61] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[64] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[65] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[66] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[67] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[68] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[69] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[70] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[71] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[72] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[73] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[74] "Product Information. Micronase (glyburide)." Pharmacia and Upjohn, Kalamazoo, MI.[75] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[76] Petitpierre B, Perrin L, Rudhardt M, et al "Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy." Int J Clin Pharmacol 6 (1972): 120-4[77] Pond SM, Birkett DJ, Wade DN "Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole." Clin Pharmacol Ther 22 (1977): 573-9[78] Sone H, Takahashi A, Yamada N "Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea." Ann Intern Med 134 (2001): 344[79] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[80] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[81] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[82] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[83] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[84] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[85] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[86] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[87] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[88] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[89] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[90] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[91] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[92] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[93] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[94] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM "Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism." Clin Pharmacol Ther 17 (1975): 731-4[95] Diwan PV, Sastry MS, Satyanarayana NV "Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans." Indian J Exp Biol 30 (1992): 317-9[96] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[97] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[98] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[99] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[100] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[101] Harris EL "Adverse reactions to oral antidiabetic agents." Br Med J 3 (1971): 29-30[102] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK "Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide." Br J Clin Pharmacol 30 (1990): 245-52[103] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[104] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[105] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[106] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[107] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[108] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[109] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[110] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[111] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[112] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190513, 'Aminolevulinic acid', 'Sulfisoxazole', 'Major', 'Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid.', NULL, 'Photosensitizing agents (e.', NULL, 'Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John''s wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190741/', '[1] "Product Information. Gleolan (aminolevulinic acid)." NX Development Corp, Lexington, KY.[2] "Product Information. Nulibry (fosdenopterin)." Origin Biosciences Inc, Boston, MA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190514, 'Insulin human', 'Sulfisoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190742/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190515, 'Insulin aspart (aspart protamine)', 'Sulfisoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190743/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190516, 'Insulin lispro (protamine)', 'Sulfisoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190744/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190517, 'Insulin human (zinc)', 'Sulfisoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190745/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190518, 'Insulin human (zinc extended)', 'Sulfisoxazole', 'Moderate', 'The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190746/', '[1] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[2] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[3] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[4] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[5] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[6] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[7] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[8] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[9] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[10] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[11] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[12] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[13] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[14] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[15] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[16] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[17] "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.[18] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[19] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[20] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[21] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[22] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[23] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[24] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[25] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[26] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[27] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[28] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[29] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[30] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[31] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[32] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[33] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[34] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[35] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[36] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[37] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[38] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[41] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[42] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[43] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[44] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[45] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[46] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[47] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[48] "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[49] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[50] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[51] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[52] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[53] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[54] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[55] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[56] "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[57] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[58] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[59] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[60] "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation, Valencia, CA.[61] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[64] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[65] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[66] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[67] Vuorinen-Markkola H, Yki-Jarvinen H "Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus." Metabolism 44 (1995): 85-9[68] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[69] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[70] "Product Information. Humulin 70/30 (insulin isophane-insulin regular)." Lilly, Eli and Company, Indianapolis, IN.[71] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[72] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[73] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[74] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[75] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[76] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K "Drug-induced hypoglycaemia: an update." Drug Saf 34 (2011): 21-45[77] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[78] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[79] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[80] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[81] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[82] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[83] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[84] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[85] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[86] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190519, 'Aminobenzoic acid', 'Sulfisoxazole', 'Major', 'Potassium aminobenzoate may inactivate antibacterial sulfonamides. Sulfonamides are structural analogues and competitive inhibitors of para-aminobenzoic acid, which is required by bacterial folic acid synthesis. Therefore, sufficient concentrations of potassium para-aminobenzoate may antagonize the antibacterial effects of sulfonamides.', NULL, 'The manufacturer considers concomitant use contraindicated.', NULL, 'The manufacturer considers concomitant use contraindicated.', 'Antagonism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190747/', '[1] "Product Information. Potaba (potassium aminobenzoate)." Glenwood Inc, Englewood, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190520, 'Tetracaine (topical)', 'Sulfisoxazole', 'Moderate', 'Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190748/', '[1] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009): 837-45[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Hurricaine (benzocaine topical)." Beutlich, Waukegan, IL.[4] "Product Information. Chloraseptic (benzocaine-menthol topical)." Prestige Brands (formerly MedTech), Tarrytown, NY.[5] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011): 757-61[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Karim A, Ahmed S, Siddiqui R, Mattana J "Methemoglobinemia complicating topical lidocaine used during endoscopic procedures." Am J Med 111 (2001): 150-3', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190521, 'Thiopental', 'Sulfisoxazole', 'Minor', 'Sulfisoxazole may enhance and prolong the effects of thiopental. The mechanism is not fully understood. Reductions in thiopental dosage may be necessary.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190749/', '[1] Csogor SI, Papp J "Competition between sulphonamides and thiopental for the binding sites of plasma proteins." Arzneimittelforschung 20 (1970): 1925-7[2] Malmborg AS "Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base." J Antimicrob Chemother 5 (1979): 591-9[3] Welling PG, Huang H, Hewitt PF, Lyons LL "Bioavailability of erythromycin stearate: influence of food and fluid volume." J Pharm Sci 67 (1978): 764-6[4] Welling PG, Elliott RL, Pitterle ME, et al "Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate." J Pharm Sci 68 (1979): 150-5[5] Welling PG "Influence of food and diet on gastrointestinal drug absorption: a review." J Pharmacokinet Biopharm 5 (1977): 291-334[6] Kanazawa S, Ohkubo T, Sugawara K "The effects of grapefruit juice on the pharmacokinetics of erythromycin." Eur J Clin Pharmacol 56 (2001): 799-803[7] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW "Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation." J Clin Pharmacol 29 (1989): 79-84[8] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC "Bioavailability of erythromycin ethylsuccinate in pediatric patients." J Clin Pharmacol 18 (1978): 194-202', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190522, 'Tolbutamide', 'Sulfisoxazole', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190750/', '[1] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[2] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[3] Field JB, Ohta M, Boyle C, Remer A "Potentiation of acetohexamide hypoglycemia by phenylbutazone." N Engl J Med 277 (1967): 889-94[4] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[5] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[6] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J "Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole." Diabet Med 4 (1987): 245-7[7] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[8] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT "Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride." Clin Pharmacol Ther 69 (2001): 194-200[9] Ravic M, Johnston A, Turner P "Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs." Postgrad Med J 66 (1990): s30-4[10] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[11] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[12] Tran PO, Gleason CE, Robertson RP "Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function." Diabetes 51 (2002): 1772-8[13] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[14] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[15] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[16] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[17] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[18] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[19] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[20] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[21] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA "Effect of pirprofen on glibenclamide kinetics and response." Br J Clin Pharmacol 14 (1982): 123-6[22] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[23] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[24] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[25] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[26] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[28] Sawka AM, Burgart V, Zimmerman D "Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors." Diabetes Care 24 (2001): 1845-6[29] Wing LM, Miners JO "Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition." Br J Clin Pharmacol 20 (1985): 482-5[30] Tremaine LM, Wilner KD, Preskorn SH "A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide." Clin Pharmacokinet 32(Suppl 1) (1997): 31-36[31] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Tannenbaum H, Anderson LG, Soeldner JS "Phenylbutazone-tolbutamide drug interaction." N Engl J Med 290 (1974): 344[33] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[34] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[35] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB "Aspirin-induced hypoglycaemia in a patient on haemodialysis." Lancet 2 (1971): 1092-3[36] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[37] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[38] Kradjan WA, Witt DM, Opheim KE, Wood FC "Lack of interaction between glipizide and co-trimoxazole." J Clin Pharmacol 34 (1994): 997-1002[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[41] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[42] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[43] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[44] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[45] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[46] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[47] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[48] Lozada A, Dujovne CA "Drug interactions with fibric acids." Pharmacol Ther 63 (1994): 163-76[49] Shah SJ, Bhandarkar SD, Satoskar RS "Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone." Int J Clin Pharmacol Ther Toxicol 22 (1984): 470-2[50] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[51] Nikkila EA, Ylikahri R, Huttunen JK "Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia." Proc R Soc Med 69 (1976): 58-63[52] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[53] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[54] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[55] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[56] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[57] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[58] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[59] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[60] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[61] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[64] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[65] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[66] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[67] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[68] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[69] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[70] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[71] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[72] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[73] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[74] "Product Information. Micronase (glyburide)." Pharmacia and Upjohn, Kalamazoo, MI.[75] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[76] Petitpierre B, Perrin L, Rudhardt M, et al "Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy." Int J Clin Pharmacol 6 (1972): 120-4[77] Pond SM, Birkett DJ, Wade DN "Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole." Clin Pharmacol Ther 22 (1977): 573-9[78] Sone H, Takahashi A, Yamada N "Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea." Ann Intern Med 134 (2001): 344[79] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[80] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[81] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[82] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[83] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[84] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[85] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[86] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[87] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[88] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[89] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[90] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[91] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[92] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[93] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[94] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM "Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism." Clin Pharmacol Ther 17 (1975): 731-4[95] Diwan PV, Sastry MS, Satyanarayana NV "Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans." Indian J Exp Biol 30 (1992): 317-9[96] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[97] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[98] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[99] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[100] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[101] Harris EL "Adverse reactions to oral antidiabetic agents." Br Med J 3 (1971): 29-30[102] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK "Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide." Br J Clin Pharmacol 30 (1990): 245-52[103] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[104] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[105] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[106] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[107] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[108] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[109] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[110] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[111] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[112] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190523, 'Tivozanib', 'Medroxyprogesterone acetate', 'Moderate', 'RECOMMENDED: Coadministration with tivozanib may decrease the efficacy of contraceptive hormones. However, the nature of the interaction has not been confirmed and clinical data are lacking.', NULL, 'Until more information is known, caution is advised when tivozanib is prescribed concomitantly with hormonal contraceptives.', NULL, 'Until more information is known, caution is advised when tivozanib is prescribed concomitantly with hormonal contraceptives. Some authorities recommend that female patients of childbearing potential use an additional method of contraception. An acceptable barrier method (e.g., diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male condom, female condom) in addition to the hormonal contraceptive of choice may be advisable during the duration of tivozanib therapy and for at least one month after completing therapy.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190751/', '[1] "Product Information. Fotivda (tivozanib)." Aveo Pharmaceuticals, Inc., Boston, MA.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[4] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190524, 'Anisindione', 'Moricizine', 'Minor', 'According to one case report, prothrombin time was elevated in a patient who was stable on warfarin and who then received moricizine. Controlled studies, however, have revealed only that serum warfarin half-life is decreased during coadministration. These studies have found no significant change in the prothrombin time. Similar effects may occur with other oral anticoagulants. Management consists of following the patient''s prothrombin time or INR during coadministration. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190752/', '[1] Benedek IH, King SY, Powell RJ, et al "Effect of moricizine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers." J Clin Pharmacol 32 (1992): 558-63[2] Serpa MD, Cossolias J, McGreevy MJ "Moricizine-warfarin: a possible drug interaction." Ann Pharmacother 26 (1992): 127[3] Guo LQ, Yamazoe Y "Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines." Acta Pharmacol Sin 25 (2004): 129-36[4] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3[5] Suvarna R, Pirmohamed M, Henderson L "Possible interaction between warfarin and cranberry juice." BMJ 327 (2003): 1454[6] Lee M, Schwartz RN, Sharifi R "Warfarin resistance and vitamin K." Ann Intern Med 94 (1981): 140-1[7] Beckey NP, Korman LB, Parra D "Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy." Pharmacotherapy 19 (1999): 1075-9[8] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G "Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy." Eur J Clin Pharmacol 63 (2007): 565-70[9] Kempin SJ "Warfarin resistance caused by broccoli." N Engl J Med 308 (1983): 1229-30[10] Westfall LK "An unrecognized cause of warfarin resistance." Drug Intell Clin Pharm 15 (1981): 131[11] Kuykendall JR, Houle MD, Rhodes RS "Possible warfarin failure due to interaction with smokeless tobacco." Ann Pharmacother 38 (2004): 595-7[12] Walker FB "Myocardial infarction after diet-induced warfarin resistance." Arch Intern Med 144 (1984): 2089-90[13] Pedersen FM, Hamberg O, Hess K, Ovesen L "The effect of dietary vitamin K on warfarin-induced anticoagulation." J Intern Med 229 (1991): 517-20[14] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[15] Griffith LD, Olvey SE, Triplett WC "Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus." Crit Care Med 10 (1982): 799-800[16] Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines "Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm." ([2003 Sept]):[18] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[19] Karlson B, Leijd B, Hellstrom K "On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment." Acta Med Scand 220 (1986): 347-50[20] O''Reilly RA, Rytand DA ""Resistance" to warfarin due to unrecognized vitamin K supplementation." N Engl J Med 303 (1980): 160-1[21] Kazmier FJ, Spittell JA Jr "Coumarin drug interactions." Mayo Clin Proc 45 (1970): 249-55[22] Cambria-Kiely JA "Effect of soy milk on warfarin efficacy." Ann Pharmacother 36 (2002): 1893-6[23] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT "Anticoagulation instability with life-threatening complication after dietary modification." Postgrad Med J 66 (1990): 855-7[24] Hamann GL, Campbell JD, George CM "Warfarin-cranberry juice interaction." Ann Pharmacother 45 (2011): e17[25] Monterrey-Rodriguez J "Interaction between warfarin and mango fruit." Ann Pharmacother 36 (2002): 940-1[26] Griffiths AP, Beddall A, Pegler S "Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin." J R Soc Health 128 (2008): 324-6[27] Roberts D, Flanagan P "Case report: Cranberry juice and warfarin." Home Healthc Nurse 29 (2011): 92-7[28] MacLeod SM, Sellers EM "Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants." Drugs 11 (1976): 461-70[29] Jarvis S, Li C, Bogle RG "Possible interaction between pomegranate juice and warfarin." Emerg Med J 27 (2010): 74-5[30] Parr MD, Record KE, Griffith GL, et al "Effect of enteral nutrition on warfarin therapy." Clin Pharm 1 (1982): 274-6[31] Sullivan DM, Ford MA, Boyden TW "Grapefruit juice and the response to warfarin." Am J Health Syst Pharm 55 (1998): 1581-3[32] Howard PA, Hannaman KN "Warfarin resistance linked to enteral nutrition products." J Am Diet Assoc 85 (1985): 713-5[33] Rindone JP, Murphy TW "Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding." Am J Ther 13 (2006): 283-4[34] Harrell CC, Kline SS "Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin." Jama J Am Med Assn 282 (1999): 1133-4[35] Grant P "Warfarin and cranberry juice: an interaction?" J Heart Valve Dis 13 (2004): 25-6[36] Ge B, Zhang Z, Zuo Z "Updates on the clinical evidenced herb-warfarin interactions." Evid Based Complement Alternat Med 2014 (2014): 957362[37] Zallman JA, Lee DP, Jeffrey PL "Liquid nutrition as a cause of warfarin resistance." Am J Hosp Pharm 38 (1981): 1174[38] Watson AJ, Pegg M, Green JR "Enteral feeds may antagonise warfarin." Br Med J 288 (1984): 557[39] Andersen P, Godal HC "Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K." Acta Med Scand 198 (1975): 269-70', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190525, 'Moricizine', 'Arbutamine', 'Major', 'Arbutamine may precipitate or exacerbate supraventricular or ventricular arrhythmias due to its sympathomimetic effects.', NULL, 'The manufacturer recommends that arbutamine not be given concurrently with proarrhythmic drugs.', NULL, 'The manufacturer recommends that arbutamine not be given concurrently with proarrhythmic drugs.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190753/', '[1] "Product Information. GenESA (arbutamine)." Gensia Inc, San Diego, CA.[2] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[3] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190526, 'Dicoumarol', 'Moricizine', 'Minor', 'According to one case report, prothrombin time was elevated in a patient who was stable on warfarin and who then received moricizine. Controlled studies, however, have revealed only that serum warfarin half-life is decreased during coadministration. These studies have found no significant change in the prothrombin time. Similar effects may occur with other oral anticoagulants. Management consists of following the patient''s prothrombin time or INR during coadministration. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190754/', '[1] Benedek IH, King SY, Powell RJ, et al "Effect of moricizine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers." J Clin Pharmacol 32 (1992): 558-63[2] Serpa MD, Cossolias J, McGreevy MJ "Moricizine-warfarin: a possible drug interaction." Ann Pharmacother 26 (1992): 127[3] Guo LQ, Yamazoe Y "Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines." Acta Pharmacol Sin 25 (2004): 129-36[4] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3[5] Suvarna R, Pirmohamed M, Henderson L "Possible interaction between warfarin and cranberry juice." BMJ 327 (2003): 1454[6] Lee M, Schwartz RN, Sharifi R "Warfarin resistance and vitamin K." Ann Intern Med 94 (1981): 140-1[7] Beckey NP, Korman LB, Parra D "Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy." Pharmacotherapy 19 (1999): 1075-9[8] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G "Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy." Eur J Clin Pharmacol 63 (2007): 565-70[9] Kempin SJ "Warfarin resistance caused by broccoli." N Engl J Med 308 (1983): 1229-30[10] Westfall LK "An unrecognized cause of warfarin resistance." Drug Intell Clin Pharm 15 (1981): 131[11] Kuykendall JR, Houle MD, Rhodes RS "Possible warfarin failure due to interaction with smokeless tobacco." Ann Pharmacother 38 (2004): 595-7[12] Walker FB "Myocardial infarction after diet-induced warfarin resistance." Arch Intern Med 144 (1984): 2089-90[13] Pedersen FM, Hamberg O, Hess K, Ovesen L "The effect of dietary vitamin K on warfarin-induced anticoagulation." J Intern Med 229 (1991): 517-20[14] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[15] Griffith LD, Olvey SE, Triplett WC "Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus." Crit Care Med 10 (1982): 799-800[16] Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines "Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm." ([2003 Sept]):[18] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[19] Karlson B, Leijd B, Hellstrom K "On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment." Acta Med Scand 220 (1986): 347-50[20] O''Reilly RA, Rytand DA ""Resistance" to warfarin due to unrecognized vitamin K supplementation." N Engl J Med 303 (1980): 160-1[21] Kazmier FJ, Spittell JA Jr "Coumarin drug interactions." Mayo Clin Proc 45 (1970): 249-55[22] Cambria-Kiely JA "Effect of soy milk on warfarin efficacy." Ann Pharmacother 36 (2002): 1893-6[23] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT "Anticoagulation instability with life-threatening complication after dietary modification." Postgrad Med J 66 (1990): 855-7[24] Hamann GL, Campbell JD, George CM "Warfarin-cranberry juice interaction." Ann Pharmacother 45 (2011): e17[25] Monterrey-Rodriguez J "Interaction between warfarin and mango fruit." Ann Pharmacother 36 (2002): 940-1[26] Griffiths AP, Beddall A, Pegler S "Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin." J R Soc Health 128 (2008): 324-6[27] Roberts D, Flanagan P "Case report: Cranberry juice and warfarin." Home Healthc Nurse 29 (2011): 92-7[28] MacLeod SM, Sellers EM "Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants." Drugs 11 (1976): 461-70[29] Jarvis S, Li C, Bogle RG "Possible interaction between pomegranate juice and warfarin." Emerg Med J 27 (2010): 74-5[30] Parr MD, Record KE, Griffith GL, et al "Effect of enteral nutrition on warfarin therapy." Clin Pharm 1 (1982): 274-6[31] Sullivan DM, Ford MA, Boyden TW "Grapefruit juice and the response to warfarin." Am J Health Syst Pharm 55 (1998): 1581-3[32] Howard PA, Hannaman KN "Warfarin resistance linked to enteral nutrition products." J Am Diet Assoc 85 (1985): 713-5[33] Rindone JP, Murphy TW "Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding." Am J Ther 13 (2006): 283-4[34] Harrell CC, Kline SS "Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin." Jama J Am Med Assn 282 (1999): 1133-4[35] Grant P "Warfarin and cranberry juice: an interaction?" J Heart Valve Dis 13 (2004): 25-6[36] Ge B, Zhang Z, Zuo Z "Updates on the clinical evidenced herb-warfarin interactions." Evid Based Complement Alternat Med 2014 (2014): 957362[37] Zallman JA, Lee DP, Jeffrey PL "Liquid nutrition as a cause of warfarin resistance." Am J Hosp Pharm 38 (1981): 1174[38] Watson AJ, Pegg M, Green JR "Enteral feeds may antagonise warfarin." Br Med J 288 (1984): 557[39] Andersen P, Godal HC "Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K." Acta Med Scand 198 (1975): 269-70', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190527, 'Oxtriphylline', 'Moricizine', 'Minor', 'Moricizine may increase the plasma clearance of theophylline by 46% to 68% and decrease theophylline half-life by 20% to 34%. Conversely, theophylline toxicity may occur when moricizine is discontinued. The mechanism is unknown, but may be related to hepatic enzyme induction. Management consists of monitoring the patient for theophylline efficacy, checking levels if indicated, and adjusting theophylline dosage accordingly. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190755/', '[1] Upton RA "Pharmacokinetic interactions between theophylline and other medication (Part II)." Clin Pharmacokinet 20 (1991): 135-50[2] Pieniaszek HJ Jr, Davidson AF, Benedek IH "Effect of moricizine on the pharmacokinetics of single-dose theophylline in healthy subjects." Ther Drug Monit 15 (1993): 199-203[3] Siddoway LA, Schwartz SL, Barbey JT, Woosley RL "Clinical pharmacokinetics of moricizine." Am J Cardiol 65 (1990): d21-5; disc. D68-71', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190528, 'Tacrine', 'Moricizine', 'Moderate', 'Since acetylcholinesterase inhibitors can cause bradycardia and heart block due to vagotonic effects on the sinoatrial and atrioventricular nodes, additive effects may occur with other agents that also possess bradycardic effects such as beta-blockers, calcium channel blockers, digitalis, some protease inhibitors (atazanavir, lopinavir-ritonavir, saquinavir), amiodarone, dronedarone, moricizine, lacosamide, and mefloquine.', NULL, 'Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs.', NULL, 'Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs. Patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190756/', '[1] "Product Information. Razadyne (galantamine)." Johnson and Johnson Medical Inc, Arlington, TX.[2] "Product Information. Cognex (tacrine)." Parke-Davis, Morris Plains, NJ.[3] Tiseo PJ, Perdomo CA, Friedhoff LT "Concurrent administration of donepezil HCI and digoxin: assessment of pharmacokinetic changes." Br J Clin Pharmacol 46(Suppl 1) (1998): 40-4[4] Tavassoli N, Sommet A, Lapeyre-Mestre M, Bagheri H, Montrastruc JL "Drug interactions with cholinesterase inhibitors : an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (vidal, british national formulary)." Drug Saf 30 (2007): 1063-71[5] "Product Information. Exelon (rivastigmine)" Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Aricept (donepezil)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190529, 'Iron', 'Cinoxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190757/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190530, 'Iron', 'Enoxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190758/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190531, 'Iron', 'Gallium chloride Ga-67', 'Moderate', 'The concomitant use of certain medications (e.g., cytarabine, fluorouracil, methotrexate, and iron) may cause displacement of gallium citrate Ga-67 from plasma protein binding sites and interfere with test results.', NULL, 'Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.', NULL, 'Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.', 'Distribution', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190759/', '[1] "Product Information. Gallium Citrate Ga-67 (gallium citrate 67 Ga (gallium citrate 67Ga))." Bristol-Myers Squibb, Princeton, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190532, 'Iron', 'Gatifloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190760/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190533, 'Iron', 'Grepafloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190761/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190534, 'Iron', 'Lomefloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190762/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190535, 'Iron', 'Magaldrate', 'Moderate', 'INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190763/', '[1] Gugler R, Allgayer H "Effects of antacids on the clinical pharmacokinetics of drugs. An update." Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA "In-vitro interactions of oral hemantics and antacid suspensions." Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA "In-vitro interactions of oral hematinics." Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM "Effect of aluminum hydroxide on iron absorption." Kidney Int 8 (1975): 417[5] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L "Influence of a liquid antacid on the absorption of different iron salts." Scand J Haematol Suppl 28 (1976): 65-77[7] O''Neil-Cutting MA, Crosby WH "The effect of antacids on the absorption of simultaneously ingested iron." JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R "Effect of magnesium hydroxide on iron absorption after ferrous sulfate." Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF "Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial." Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ "Effect of orally administered magnesium hydroxide in experimental iron intoxication." J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH "Effect of phosphate binders on supplemental iron absorption in healthy subjects." J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE "Inhibition of iron absorption by magnesium trisilicate." Med J Aust 2 (1969): 95-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190536, 'Iron', 'Magnesium carbonate', 'Moderate', 'INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190764/', '[1] Gugler R, Allgayer H "Effects of antacids on the clinical pharmacokinetics of drugs. An update." Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA "In-vitro interactions of oral hemantics and antacid suspensions." Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA "In-vitro interactions of oral hematinics." Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM "Effect of aluminum hydroxide on iron absorption." Kidney Int 8 (1975): 417[5] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L "Influence of a liquid antacid on the absorption of different iron salts." Scand J Haematol Suppl 28 (1976): 65-77[7] O''Neil-Cutting MA, Crosby WH "The effect of antacids on the absorption of simultaneously ingested iron." JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R "Effect of magnesium hydroxide on iron absorption after ferrous sulfate." Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF "Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial." Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ "Effect of orally administered magnesium hydroxide in experimental iron intoxication." J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH "Effect of phosphate binders on supplemental iron absorption in healthy subjects." J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE "Inhibition of iron absorption by magnesium trisilicate." Med J Aust 2 (1969): 95-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190537, 'Iron', 'Magnesium hydroxide', 'Moderate', 'INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190765/', '[1] Gugler R, Allgayer H "Effects of antacids on the clinical pharmacokinetics of drugs. An update." Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA "In-vitro interactions of oral hemantics and antacid suspensions." Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA "In-vitro interactions of oral hematinics." Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM "Effect of aluminum hydroxide on iron absorption." Kidney Int 8 (1975): 417[5] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L "Influence of a liquid antacid on the absorption of different iron salts." Scand J Haematol Suppl 28 (1976): 65-77[7] O''Neil-Cutting MA, Crosby WH "The effect of antacids on the absorption of simultaneously ingested iron." JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R "Effect of magnesium hydroxide on iron absorption after ferrous sulfate." Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF "Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial." Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ "Effect of orally administered magnesium hydroxide in experimental iron intoxication." J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH "Effect of phosphate binders on supplemental iron absorption in healthy subjects." J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE "Inhibition of iron absorption by magnesium trisilicate." Med J Aust 2 (1969): 95-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190538, 'Iron', 'Nalidixic acid', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of nalidixic acid. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of nalidixic acid by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190766/', '[1] "Product Information. NegGram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190539, 'Iron', 'Oxytetracycline', 'Moderate', 'The bioavailability of oral tetracyclines and iron salts may be significantly decreased during concurrent administration. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the iron cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'Coadministration of a tetracycline with any iron-containing product should be avoided if possible.', NULL, 'Coadministration of a tetracycline with any iron-containing product should be avoided if possible. Otherwise, patients should be advised to stagger the times of administration by at least three to four hours, although separating the doses may not prevent the interaction with doxycycline.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190767/', '[1] Gothoni G, Neuvonen PJ, Mattila M, Hackman R "Iron-tetracycline interaction: effect of time interval between the drugs." Acta Med Scand 191 (1972): 409-11[2] Campbell NR, Hasinoff BB "Iron supplements: a common cause of drug interactions." Br J Clin Pharmacol 31 (1991): 251-5[3] "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc., Boston, MA.[4] Neuvonen PJ "Interactions with the absorption of tetracyclines." Drugs 11 (1976): 45-54[5] Venho VM, Salonen RO, Mattila MJ "Modification of the pharmacokinetics of doxycycline in man by ferrous sulphate or charcoal." Eur J Clin Pharmacol 14 (1978): 277-80[6] Neuvonen PJ, Gothoni G, Hackman R, Bjorksten K "Interference of iron with the absorption of tetracyclines in man." Br Med J 4 (1970): 532-4[7] "Product Information. Minocin (minocycline)." Lederle Laboratories, Wayne, NJ.[8] Greenberger NJ "Absorption of tetracyclines: interference by iron." Ann Intern Med 74 (1971): 792-3[9] "Product Information. Seysara (sarecycline)." Allergan Inc, Irvine, CA.[10] Neuvonen PJ, Penttila O "Effect of oral ferrous sulphate on the half-life of doxycycline in man." Eur J Clin Pharmacol 7 (1974): 361-3[11] Bateman FJ "Effects of tetracyclines." Br Med J 4 (1970): 802[12] "Product Information. Achromycin (tetracycline)." Lederle Laboratories, Wayne, NJ.[13] "Product Information. Declomycin (demeclocycline)." Lederle Laboratories, Wayne, NJ.[14] "Product Information. Feosol Tablets (ferrous sulfate)." SmithKline Beecham, Philadelphia, PA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190540, 'Iron', 'Saw palmetto', 'Minor', 'The tannic acid present in some herbs like St. John''s wort and saw palmetto may inhibit the absorption of iron. The administration of these herbs and iron-containing supplements should be separated by several hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190768/', '[1] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190541, 'Iron', 'Sparfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190769/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190542, 'Iron', 'St. John''s Wort', 'Minor', 'The tannic acid present in some herbs like St. John''s wort and saw palmetto may inhibit the absorption of iron. The administration of these herbs and iron-containing supplements should be separated by several hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190770/', '[1] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190543, 'Iron', 'Tiludronic acid', 'Moderate', 'INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.', NULL, 'Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.', NULL, 'Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190771/', '[1] "Product Information. Boniva (ibandronate)." Roche Laboratories, Nutley, NJ.[2] "Product Information. Fosamax (alendronate)." Merck & Co, Inc, West Point, PA.[3] "Product Information. Skelid (tilundronate)." Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF "Nutrient-drug interactions." Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] "Product Information. Bonefos (clodronate)." Rhone-Poulenc Rorer Canada Inc, Laval, QC.[6] "Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] "Product Information. Skelid (tilundronate)." Sanofi Winthrop Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190544, 'Iron', 'Trovafloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190772/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190545, 'Iron', 'Vitamin E', 'Moderate', 'Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia.', NULL, 'Patients receiving iron therapy for iron deficiency anemia should be monitored for potentially reduced hematologic response if vitamin E is administered concomitantly.', NULL, 'Patients receiving iron therapy for iron deficiency anemia should be monitored for potentially reduced hematologic response if vitamin E is administered concomitantly.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190773/', '[1] Melhorn DK, Gross S "Relationships between iron-dextran and vitamin E in iron deficiency anemia in children." J Lab Clin Med 74 (1969): 789-802[2] Graeber JE, Williams ML, Oski FA "The use of intramuscular vitamin E in the premature infant. Optimum dose and iron interaction." J Pediatr 90 (1977): 282-4', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190546, 'Iron', 'Zinc gluconate', 'Minor', 'Iron and zinc may reduce each other''s absorption when they are coadministered orally. The mechanism of interaction is unknown. In clinical studies, concurrent supplementation with iron and zinc was associated with reduced efficacy in improving the growth and iron and zinc status of malnourished infants compared to supplementation with either one alone. In any case, the clinical significance is probably minimal in healthy individuals. However, monitoring for reduced therapeutic response may be advisable in malnourished patients. Limited data suggest that the magnitude of the interaction may be lessened by separating the times of administration of each by 12 hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190774/', '[1] Sreedhar B "Conflicting evidence of iron and zinc interactions in humans: does iron affect zinc absorption?" Am J Clin Nutr 78 (2003): 1226; author reply 1226-7[2] Lind T, Lonnerdal B, Stenlund H, et al. "A community-based randomized controlled trial of iron and zinc supplementation in Indonesian infants: interactions between iron and zinc." Am J Clin Nutr 77 (2003): 883-90', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190547, 'Gallium chloride Ga-67', 'Ferumoxides', 'Moderate', 'The concomitant use of certain medications (e.g., cytarabine, fluorouracil, methotrexate, and iron) may cause displacement of gallium citrate Ga-67 from plasma protein binding sites and interfere with test results.', NULL, 'Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.', NULL, 'Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.', 'Distribution', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190775/', '[1] "Product Information. Gallium Citrate Ga-67 (gallium citrate 67 Ga (gallium citrate 67Ga))." Bristol-Myers Squibb, Princeton, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190548, 'Iopanoic acid', 'Ferumoxides', 'Moderate', 'INTERVAL: Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravenous contrast agents. The mechanism of interaction has not been described.', NULL, 'Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.', NULL, 'Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190776/', '[1] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.[2] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[3] "Product Information. Omniscan (gadodiamide)." Novation, Irving, TX.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190549, 'Iopodic acid', 'Ferumoxides', 'Moderate', 'INTERVAL: Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravenous contrast agents. The mechanism of interaction has not been described.', NULL, 'Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.', NULL, 'Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190777/', '[1] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.[2] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[3] "Product Information. Omniscan (gadodiamide)." Novation, Irving, TX.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190550, 'Ferumoxides', 'Tyropanoic acid', 'Moderate', 'INTERVAL: Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravenous contrast agents. The mechanism of interaction has not been described.', NULL, 'Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.', NULL, 'Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190778/', '[1] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.[2] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[3] "Product Information. Omniscan (gadodiamide)." Novation, Irving, TX.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190551, 'Ferrous fumarate', 'Aluminum hydroxide', 'Moderate', 'INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190779/', '[1] Gugler R, Allgayer H "Effects of antacids on the clinical pharmacokinetics of drugs. An update." Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA "In-vitro interactions of oral hemantics and antacid suspensions." Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA "In-vitro interactions of oral hematinics." Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM "Effect of aluminum hydroxide on iron absorption." Kidney Int 8 (1975): 417[5] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L "Influence of a liquid antacid on the absorption of different iron salts." Scand J Haematol Suppl 28 (1976): 65-77[7] O''Neil-Cutting MA, Crosby WH "The effect of antacids on the absorption of simultaneously ingested iron." JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R "Effect of magnesium hydroxide on iron absorption after ferrous sulfate." Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF "Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial." Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ "Effect of orally administered magnesium hydroxide in experimental iron intoxication." J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH "Effect of phosphate binders on supplemental iron absorption in healthy subjects." J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE "Inhibition of iron absorption by magnesium trisilicate." Med J Aust 2 (1969): 95-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190552, 'Ferrous fumarate', 'Cinoxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190780/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190553, 'Ferrous fumarate', 'Enoxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190781/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190554, 'Gallium chloride Ga-67', 'Ferrous fumarate', 'Moderate', 'The concomitant use of certain medications (e.g., cytarabine, fluorouracil, methotrexate, and iron) may cause displacement of gallium citrate Ga-67 from plasma protein binding sites and interfere with test results.', NULL, 'Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.', NULL, 'Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.', 'Distribution', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190782/', '[1] "Product Information. Gallium Citrate Ga-67 (gallium citrate 67 Ga (gallium citrate 67Ga))." Bristol-Myers Squibb, Princeton, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190555, 'Gatifloxacin', 'Ferrous fumarate', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190783/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190556, 'Grepafloxacin', 'Ferrous fumarate', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190784/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190557, 'Ferrous fumarate', 'Lomefloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190785/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190558, 'Ferrous fumarate', 'Magaldrate', 'Moderate', 'INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190786/', '[1] Gugler R, Allgayer H "Effects of antacids on the clinical pharmacokinetics of drugs. An update." Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA "In-vitro interactions of oral hemantics and antacid suspensions." Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA "In-vitro interactions of oral hematinics." Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM "Effect of aluminum hydroxide on iron absorption." Kidney Int 8 (1975): 417[5] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L "Influence of a liquid antacid on the absorption of different iron salts." Scand J Haematol Suppl 28 (1976): 65-77[7] O''Neil-Cutting MA, Crosby WH "The effect of antacids on the absorption of simultaneously ingested iron." JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R "Effect of magnesium hydroxide on iron absorption after ferrous sulfate." Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF "Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial." Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ "Effect of orally administered magnesium hydroxide in experimental iron intoxication." J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH "Effect of phosphate binders on supplemental iron absorption in healthy subjects." J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE "Inhibition of iron absorption by magnesium trisilicate." Med J Aust 2 (1969): 95-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190559, 'Ferrous fumarate', 'Magnesium carbonate', 'Moderate', 'INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190787/', '[1] Gugler R, Allgayer H "Effects of antacids on the clinical pharmacokinetics of drugs. An update." Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA "In-vitro interactions of oral hemantics and antacid suspensions." Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA "In-vitro interactions of oral hematinics." Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM "Effect of aluminum hydroxide on iron absorption." Kidney Int 8 (1975): 417[5] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L "Influence of a liquid antacid on the absorption of different iron salts." Scand J Haematol Suppl 28 (1976): 65-77[7] O''Neil-Cutting MA, Crosby WH "The effect of antacids on the absorption of simultaneously ingested iron." JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R "Effect of magnesium hydroxide on iron absorption after ferrous sulfate." Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF "Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial." Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ "Effect of orally administered magnesium hydroxide in experimental iron intoxication." J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH "Effect of phosphate binders on supplemental iron absorption in healthy subjects." J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE "Inhibition of iron absorption by magnesium trisilicate." Med J Aust 2 (1969): 95-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190560, 'Ferrous fumarate', 'Magnesium hydroxide', 'Moderate', 'INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190788/', '[1] Gugler R, Allgayer H "Effects of antacids on the clinical pharmacokinetics of drugs. An update." Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA "In-vitro interactions of oral hemantics and antacid suspensions." Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA "In-vitro interactions of oral hematinics." Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM "Effect of aluminum hydroxide on iron absorption." Kidney Int 8 (1975): 417[5] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L "Influence of a liquid antacid on the absorption of different iron salts." Scand J Haematol Suppl 28 (1976): 65-77[7] O''Neil-Cutting MA, Crosby WH "The effect of antacids on the absorption of simultaneously ingested iron." JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R "Effect of magnesium hydroxide on iron absorption after ferrous sulfate." Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF "Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial." Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ "Effect of orally administered magnesium hydroxide in experimental iron intoxication." J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH "Effect of phosphate binders on supplemental iron absorption in healthy subjects." J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE "Inhibition of iron absorption by magnesium trisilicate." Med J Aust 2 (1969): 95-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190561, 'Ferrous fumarate', 'Nalidixic acid', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of nalidixic acid. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of nalidixic acid by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190789/', '[1] "Product Information. NegGram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190562, 'Ferrous fumarate', 'Oxytetracycline', 'Moderate', 'The bioavailability of oral tetracyclines and iron salts may be significantly decreased during concurrent administration. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the iron cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'Coadministration of a tetracycline with any iron-containing product should be avoided if possible.', NULL, 'Coadministration of a tetracycline with any iron-containing product should be avoided if possible. Otherwise, patients should be advised to stagger the times of administration by at least three to four hours, although separating the doses may not prevent the interaction with doxycycline.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190790/', '[1] Gothoni G, Neuvonen PJ, Mattila M, Hackman R "Iron-tetracycline interaction: effect of time interval between the drugs." Acta Med Scand 191 (1972): 409-11[2] Campbell NR, Hasinoff BB "Iron supplements: a common cause of drug interactions." Br J Clin Pharmacol 31 (1991): 251-5[3] "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc., Boston, MA.[4] Neuvonen PJ "Interactions with the absorption of tetracyclines." Drugs 11 (1976): 45-54[5] Venho VM, Salonen RO, Mattila MJ "Modification of the pharmacokinetics of doxycycline in man by ferrous sulphate or charcoal." Eur J Clin Pharmacol 14 (1978): 277-80[6] Neuvonen PJ, Gothoni G, Hackman R, Bjorksten K "Interference of iron with the absorption of tetracyclines in man." Br Med J 4 (1970): 532-4[7] "Product Information. Minocin (minocycline)." Lederle Laboratories, Wayne, NJ.[8] Greenberger NJ "Absorption of tetracyclines: interference by iron." Ann Intern Med 74 (1971): 792-3[9] "Product Information. Seysara (sarecycline)." Allergan Inc, Irvine, CA.[10] Neuvonen PJ, Penttila O "Effect of oral ferrous sulphate on the half-life of doxycycline in man." Eur J Clin Pharmacol 7 (1974): 361-3[11] Bateman FJ "Effects of tetracyclines." Br Med J 4 (1970): 802[12] "Product Information. Achromycin (tetracycline)." Lederle Laboratories, Wayne, NJ.[13] "Product Information. Declomycin (demeclocycline)." Lederle Laboratories, Wayne, NJ.[14] "Product Information. Feosol Tablets (ferrous sulfate)." SmithKline Beecham, Philadelphia, PA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190563, 'Ferrous fumarate', 'Saw palmetto', 'Minor', 'The tannic acid present in some herbs like St. John''s wort and saw palmetto may inhibit the absorption of iron. The administration of these herbs and iron-containing supplements should be separated by several hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190791/', '[1] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190564, 'Ferrous fumarate', 'Sparfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190792/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190565, 'Ferrous fumarate', 'St. John''s Wort', 'Minor', 'The tannic acid present in some herbs like St. John''s wort and saw palmetto may inhibit the absorption of iron. The administration of these herbs and iron-containing supplements should be separated by several hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190793/', '[1] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190566, 'Ferrous fumarate', 'Tiludronic acid', 'Moderate', 'INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.', NULL, 'Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.', NULL, 'Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190794/', '[1] "Product Information. Boniva (ibandronate)." Roche Laboratories, Nutley, NJ.[2] "Product Information. Fosamax (alendronate)." Merck & Co, Inc, West Point, PA.[3] "Product Information. Skelid (tilundronate)." Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF "Nutrient-drug interactions." Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] "Product Information. Bonefos (clodronate)." Rhone-Poulenc Rorer Canada Inc, Laval, QC.[6] "Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] "Product Information. Skelid (tilundronate)." Sanofi Winthrop Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190567, 'Ferrous fumarate', 'Trovafloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190795/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190568, 'Ferrous fumarate', 'Vitamin E', 'Moderate', 'Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia.', NULL, 'Patients receiving iron therapy for iron deficiency anemia should be monitored for potentially reduced hematologic response if vitamin E is administered concomitantly.', NULL, 'Patients receiving iron therapy for iron deficiency anemia should be monitored for potentially reduced hematologic response if vitamin E is administered concomitantly.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190796/', '[1] Melhorn DK, Gross S "Relationships between iron-dextran and vitamin E in iron deficiency anemia in children." J Lab Clin Med 74 (1969): 789-802[2] Graeber JE, Williams ML, Oski FA "The use of intramuscular vitamin E in the premature infant. Optimum dose and iron interaction." J Pediatr 90 (1977): 282-4', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190569, 'Ferrous fumarate', 'Zinc gluconate', 'Minor', 'Iron and zinc may reduce each other''s absorption when they are coadministered orally. The mechanism of interaction is unknown. In clinical studies, concurrent supplementation with iron and zinc was associated with reduced efficacy in improving the growth and iron and zinc status of malnourished infants compared to supplementation with either one alone. In any case, the clinical significance is probably minimal in healthy individuals. However, monitoring for reduced therapeutic response may be advisable in malnourished patients. Limited data suggest that the magnitude of the interaction may be lessened by separating the times of administration of each by 12 hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190797/', '[1] Sreedhar B "Conflicting evidence of iron and zinc interactions in humans: does iron affect zinc absorption?" Am J Clin Nutr 78 (2003): 1226; author reply 1226-7[2] Lind T, Lonnerdal B, Stenlund H, et al. "A community-based randomized controlled trial of iron and zinc supplementation in Indonesian infants: interactions between iron and zinc." Am J Clin Nutr 77 (2003): 883-90', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190570, 'Ferrous gluconate', 'Aluminum hydroxide', 'Moderate', 'INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190798/', '[1] Gugler R, Allgayer H "Effects of antacids on the clinical pharmacokinetics of drugs. An update." Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA "In-vitro interactions of oral hemantics and antacid suspensions." Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA "In-vitro interactions of oral hematinics." Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM "Effect of aluminum hydroxide on iron absorption." Kidney Int 8 (1975): 417[5] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L "Influence of a liquid antacid on the absorption of different iron salts." Scand J Haematol Suppl 28 (1976): 65-77[7] O''Neil-Cutting MA, Crosby WH "The effect of antacids on the absorption of simultaneously ingested iron." JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R "Effect of magnesium hydroxide on iron absorption after ferrous sulfate." Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF "Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial." Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ "Effect of orally administered magnesium hydroxide in experimental iron intoxication." J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH "Effect of phosphate binders on supplemental iron absorption in healthy subjects." J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE "Inhibition of iron absorption by magnesium trisilicate." Med J Aust 2 (1969): 95-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190571, 'Ferrous gluconate', 'Cinoxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190799/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190572, 'Ferrous gluconate', 'Enoxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190800/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190573, 'Gallium chloride Ga-67', 'Ferrous gluconate', 'Moderate', 'The concomitant use of certain medications (e.g., cytarabine, fluorouracil, methotrexate, and iron) may cause displacement of gallium citrate Ga-67 from plasma protein binding sites and interfere with test results.', NULL, 'Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.', NULL, 'Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.', 'Distribution', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190801/', '[1] "Product Information. Gallium Citrate Ga-67 (gallium citrate 67 Ga (gallium citrate 67Ga))." Bristol-Myers Squibb, Princeton, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190574, 'Gatifloxacin', 'Ferrous gluconate', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190802/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190575, 'Grepafloxacin', 'Ferrous gluconate', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190803/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190576, 'Ferrous gluconate', 'Lomefloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190804/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190577, 'Ferrous gluconate', 'Magaldrate', 'Moderate', 'INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190805/', '[1] Gugler R, Allgayer H "Effects of antacids on the clinical pharmacokinetics of drugs. An update." Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA "In-vitro interactions of oral hemantics and antacid suspensions." Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA "In-vitro interactions of oral hematinics." Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM "Effect of aluminum hydroxide on iron absorption." Kidney Int 8 (1975): 417[5] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L "Influence of a liquid antacid on the absorption of different iron salts." Scand J Haematol Suppl 28 (1976): 65-77[7] O''Neil-Cutting MA, Crosby WH "The effect of antacids on the absorption of simultaneously ingested iron." JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R "Effect of magnesium hydroxide on iron absorption after ferrous sulfate." Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF "Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial." Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ "Effect of orally administered magnesium hydroxide in experimental iron intoxication." J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH "Effect of phosphate binders on supplemental iron absorption in healthy subjects." J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE "Inhibition of iron absorption by magnesium trisilicate." Med J Aust 2 (1969): 95-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190578, 'Ferrous gluconate', 'Magnesium carbonate', 'Moderate', 'INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190806/', '[1] Gugler R, Allgayer H "Effects of antacids on the clinical pharmacokinetics of drugs. An update." Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA "In-vitro interactions of oral hemantics and antacid suspensions." Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA "In-vitro interactions of oral hematinics." Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM "Effect of aluminum hydroxide on iron absorption." Kidney Int 8 (1975): 417[5] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L "Influence of a liquid antacid on the absorption of different iron salts." Scand J Haematol Suppl 28 (1976): 65-77[7] O''Neil-Cutting MA, Crosby WH "The effect of antacids on the absorption of simultaneously ingested iron." JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R "Effect of magnesium hydroxide on iron absorption after ferrous sulfate." Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF "Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial." Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ "Effect of orally administered magnesium hydroxide in experimental iron intoxication." J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH "Effect of phosphate binders on supplemental iron absorption in healthy subjects." J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE "Inhibition of iron absorption by magnesium trisilicate." Med J Aust 2 (1969): 95-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190579, 'Ferrous gluconate', 'Magnesium hydroxide', 'Moderate', 'INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190807/', '[1] Gugler R, Allgayer H "Effects of antacids on the clinical pharmacokinetics of drugs. An update." Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA "In-vitro interactions of oral hemantics and antacid suspensions." Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA "In-vitro interactions of oral hematinics." Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM "Effect of aluminum hydroxide on iron absorption." Kidney Int 8 (1975): 417[5] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L "Influence of a liquid antacid on the absorption of different iron salts." Scand J Haematol Suppl 28 (1976): 65-77[7] O''Neil-Cutting MA, Crosby WH "The effect of antacids on the absorption of simultaneously ingested iron." JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R "Effect of magnesium hydroxide on iron absorption after ferrous sulfate." Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF "Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial." Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ "Effect of orally administered magnesium hydroxide in experimental iron intoxication." J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH "Effect of phosphate binders on supplemental iron absorption in healthy subjects." J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE "Inhibition of iron absorption by magnesium trisilicate." Med J Aust 2 (1969): 95-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190580, 'Ferrous gluconate', 'Nalidixic acid', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of nalidixic acid. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of nalidixic acid by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190808/', '[1] "Product Information. NegGram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190581, 'Ferrous gluconate', 'Oxytetracycline', 'Moderate', 'The bioavailability of oral tetracyclines and iron salts may be significantly decreased during concurrent administration. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the iron cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'Coadministration of a tetracycline with any iron-containing product should be avoided if possible.', NULL, 'Coadministration of a tetracycline with any iron-containing product should be avoided if possible. Otherwise, patients should be advised to stagger the times of administration by at least three to four hours, although separating the doses may not prevent the interaction with doxycycline.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190809/', '[1] Gothoni G, Neuvonen PJ, Mattila M, Hackman R "Iron-tetracycline interaction: effect of time interval between the drugs." Acta Med Scand 191 (1972): 409-11[2] Campbell NR, Hasinoff BB "Iron supplements: a common cause of drug interactions." Br J Clin Pharmacol 31 (1991): 251-5[3] "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc., Boston, MA.[4] Neuvonen PJ "Interactions with the absorption of tetracyclines." Drugs 11 (1976): 45-54[5] Venho VM, Salonen RO, Mattila MJ "Modification of the pharmacokinetics of doxycycline in man by ferrous sulphate or charcoal." Eur J Clin Pharmacol 14 (1978): 277-80[6] Neuvonen PJ, Gothoni G, Hackman R, Bjorksten K "Interference of iron with the absorption of tetracyclines in man." Br Med J 4 (1970): 532-4[7] "Product Information. Minocin (minocycline)." Lederle Laboratories, Wayne, NJ.[8] Greenberger NJ "Absorption of tetracyclines: interference by iron." Ann Intern Med 74 (1971): 792-3[9] "Product Information. Seysara (sarecycline)." Allergan Inc, Irvine, CA.[10] Neuvonen PJ, Penttila O "Effect of oral ferrous sulphate on the half-life of doxycycline in man." Eur J Clin Pharmacol 7 (1974): 361-3[11] Bateman FJ "Effects of tetracyclines." Br Med J 4 (1970): 802[12] "Product Information. Achromycin (tetracycline)." Lederle Laboratories, Wayne, NJ.[13] "Product Information. Declomycin (demeclocycline)." Lederle Laboratories, Wayne, NJ.[14] "Product Information. Feosol Tablets (ferrous sulfate)." SmithKline Beecham, Philadelphia, PA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190582, 'Ferrous gluconate', 'Saw palmetto', 'Minor', 'The tannic acid present in some herbs like St. John''s wort and saw palmetto may inhibit the absorption of iron. The administration of these herbs and iron-containing supplements should be separated by several hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190810/', '[1] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190583, 'Ferrous gluconate', 'Sparfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190811/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190584, 'Ferrous gluconate', 'St. John''s Wort', 'Minor', 'The tannic acid present in some herbs like St. John''s wort and saw palmetto may inhibit the absorption of iron. The administration of these herbs and iron-containing supplements should be separated by several hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190812/', '[1] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190585, 'Ferrous gluconate', 'Tiludronic acid', 'Moderate', 'INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.', NULL, 'Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.', NULL, 'Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190813/', '[1] "Product Information. Boniva (ibandronate)." Roche Laboratories, Nutley, NJ.[2] "Product Information. Fosamax (alendronate)." Merck & Co, Inc, West Point, PA.[3] "Product Information. Skelid (tilundronate)." Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF "Nutrient-drug interactions." Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] "Product Information. Bonefos (clodronate)." Rhone-Poulenc Rorer Canada Inc, Laval, QC.[6] "Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] "Product Information. Skelid (tilundronate)." Sanofi Winthrop Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190586, 'Ferrous gluconate', 'Trovafloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190814/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190587, 'Ferrous gluconate', 'Vitamin E', 'Moderate', 'Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia.', NULL, 'Patients receiving iron therapy for iron deficiency anemia should be monitored for potentially reduced hematologic response if vitamin E is administered concomitantly.', NULL, 'Patients receiving iron therapy for iron deficiency anemia should be monitored for potentially reduced hematologic response if vitamin E is administered concomitantly.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190815/', '[1] Melhorn DK, Gross S "Relationships between iron-dextran and vitamin E in iron deficiency anemia in children." J Lab Clin Med 74 (1969): 789-802[2] Graeber JE, Williams ML, Oski FA "The use of intramuscular vitamin E in the premature infant. Optimum dose and iron interaction." J Pediatr 90 (1977): 282-4', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190588, 'Ferrous gluconate', 'Zinc gluconate', 'Minor', 'Iron and zinc may reduce each other''s absorption when they are coadministered orally. The mechanism of interaction is unknown. In clinical studies, concurrent supplementation with iron and zinc was associated with reduced efficacy in improving the growth and iron and zinc status of malnourished infants compared to supplementation with either one alone. In any case, the clinical significance is probably minimal in healthy individuals. However, monitoring for reduced therapeutic response may be advisable in malnourished patients. Limited data suggest that the magnitude of the interaction may be lessened by separating the times of administration of each by 12 hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190816/', '[1] Sreedhar B "Conflicting evidence of iron and zinc interactions in humans: does iron affect zinc absorption?" Am J Clin Nutr 78 (2003): 1226; author reply 1226-7[2] Lind T, Lonnerdal B, Stenlund H, et al. "A community-based randomized controlled trial of iron and zinc supplementation in Indonesian infants: interactions between iron and zinc." Am J Clin Nutr 77 (2003): 883-90', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190589, 'Ferrous sulfate anhydrous', 'Aluminum hydroxide', 'Moderate', 'INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190817/', '[1] Gugler R, Allgayer H "Effects of antacids on the clinical pharmacokinetics of drugs. An update." Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA "In-vitro interactions of oral hemantics and antacid suspensions." Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA "In-vitro interactions of oral hematinics." Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM "Effect of aluminum hydroxide on iron absorption." Kidney Int 8 (1975): 417[5] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L "Influence of a liquid antacid on the absorption of different iron salts." Scand J Haematol Suppl 28 (1976): 65-77[7] O''Neil-Cutting MA, Crosby WH "The effect of antacids on the absorption of simultaneously ingested iron." JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R "Effect of magnesium hydroxide on iron absorption after ferrous sulfate." Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF "Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial." Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ "Effect of orally administered magnesium hydroxide in experimental iron intoxication." J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH "Effect of phosphate binders on supplemental iron absorption in healthy subjects." J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE "Inhibition of iron absorption by magnesium trisilicate." Med J Aust 2 (1969): 95-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190590, 'Ferrous sulfate anhydrous', 'Cinoxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190818/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190591, 'Ferrous sulfate anhydrous', 'Enoxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190819/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190592, 'Gallium chloride Ga-67', 'Ferrous sulfate anhydrous', 'Moderate', 'The concomitant use of certain medications (e.g., cytarabine, fluorouracil, methotrexate, and iron) may cause displacement of gallium citrate Ga-67 from plasma protein binding sites and interfere with test results.', NULL, 'Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.', NULL, 'Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.', 'Distribution', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190820/', '[1] "Product Information. Gallium Citrate Ga-67 (gallium citrate 67 Ga (gallium citrate 67Ga))." Bristol-Myers Squibb, Princeton, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190593, 'Gatifloxacin', 'Ferrous sulfate anhydrous', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190821/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190594, 'Grepafloxacin', 'Ferrous sulfate anhydrous', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190822/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190595, 'Ferrous sulfate anhydrous', 'Lomefloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190823/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190596, 'Ferrous sulfate anhydrous', 'Magaldrate', 'Moderate', 'INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190824/', '[1] Gugler R, Allgayer H "Effects of antacids on the clinical pharmacokinetics of drugs. An update." Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA "In-vitro interactions of oral hemantics and antacid suspensions." Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA "In-vitro interactions of oral hematinics." Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM "Effect of aluminum hydroxide on iron absorption." Kidney Int 8 (1975): 417[5] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L "Influence of a liquid antacid on the absorption of different iron salts." Scand J Haematol Suppl 28 (1976): 65-77[7] O''Neil-Cutting MA, Crosby WH "The effect of antacids on the absorption of simultaneously ingested iron." JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R "Effect of magnesium hydroxide on iron absorption after ferrous sulfate." Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF "Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial." Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ "Effect of orally administered magnesium hydroxide in experimental iron intoxication." J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH "Effect of phosphate binders on supplemental iron absorption in healthy subjects." J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE "Inhibition of iron absorption by magnesium trisilicate." Med J Aust 2 (1969): 95-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190597, 'Ferrous sulfate anhydrous', 'Magnesium carbonate', 'Moderate', 'INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190825/', '[1] Gugler R, Allgayer H "Effects of antacids on the clinical pharmacokinetics of drugs. An update." Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA "In-vitro interactions of oral hemantics and antacid suspensions." Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA "In-vitro interactions of oral hematinics." Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM "Effect of aluminum hydroxide on iron absorption." Kidney Int 8 (1975): 417[5] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L "Influence of a liquid antacid on the absorption of different iron salts." Scand J Haematol Suppl 28 (1976): 65-77[7] O''Neil-Cutting MA, Crosby WH "The effect of antacids on the absorption of simultaneously ingested iron." JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R "Effect of magnesium hydroxide on iron absorption after ferrous sulfate." Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF "Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial." Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ "Effect of orally administered magnesium hydroxide in experimental iron intoxication." J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH "Effect of phosphate binders on supplemental iron absorption in healthy subjects." J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE "Inhibition of iron absorption by magnesium trisilicate." Med J Aust 2 (1969): 95-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190598, 'Ferrous sulfate anhydrous', 'Magnesium hydroxide', 'Moderate', 'INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190826/', '[1] Gugler R, Allgayer H "Effects of antacids on the clinical pharmacokinetics of drugs. An update." Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA "In-vitro interactions of oral hemantics and antacid suspensions." Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA "In-vitro interactions of oral hematinics." Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM "Effect of aluminum hydroxide on iron absorption." Kidney Int 8 (1975): 417[5] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L "Influence of a liquid antacid on the absorption of different iron salts." Scand J Haematol Suppl 28 (1976): 65-77[7] O''Neil-Cutting MA, Crosby WH "The effect of antacids on the absorption of simultaneously ingested iron." JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R "Effect of magnesium hydroxide on iron absorption after ferrous sulfate." Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF "Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial." Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ "Effect of orally administered magnesium hydroxide in experimental iron intoxication." J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH "Effect of phosphate binders on supplemental iron absorption in healthy subjects." J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE "Inhibition of iron absorption by magnesium trisilicate." Med J Aust 2 (1969): 95-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190599, 'Ferrous sulfate anhydrous', 'Nalidixic acid', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of nalidixic acid. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of nalidixic acid by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190827/', '[1] "Product Information. NegGram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190600, 'Ferrous sulfate anhydrous', 'Oxytetracycline', 'Moderate', 'The bioavailability of oral tetracyclines and iron salts may be significantly decreased during concurrent administration. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the iron cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'Coadministration of a tetracycline with any iron-containing product should be avoided if possible.', NULL, 'Coadministration of a tetracycline with any iron-containing product should be avoided if possible. Otherwise, patients should be advised to stagger the times of administration by at least three to four hours, although separating the doses may not prevent the interaction with doxycycline.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190828/', '[1] Gothoni G, Neuvonen PJ, Mattila M, Hackman R "Iron-tetracycline interaction: effect of time interval between the drugs." Acta Med Scand 191 (1972): 409-11[2] Campbell NR, Hasinoff BB "Iron supplements: a common cause of drug interactions." Br J Clin Pharmacol 31 (1991): 251-5[3] "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc., Boston, MA.[4] Neuvonen PJ "Interactions with the absorption of tetracyclines." Drugs 11 (1976): 45-54[5] Venho VM, Salonen RO, Mattila MJ "Modification of the pharmacokinetics of doxycycline in man by ferrous sulphate or charcoal." Eur J Clin Pharmacol 14 (1978): 277-80[6] Neuvonen PJ, Gothoni G, Hackman R, Bjorksten K "Interference of iron with the absorption of tetracyclines in man." Br Med J 4 (1970): 532-4[7] "Product Information. Minocin (minocycline)." Lederle Laboratories, Wayne, NJ.[8] Greenberger NJ "Absorption of tetracyclines: interference by iron." Ann Intern Med 74 (1971): 792-3[9] "Product Information. Seysara (sarecycline)." Allergan Inc, Irvine, CA.[10] Neuvonen PJ, Penttila O "Effect of oral ferrous sulphate on the half-life of doxycycline in man." Eur J Clin Pharmacol 7 (1974): 361-3[11] Bateman FJ "Effects of tetracyclines." Br Med J 4 (1970): 802[12] "Product Information. Achromycin (tetracycline)." Lederle Laboratories, Wayne, NJ.[13] "Product Information. Declomycin (demeclocycline)." Lederle Laboratories, Wayne, NJ.[14] "Product Information. Feosol Tablets (ferrous sulfate)." SmithKline Beecham, Philadelphia, PA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190601, 'Ferrous sulfate anhydrous', 'Saw palmetto', 'Minor', 'The tannic acid present in some herbs like St. John''s wort and saw palmetto may inhibit the absorption of iron. The administration of these herbs and iron-containing supplements should be separated by several hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190829/', '[1] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190602, 'Ferrous sulfate anhydrous', 'Sparfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190830/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190603, 'Ferrous sulfate anhydrous', 'St. John''s Wort', 'Minor', 'The tannic acid present in some herbs like St. John''s wort and saw palmetto may inhibit the absorption of iron. The administration of these herbs and iron-containing supplements should be separated by several hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190831/', '[1] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190604, 'Ferrous sulfate anhydrous', 'Tiludronic acid', 'Moderate', 'INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.', NULL, 'Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.', NULL, 'Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190832/', '[1] "Product Information. Boniva (ibandronate)." Roche Laboratories, Nutley, NJ.[2] "Product Information. Fosamax (alendronate)." Merck & Co, Inc, West Point, PA.[3] "Product Information. Skelid (tilundronate)." Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF "Nutrient-drug interactions." Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] "Product Information. Bonefos (clodronate)." Rhone-Poulenc Rorer Canada Inc, Laval, QC.[6] "Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] "Product Information. Skelid (tilundronate)." Sanofi Winthrop Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190605, 'Ferrous sulfate anhydrous', 'Trovafloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190833/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190606, 'Ferrous sulfate anhydrous', 'Vitamin E', 'Moderate', 'Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia.', NULL, 'Patients receiving iron therapy for iron deficiency anemia should be monitored for potentially reduced hematologic response if vitamin E is administered concomitantly.', NULL, 'Patients receiving iron therapy for iron deficiency anemia should be monitored for potentially reduced hematologic response if vitamin E is administered concomitantly.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190834/', '[1] Melhorn DK, Gross S "Relationships between iron-dextran and vitamin E in iron deficiency anemia in children." J Lab Clin Med 74 (1969): 789-802[2] Graeber JE, Williams ML, Oski FA "The use of intramuscular vitamin E in the premature infant. Optimum dose and iron interaction." J Pediatr 90 (1977): 282-4', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190607, 'Ferrous sulfate anhydrous', 'Zinc gluconate', 'Minor', 'Iron and zinc may reduce each other''s absorption when they are coadministered orally. The mechanism of interaction is unknown. In clinical studies, concurrent supplementation with iron and zinc was associated with reduced efficacy in improving the growth and iron and zinc status of malnourished infants compared to supplementation with either one alone. In any case, the clinical significance is probably minimal in healthy individuals. However, monitoring for reduced therapeutic response may be advisable in malnourished patients. Limited data suggest that the magnitude of the interaction may be lessened by separating the times of administration of each by 12 hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190835/', '[1] Sreedhar B "Conflicting evidence of iron and zinc interactions in humans: does iron affect zinc absorption?" Am J Clin Nutr 78 (2003): 1226; author reply 1226-7[2] Lind T, Lonnerdal B, Stenlund H, et al. "A community-based randomized controlled trial of iron and zinc supplementation in Indonesian infants: interactions between iron and zinc." Am J Clin Nutr 77 (2003): 883-90', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190608, 'Abarelix', 'Magnesium hydroxide', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190836/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190609, 'Aluminum hydroxide', 'Acetohexamide', 'Moderate', 'INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.', NULL, 'Sulfonylureas should be administered at least two hours before or after antacids when possible.', NULL, 'Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190837/', '[1] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[2] Prendergast BD "Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents." Clin Pharm 3 (1984): 473-85[3] "Product Information. Micronase (glyburide)." Pharmacia and Upjohn, Kalamazoo, MI.[4] Kivisto KT, Neuvonen PJ "Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide." Eur J Clin Pharmacol 42 (1992): 675-80[5] Kolterman OG "Glyburide in non-insulin-dependent diabetes: an update." Clin Ther 14 (1992): 196-213[6] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[7] Kivisto KT, Neuvonen PJ "Enhancement of absorption and effect of glipizide by magnesium hydroxide." Clin Pharmacol Ther 49 (1991): 39-43[8] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[9] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[15] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[16] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[17] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190610, 'Astemizole', 'Magnesium hydroxide', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190838/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190611, 'Aluminum hydroxide', 'Bacampicillin', 'Moderate', 'Coadministration with antacids, H2-receptor antagonists, proton pump inhibitors, or other agents with acid neutralizing or reducing effects may decrease the oral bioavailability and plasma concentrations of ampicillin from bacampicillin. The exact mechanism of interaction is unknown but may be related to degradation of the prodrug when gastric pH is increased.', NULL, 'The possibility of a reduced or subtherapeutic response to bacampicillin should be considered during coadministration with antacids, H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH.', NULL, 'The possibility of a reduced or subtherapeutic response to bacampicillin should be considered during coadministration with antacids, H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. Preferably, these agents should be avoided during therapy with bacampicillin, or an alternative antibiotic be prescribed if these medications cannot be discontinued. Patients treated with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) may minimize the effects of the interaction with bacampicillin by separating the times of administration by at least 2 hours.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190839/', '[1] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[2] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS "Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil." Br J Clin Pharmacol 18 (1984): 535-9', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190612, 'Bendroflumethiazide', 'Magnesium hydroxide', 'Moderate', 'The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190840/', '[1] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[2] Blumenthal M, Goldberg A, Brinckmann J, eds. "Herbal Medicine: Expanded Commission E Monographs." Newton, MA: Integrative Medicine Communications (2000):[3] Atsmon J, Dolev E "Drug-induced hypomagnesaemia : scope and management." Drug Saf 28 (2005): 763-88[4] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8[5] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190613, 'Benzthiazide', 'Magnesium hydroxide', 'Moderate', 'The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190841/', '[1] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[2] Blumenthal M, Goldberg A, Brinckmann J, eds. "Herbal Medicine: Expanded Commission E Monographs." Newton, MA: Integrative Medicine Communications (2000):[3] Atsmon J, Dolev E "Drug-induced hypomagnesaemia : scope and management." Drug Saf 28 (2005): 763-88[4] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8[5] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190614, 'Aluminum hydroxide', 'Bromfenac', 'Minor', 'The concomitant administration of bromfenac with an aluminum hydroxide-containing antacid has led to a reduction in peak plasma levels of bromfenac by 36%. The overall extent of absorption was not affected. No special precautions appear necessary.', NULL, '-', NULL, '-', 'Others', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190842/', '[1] "Product Information. Duract (bromfenac)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Duract (bromfenac)." Wyeth-Ayerst Laboratories, Philadelphia, PA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190615, 'Aluminum hydroxide', 'Cabotegravir', 'Moderate', 'INTERVAL: Coadministration with antacids may decrease the bioavailability of oral cabotegravir. The proposed mechanism likely involves a pH-dependent reduction in dissolution and absorption of cabotegravir, which is poorly soluble over a wide pH range. The interaction has not been studied specifically with antacids.', NULL, 'To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of cabotegravir, antacids or other medications that contain antacids (e.', NULL, 'To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of cabotegravir, antacids or other medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) should be administered at least 2 hours before or 4 hours after the oral cabotegravir dose.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190843/', '[1] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190616, 'Iron', 'Aluminum hydroxide', 'Moderate', 'INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190844/', '[1] Gugler R, Allgayer H "Effects of antacids on the clinical pharmacokinetics of drugs. An update." Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA "In-vitro interactions of oral hemantics and antacid suspensions." Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA "In-vitro interactions of oral hematinics." Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM "Effect of aluminum hydroxide on iron absorption." Kidney Int 8 (1975): 417[5] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L "Influence of a liquid antacid on the absorption of different iron salts." Scand J Haematol Suppl 28 (1976): 65-77[7] O''Neil-Cutting MA, Crosby WH "The effect of antacids on the absorption of simultaneously ingested iron." JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R "Effect of magnesium hydroxide on iron absorption after ferrous sulfate." Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF "Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial." Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ "Effect of orally administered magnesium hydroxide in experimental iron intoxication." J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH "Effect of phosphate binders on supplemental iron absorption in healthy subjects." J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE "Inhibition of iron absorption by magnesium trisilicate." Med J Aust 2 (1969): 95-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190617, 'Aluminum hydroxide', 'Cinoxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190845/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190618, 'Cisapride', 'Magnesium hydroxide', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190846/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190619, 'Dicoumarol', 'Magnesium hydroxide', 'Minor', 'Limited data suggest that concurrent administration of magnesium hydroxide or magnesium oxide may increase the oral bioavailability of dicumarol. The mechanism of interaction is unknown. Given the widespread use of magnesium antacids and the limited evidence of a clinically significant interaction, no special precautions appear to be necessary when dicumarol is prescribed with magnesium hydroxide or magnesium oxide. However, a switch to a different antacid may be appropriate if an interaction is suspected.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190847/', '[1] D''Arcy PF, McElnay JC "Drug-antacid interactions: assessment of clinical importance." Drug Intell Clin Pharm 21 (1987): 607-17[2] Ambre JJ, Fischer LJ "Effect of coadministration of aluminum and magnesium hydroxides on absorption of anticoagulants in man." Clin Pharmacol Ther 14 (1973): 231-7[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Guo LQ, Yamazoe Y "Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines." Acta Pharmacol Sin 25 (2004): 129-36[6] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3[7] Suvarna R, Pirmohamed M, Henderson L "Possible interaction between warfarin and cranberry juice." BMJ 327 (2003): 1454[8] Lee M, Schwartz RN, Sharifi R "Warfarin resistance and vitamin K." Ann Intern Med 94 (1981): 140-1[9] Beckey NP, Korman LB, Parra D "Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy." Pharmacotherapy 19 (1999): 1075-9[10] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G "Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy." Eur J Clin Pharmacol 63 (2007): 565-70[11] Kempin SJ "Warfarin resistance caused by broccoli." N Engl J Med 308 (1983): 1229-30[12] Westfall LK "An unrecognized cause of warfarin resistance." Drug Intell Clin Pharm 15 (1981): 131[13] Kuykendall JR, Houle MD, Rhodes RS "Possible warfarin failure due to interaction with smokeless tobacco." Ann Pharmacother 38 (2004): 595-7[14] Walker FB "Myocardial infarction after diet-induced warfarin resistance." Arch Intern Med 144 (1984): 2089-90[15] Pedersen FM, Hamberg O, Hess K, Ovesen L "The effect of dietary vitamin K on warfarin-induced anticoagulation." J Intern Med 229 (1991): 517-20[16] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[17] Griffith LD, Olvey SE, Triplett WC "Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus." Crit Care Med 10 (1982): 799-800[18] Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83[19] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines "Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm." ([2003 Sept]):[20] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[21] Karlson B, Leijd B, Hellstrom K "On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment." Acta Med Scand 220 (1986): 347-50[22] O''Reilly RA, Rytand DA ""Resistance" to warfarin due to unrecognized vitamin K supplementation." N Engl J Med 303 (1980): 160-1[23] Kazmier FJ, Spittell JA Jr "Coumarin drug interactions." Mayo Clin Proc 45 (1970): 249-55[24] Cambria-Kiely JA "Effect of soy milk on warfarin efficacy." Ann Pharmacother 36 (2002): 1893-6[25] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT "Anticoagulation instability with life-threatening complication after dietary modification." Postgrad Med J 66 (1990): 855-7[26] Hamann GL, Campbell JD, George CM "Warfarin-cranberry juice interaction." Ann Pharmacother 45 (2011): e17[27] Monterrey-Rodriguez J "Interaction between warfarin and mango fruit." Ann Pharmacother 36 (2002): 940-1[28] Griffiths AP, Beddall A, Pegler S "Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin." J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P "Case report: Cranberry juice and warfarin." Home Healthc Nurse 29 (2011): 92-7[30] MacLeod SM, Sellers EM "Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants." Drugs 11 (1976): 461-70[31] Jarvis S, Li C, Bogle RG "Possible interaction between pomegranate juice and warfarin." Emerg Med J 27 (2010): 74-5[32] Parr MD, Record KE, Griffith GL, et al "Effect of enteral nutrition on warfarin therapy." Clin Pharm 1 (1982): 274-6[33] Sullivan DM, Ford MA, Boyden TW "Grapefruit juice and the response to warfarin." Am J Health Syst Pharm 55 (1998): 1581-3[34] Howard PA, Hannaman KN "Warfarin resistance linked to enteral nutrition products." J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW "Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding." Am J Ther 13 (2006): 283-4[36] Harrell CC, Kline SS "Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin." Jama J Am Med Assn 282 (1999): 1133-4[37] Grant P "Warfarin and cranberry juice: an interaction?" J Heart Valve Dis 13 (2004): 25-6[38] Ge B, Zhang Z, Zuo Z "Updates on the clinical evidenced herb-warfarin interactions." Evid Based Complement Alternat Med 2014 (2014): 957362[39] Zallman JA, Lee DP, Jeffrey PL "Liquid nutrition as a cause of warfarin resistance." Am J Hosp Pharm 38 (1981): 1174[40] Watson AJ, Pegg M, Green JR "Enteral feeds may antagonise warfarin." Br Med J 288 (1984): 557[41] Andersen P, Godal HC "Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K." Acta Med Scand 198 (1975): 269-70', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190620, 'Aluminum hydroxide', 'Digitoxin', 'Minor', 'Concurrent administration of antacids may decrease the oral bioavailability of digoxin and digitoxin. When digoxin and digitoxin are coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering digoxin or digitoxin at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190848/', '[1] McElnay JC, Harron DW, D''Arcy PF, Eagle MR "Interaction of digoxin with antacid constituents." Br Med J 1 (1978): 1554[2] Marcus FI "Pharmacokinetic interactions between digoxin and other drugs." J Am Coll Cardiol 5 (1985): a82-90[3] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[4] Saris SD, Lowenthal DT, Affrime MB "Steady-state digoxin concentration during oral mexiletine administration." Curr Ther Res Clin Exp 34 (1983): 662-6[5] Rodin SM, Johnson BF "Pharmacokinetic interactions with digoxin." Clin Pharmacokinet 15 (1988): 227-44[6] Allen MD, Greenblatt DJ, Harmatz JS, Smith TW "Effect of magnesium--aluminum hydroxide and kaolin--pectin on absorption of digoxin from tablets and capsules." J Clin Pharmacol 21 (1981): 26-30[7] Bonelli J, Hruby K, Magometschnigg D, Hitzenberger G, Kaik G "The bio-availability of beta-acetyldigoxine alone and combined with aluminum hydroxide and magnesium hydroxide (Alucol)." Int J Clin Pharmacol Biopharm 15 (1977): 337-9[8] Brown DD, Juhl RP "Decreased bioavailability of digoxin due to antacids and kaolin-pectin." N Engl J Med 295 (1976): 1034-7[9] D''Arcy PF, McElnay JC "Drug-antacid interactions: assessment of clinical importance." Drug Intell Clin Pharm 21 (1987): 607-17', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190621, 'Enoxacin', 'Aluminum hydroxide', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190849/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190622, 'Gatifloxacin', 'Aluminum hydroxide', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190850/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190623, 'Grepafloxacin', 'Aluminum hydroxide', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190851/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190624, 'Halofantrine', 'Magnesium hydroxide', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190852/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190625, 'Hydroflumethiazide', 'Magnesium hydroxide', 'Moderate', 'The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190853/', '[1] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[2] Blumenthal M, Goldberg A, Brinckmann J, eds. "Herbal Medicine: Expanded Commission E Monographs." Newton, MA: Integrative Medicine Communications (2000):[3] Atsmon J, Dolev E "Drug-induced hypomagnesaemia : scope and management." Drug Saf 28 (2005): 763-88[4] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8[5] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190626, 'Iron protein succinylate', 'Aluminum hydroxide', 'Moderate', 'INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', NULL, 'To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190854/', '[1] Gugler R, Allgayer H "Effects of antacids on the clinical pharmacokinetics of drugs. An update." Clin Pharmacokinet 18 (1990): 210-9[2] Coste JF, De Barbi VA, Keil LB, Needle MA "In-vitro interactions of oral hemantics and antacid suspensions." Curr Ther Res Clin Exp 22 (1977): 205-16[3] Coste JF, de Bari VA, Keil LB, Needle MA "In-vitro interactions of oral hematinics." Curr Ther Res Clin Exp 22 (1977): 205-15[4] Rastogi SP, Padilla F, Boyd CM "Effect of aluminum hydroxide on iron absorption." Kidney Int 8 (1975): 417[5] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[6] Ekenved G, Halvorsen L, Solvell L "Influence of a liquid antacid on the absorption of different iron salts." Scand J Haematol Suppl 28 (1976): 65-77[7] O''Neil-Cutting MA, Crosby WH "The effect of antacids on the absorption of simultaneously ingested iron." JAMA 255 (1986): 1468-70[8] Wallace KL, Curry SC, LoVecchio F, Raschke R "Effect of magnesium hydroxide on iron absorption after ferrous sulfate." Ann Emerg Med 34 (1999): 685-6[9] Snyder BK, Clark RF "Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: A randomized controlled trial." Ann Emerg Med 33 (1999): 400-5[10] Corby DG, McCullen AH, Chadwick EW, Decker WJ "Effect of orally administered magnesium hydroxide in experimental iron intoxication." J Toxicol Clin Toxicol 23 (1985-86): 489-99[11] Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH "Effect of phosphate binders on supplemental iron absorption in healthy subjects." J Clin Pharmacol 42 (2002): 1171-6[12] Hall GJ, Davis AE "Inhibition of iron absorption by magnesium trisilicate." Med J Aust 2 (1969): 95-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190627, 'Isoniazid', 'Aluminum hydroxide', 'Minor', 'Aluminum salts may slightly decrease the absorption of isoniazid. The mechanism is not known. To prevent this interaction, isoniazid should be administered one to two hours before administration of an aluminum-containing product.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190855/', '[1] Hurwitz A, Schlozman DL "Effects of antacids on gastrointestional absorption of isoniazid in rat and man." Am Rev Respir Dis 109 (1974): 41-7[2] Hava M, Hurwitz A "The relaxing effect of aluminum and lanthanum on rat and human gastric smooth muscle in vitro." Eur J Pharmacol 156 (1973): 156-61[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Self TH, Chrisman CR, Baciewicz AM, Bronze MS "Isoniazid drug and food interactions." Am J Med Sci 317 (1999): 304-11[5] Uragoda CG, Kottegoda SR "Adverse reactions to isoniazid on ingestion of fish with a high histamine content." Tubercle 58 (1977): 83-9[6] "Product Information. INH (isoniazid)." Ciba Pharmaceuticals, Summit, NJ.[7] Smith CK, Durack DT "Isoniazid and reaction to cheese." Ann Intern Med 88 (1978): 520-1[8] Dimartini A "Isoniazid, tricyclics and the ''''cheese reaction''''." Int Clin Psychopharmacol 10 (1995): 197-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190628, 'Aluminum hydroxide', 'Lomefloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190856/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190629, 'Aluminum hydroxide', 'Nalidixic acid', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of nalidixic acid. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of nalidixic acid by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190857/', '[1] "Product Information. NegGram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190630, 'Aluminum hydroxide', 'Oxytetracycline', 'Moderate', 'INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190858/', '[1] Nguyen VX, Nix DE, Gillikin S, Schentag JJ "Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline." Antimicrob Agents Chemother 33 (1989): 434-6[2] Gotz VP, Ryerson GG "Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease." Drug Intell Clin Pharm 20 (1986): 694-6[3] Upton RA "Pharmacokinetic interactions between theophylline and other medication (Part I)." Clin Pharmacokinet 20 (1991): 66-80[4] "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc., Boston, MA.[5] "Product Information. Seysara (sarecycline)." Allergan Inc, Irvine, CA.[6] McCormack JP, Reid SE, Lawson LM "Theophylline toxicity induced by tetracycline." Clin Pharm 9 (1990): 546-9[7] Neuvonen PJ "Interactions with the absorption of tetracyclines." Drugs 11 (1976): 45-54[8] D''Arcy PF, McElnay JC "Drug-antacid interactions: assessment of clinical importance." Drug Intell Clin Pharm 21 (1987): 607-17[9] "Product Information. Declomycin (demeclocycline)." Lederle Laboratories, Wayne, NJ.[10] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[11] Garty M, Hurwitz A "Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline." Clin Pharmacol Ther 28 (1980): 203-7[12] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[13] Covington TR, Lawson LC, Young LL, eds. "Handbook of Nonprescription Drugs. 10th ed." Washington, DC: American Pharmaceutical Association (1993):[14] "Product Information. Achromycin (tetracycline)." Lederle Laboratories, Wayne, NJ.[15] "Product Information. Declomycin (demeclocycline)." Lederle Laboratories, Wayne, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190631, 'Polythiazide', 'Magnesium hydroxide', 'Moderate', 'The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190859/', '[1] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[2] Blumenthal M, Goldberg A, Brinckmann J, eds. "Herbal Medicine: Expanded Commission E Monographs." Newton, MA: Integrative Medicine Communications (2000):[3] Atsmon J, Dolev E "Drug-induced hypomagnesaemia : scope and management." Drug Saf 28 (2005): 763-88[4] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8[5] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190632, 'Probucol', 'Magnesium hydroxide', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190860/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190633, 'Aluminum hydroxide', 'Ranitidine (bismuth citrate)', 'Minor', 'Antacids and some aluminum, calcium, and magnesium salts may decrease the plasma concentrations of H2-receptor antagonists during oral coadministration. The mechanism of interaction is unknown, but may involve reduced oral absorption due to increased gastric pH. The clinical significance has not been established. As a precaution, patients may consider taking H2-receptor antagonists one to two hours before antacids.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190861/', '[1] Barzaghi N, Gatti G, Crema F, Perucca E "Impaired bioavailability of famotidine given concurrently with a potent antacid." J Clin Pharmacol 29 (1989): 670-2[2] Albin H, Vincon G, Begaud B, Bistue C, Perez P "Effect of aluminum phosphate on the bioavailability of ranitidine." Eur J Clin Pharmacol 32 (1987): 97-9[3] Covington TR, Lawson LC, Young LL, eds. "Handbook of Nonprescription Drugs. 10th ed." Washington, DC: American Pharmaceutical Association (1993):[4] Donn KH, Eshelman FN, Plachetka JR, et al "The effects of antacid and propantheline on the absorption of oral ranitidine." Pharmacotherapy 4 (1984): 89-92[5] Bachmann KA, Sullivan TJ, Jauregui L, Reese J, Miller K, Levine L "Drug interactions of h-2-receptor antagonists." Scand J Gastroenterol 29 (1994): 14-9[6] Bodemar G, Norlander B, Walan A "Diminished absorption of cimetidine caused by antacids." Lancet 02/24/79 (1979): 444-5[7] Russell WL, Lopez LM, Normann SA, et al "Effect of antacids on predicted steady-state cimetidine concentrations." Dig Dis Sci 29 (1984): 385-9[8] Shelly DW, Doering PL, Russell WL, Guild RT, Lopez LM, Perrin J "Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing." Drug Intell Clin Pharm 20 (1986): 792-5[9] Steinberg WM, Lewis JH, Katz DM "Antacids inhibit absorption of cimetidine." N Engl J Med 307 (1982): 400-4[10] Lin JH, Chremos AN, Kanovsky SM, Schwartz S, Yeh KC, Kann J "Effects of antacids and food on absorption of famotidine." Br J Clin Pharmacol 24 (1987): 551-3[11] Mihaly GW, Marino AT, Webster LK, Jones DB, Louis WJ, Smallwood RA "High dose of antacid (Mylanta II) reduces bioavailability of ranitidine." Br Med J 285 (1982): 998-9[12] Albin H, Vincon G, Demotes-Mainard F, et al "Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone." Eur J Clin Pharmacol 26 (1984): 271-3', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190634, 'Relugolix', 'Magnesium hydroxide', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190862/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190635, 'Aluminum hydroxide', 'Salicylic acid (sodium)', 'Moderate', 'Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance.', NULL, 'Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.', NULL, 'Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.', 'Excretion', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190863/', '[1] Gaspari F, Vigano G, Locatelli M, Remuzzi G "Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis." Am J Kidney Dis 11 (1988): 338-42[2] Covington TR, Lawson LC, Young LL, eds. "Handbook of Nonprescription Drugs. 10th ed." Washington, DC: American Pharmaceutical Association (1993):[3] Levy G, Lampman T, Kamath BL, Garrettson LK "Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid." N Engl J Med 293 (1975): 323-5[4] Brouwers JRBJ, Desmet PAGM "Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs." Clin Pharmacokinet 27 (1994): 462-85[5] D''Arcy PF, McElnay JC "Drug-antacid interactions: assessment of clinical importance." Drug Intell Clin Pharm 21 (1987): 607-17[6] Miners JO "Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid." Clin Pharmacokinet 17 (1989): 327-44[7] Furst DE "Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications." J Rheumatol Suppl 17 (1988): 58-62[8] Shastri RA "Effect of antacids on salicylate kinetics." Int J Clin Pharmacol Ther Toxicol 23 (1985): 480-4', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190636, 'Aluminum hydroxide', 'Sparfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190864/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190637, 'Terbutaline', 'Magnesium hydroxide', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190865/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190638, 'Terfenadine', 'Magnesium hydroxide', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190866/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190639, 'Aluminum hydroxide', 'Tiludronic acid', 'Moderate', 'INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.', NULL, 'Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.', NULL, 'Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190867/', '[1] "Product Information. Boniva (ibandronate)." Roche Laboratories, Nutley, NJ.[2] "Product Information. Fosamax (alendronate)." Merck & Co, Inc, West Point, PA.[3] "Product Information. Skelid (tilundronate)." Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF "Nutrient-drug interactions." Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] "Product Information. Bonefos (clodronate)." Rhone-Poulenc Rorer Canada Inc, Laval, QC.[6] "Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] "Product Information. Skelid (tilundronate)." Sanofi Winthrop Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190640, 'Aluminum hydroxide', 'Tolbutamide', 'Moderate', 'INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.', NULL, 'Sulfonylureas should be administered at least two hours before or after antacids when possible.', NULL, 'Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190868/', '[1] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[2] Prendergast BD "Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents." Clin Pharm 3 (1984): 473-85[3] "Product Information. Micronase (glyburide)." Pharmacia and Upjohn, Kalamazoo, MI.[4] Kivisto KT, Neuvonen PJ "Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide." Eur J Clin Pharmacol 42 (1992): 675-80[5] Kolterman OG "Glyburide in non-insulin-dependent diabetes: an update." Clin Ther 14 (1992): 196-213[6] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[7] Kivisto KT, Neuvonen PJ "Enhancement of absorption and effect of glipizide by magnesium hydroxide." Clin Pharmacol Ther 49 (1991): 39-43[8] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[9] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[15] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[16] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[17] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190641, 'Trichlormethiazide', 'Magnesium hydroxide', 'Moderate', 'The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190869/', '[1] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[2] Blumenthal M, Goldberg A, Brinckmann J, eds. "Herbal Medicine: Expanded Commission E Monographs." Newton, MA: Integrative Medicine Communications (2000):[3] Atsmon J, Dolev E "Drug-induced hypomagnesaemia : scope and management." Drug Saf 28 (2005): 763-88[4] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8[5] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190642, 'Aluminum hydroxide', 'Trovafloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190870/', '[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5[4] "Product Information. Zagam (sparfloxacin)." Rhone-Poulenc Rorer, Collegeville, PA.[5] "Product Information. Factive (gemifloxacin)." GeneSoft Inc, San Francisco, CA.[6] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H "Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate." Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al "Effect of antacid on absorption of the quinolone lomefloxacin." Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P "Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid." Antimicrob Agents Chemother 33 (1989): 1901-7[12] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH "Ciprofloxacin levels when receiving sucralfate." J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al "Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin." Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR "Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction." Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A "Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers." Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC "Sucralfate significantly reduces ciprofloxacin concentrations in serum." Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT "Different effects of products containing metal ions on the absorption of lomefloxacin." Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT "Effect of sucralfate on absorption of norfloxacin and ofloxacin." Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6[23] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al "Inhibition of enoxacin absorption by antacids or ranitidine." Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE "The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin." Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ "Sucralfate reduces the gastrointestinal absorption of norfloxacin." Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT "Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E "Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers." Antimicrob Agents Chemother 33 (1989): 1841-4[29] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S "The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin." Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H "Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium." Antimicrob Agents Chemother 43 (1999): 1067-71[32] "Product Information. Trovan (trovafloxacin)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190643, 'Aluminum hydroxide', 'Zalcitabine', 'Minor', 'Magnesium and aluminum antacids have been shown to reduce the area under the curve of zalcitabine. The mechanism has not been described but may be due to chelation or alteration in gastrointestinal pH. Zalcitabine should be administered 2 hours prior to a magnesium and/or aluminum-containing antacid. The clinical significance of this interaction is unknown.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190871/', '[1] "Product Information. HIVID (zalcitabine)." Roche Laboratories, Nutley, NJ.[2] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190644, 'Fludeoxyglucose (18F)', 'Microcrystalline cellulose', 'Moderate', 'Certain medications may interfere with the results of diagnostic studies using fludeoxyglucose F18 by increasing or decreasing uptake of the agent into tissues.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190872/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceutic, Cincinnati, OH.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190645, 'Insulin human', 'Fludeoxyglucose (18F)', 'Moderate', 'Certain medications may interfere with the results of diagnostic studies using fludeoxyglucose F18 by increasing or decreasing uptake of the agent into tissues.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190873/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceutic, Cincinnati, OH.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190646, 'Insulin aspart (aspart protamine)', 'Fludeoxyglucose (18F)', 'Moderate', 'Certain medications may interfere with the results of diagnostic studies using fludeoxyglucose F18 by increasing or decreasing uptake of the agent into tissues.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190874/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceutic, Cincinnati, OH.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190647, 'Insulin lispro (protamine)', 'Fludeoxyglucose (18F)', 'Moderate', 'Certain medications may interfere with the results of diagnostic studies using fludeoxyglucose F18 by increasing or decreasing uptake of the agent into tissues.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190875/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceutic, Cincinnati, OH.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190648, 'Insulin human (zinc)', 'Fludeoxyglucose (18F)', 'Moderate', 'Certain medications may interfere with the results of diagnostic studies using fludeoxyglucose F18 by increasing or decreasing uptake of the agent into tissues.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190876/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceutic, Cincinnati, OH.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190649, 'Insulin human (zinc extended)', 'Fludeoxyglucose (18F)', 'Moderate', 'Certain medications may interfere with the results of diagnostic studies using fludeoxyglucose F18 by increasing or decreasing uptake of the agent into tissues.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190877/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceutic, Cincinnati, OH.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190650, 'Fludeoxyglucose (18F)', 'Magnesium citrate', 'Moderate', 'Certain medications may interfere with the results of diagnostic studies using fludeoxyglucose F18 by increasing or decreasing uptake of the agent into tissues.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190878/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceutic, Cincinnati, OH.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190651, 'Fludeoxyglucose (18F)', 'Methylcellulose', 'Moderate', 'Certain medications may interfere with the results of diagnostic studies using fludeoxyglucose F18 by increasing or decreasing uptake of the agent into tissues.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190879/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceutic, Cincinnati, OH.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190652, 'Fludeoxyglucose (18F)', 'Mineral oil', 'Moderate', 'Certain medications may interfere with the results of diagnostic studies using fludeoxyglucose F18 by increasing or decreasing uptake of the agent into tissues.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190880/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceutic, Cincinnati, OH.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190653, 'Fludeoxyglucose (18F)', 'Phenolphthalein', 'Moderate', 'Certain medications may interfere with the results of diagnostic studies using fludeoxyglucose F18 by increasing or decreasing uptake of the agent into tissues.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190881/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceutic, Cincinnati, OH.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190654, 'Fludeoxyglucose (18F)', 'Plantago seed', 'Moderate', 'Certain medications may interfere with the results of diagnostic studies using fludeoxyglucose F18 by increasing or decreasing uptake of the agent into tissues.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', NULL, 'Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190882/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceutic, Cincinnati, OH.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190655, 'Flurazepam', 'Aluminum hydroxide', 'Minor', 'number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190883/', '[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI "Diazepam absorption: effect of antacids and food." Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP "Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics." Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J "Absorption rate, blood concentrations, and early response to oral chlordiazepoxide." Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS "Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids." Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J "Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption." Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP "Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics." Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ "The influence of three antacids on the absorption and clinical action of oral diazepam." Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD "Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide." Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[13] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190656, 'Flurazepam', 'Azatadine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190884/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190657, 'Flurazepam', 'Bendroflumethiazide', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190885/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190658, 'Flurazepam', 'Benzthiazide', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190886/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190659, 'Flurazepam', 'Bepridil', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190887/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190660, 'Flurazepam', 'Berotralstat', 'Moderate', 'Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6. The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.', NULL, 'Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.', NULL, 'Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190888/', '[1] "Product Information. Orladeyo (berotralstat)." BioCryst Pharmaceuticals Inc, Durham, NC.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190661, 'Flurazepam', 'Carteolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190889/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190662, 'Flurazepam', 'Clofedanol', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190890/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190663, 'Flurazepam', 'Chloral hydrate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190891/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190664, 'Flurazepam', 'Chlormezanone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190892/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190665, 'Flurazepam', 'Chlorphenesin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190893/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190666, 'Flurazepam', 'Cyclizine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190894/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190667, 'Flurazepam', 'Deserpidine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190895/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190668, 'Flurazepam', 'Dezocine', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', NULL, 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', NULL, 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190896/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190669, 'Flurazepam', 'Doxacurium', 'Moderate', 'Benzodiazepines may have variable effects on nondepolarizing muscle relaxants. Potentiation, attenuation, and no effect have all been reported.', NULL, 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', NULL, 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190897/', '[1] Feldman SA, Crawley BE "Diazepam and muscle relaxants." Br Med J 1 (1970): 691[2] Driessen JJ, Crul JF, Vree TB, van Egmond J, Booij LH "Benzodiazepines and neuromuscular blocking drugs in patients." Acta Anaesthesiol Scand 30 (1986): 642-6[3] Driessen JJ, Vree TB, van Egmond J, Booij LH, Crul JF "In vitro interaction of diazepam and oxazepam with pancuronium and suxamethonium." Br J Anaesth 56 (1984): 1131-8[4] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[5] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190670, 'Flurazepam', 'Etidocaine', 'Moderate', 'The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.', NULL, 'Caution is advised during concurrent use.', NULL, 'Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190898/', '[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190671, 'Fospropofol', 'Flurazepam', 'Moderate', 'Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.', NULL, 'Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.', NULL, 'Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly. Supportive therapy should be provided if needed.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190899/', '[1] McClune S, McKay AC, Wright PM, et al "Synergistic interaction between midazolam and propofol." Br J Anaesth 69 (1992): 240-5[2] "Product Information. Lusedra (fospropofol)." Eisai Inc, Teaneck, NJ.[3] "Product Information. Diprivan (propofol)." Zeneca Pharmaceuticals, Wilmington, DE.[4] Pavlin DJ, Coda B, Shen DD, et al "Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers." Anesthesiology 84 (1996): 23-37[5] Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5[6] Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A "Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study." Clin Pharmacol Ther 66 (1999): 110-7', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190672, 'Grepafloxacin', 'Flurazepam', 'Moderate', 'Based on in vitro inhibition data, coadministration with grepafloxacin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by grepafloxacin.', NULL, 'Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever grepafloxacin is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190900/', '[1] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190673, 'Guanabenz', 'Flurazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190901/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190674, 'Guanadrel', 'Flurazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190902/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190675, 'Guanethidine', 'Flurazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190903/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190676, 'Halothane', 'Flurazepam', 'Minor', 'Benzodiazepines may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required. In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique.', NULL, '-', NULL, '-', 'Others', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190904/', '[1] "Product Information. Ultane (sevoflurane)." Abbott Pharmaceutical, Abbott Park, IL.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190677, 'Flurazepam', 'Diamorphine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190905/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190678, 'Hydroflumethiazide', 'Flurazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190906/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190679, 'Isoniazid', 'Flurazepam', 'Moderate', 'Isoniazid may increase the pharmacologic effects of benzodiazepines by decreasing clearance and increasing half-life. The mechanism is related to the inhibition of CYP450 3A4 hepatic oxidative metabolism of benzodiazepines.', NULL, 'Patients on concomitant therapy should be monitored for altered benzodiazepine effects.', NULL, 'Patients on concomitant therapy should be monitored for altered benzodiazepine effects. Dosage reductions may be appropriate if patients experience prolonged or excessive CNS-depressant effects.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190907/', '[1] Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ "Diazepam interaction with antituberculosis drugs." Clin Pharmacol Ther 29 (1981): 671-8[2] Ochs HR, Greenblatt DJ, Knuchel M "Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation." Br J Clin Pharmacol 16 (1983): 743-6[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Self TH, Chrisman CR, Baciewicz AM, Bronze MS "Isoniazid drug and food interactions." Am J Med Sci 317 (1999): 304-11[5] Uragoda CG, Kottegoda SR "Adverse reactions to isoniazid on ingestion of fish with a high histamine content." Tubercle 58 (1977): 83-9[6] "Product Information. INH (isoniazid)." Ciba Pharmaceuticals, Summit, NJ.[7] Smith CK, Durack DT "Isoniazid and reaction to cheese." Ann Intern Med 88 (1978): 520-1[8] Dimartini A "Isoniazid, tricyclics and the ''''cheese reaction''''." Int Clin Psychopharmacol 10 (1995): 197-8[9] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[10] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190680, 'Flurazepam', 'Kava', 'Moderate', 'A case report suggests that kava may increase the central nervous system adverse effects of benzodiazepines.The exact mechanism of interaction is unknown, but an additive or synergistic CNS effect is suspected.', NULL, 'Until further information is available, concomitant use of kava and benzodiazepines is not recommended.', NULL, 'Until further information is available, concomitant use of kava and benzodiazepines is not recommended. Patients on benzodiazepines should be advised to consult their caregiver before using any alternative medicines.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190908/', '[1] Pepping J "Kava: Piper methysticum." Am J Health Syst Pharm 56 (1999): 957-60[2] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[3] Almeida JC, Grimsley EW "Coma from the health food store: interaction between kava and alprazolam." Ann Intern Med 125 (1996): 940-1[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190681, 'Flurazepam', 'Letermovir', 'Moderate', 'Coadministration with letermovir may increase the plasma concentrations of drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or organic anion transporting polypeptide protein (OATP) 1B1 and 1B3. Letermovir has been shown to be a reversible inhibitor of CYP450 2C8 in vitro, although its effect on CYP450 2C8 substrates has not been evaluated clinically. Letermovir is also a time-dependent inhibitor and inducer of CYP450 3A4 in vitro.', NULL, 'Caution is advised when letermovir is used concurrently with drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or OATP 1B1 and 1B3, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when letermovir is used concurrently with drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or OATP 1B1 and 1B3, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever letermovir is added to or withdrawn from therapy. Moreover, clinicians should be aware that the magnitude of CYP450 3A- and OATP1B1/3-mediated drug interactions with coadministered drugs may be different when letermovir is used with cyclosporine. The combined effect of the two drugs on CYP450 3A4 may be similar to that of a strong CYP450 3A4 inhibitor, hence clinicians should refer to the prescribing information for dosing recommendations of the CYP450 3A4 substrate with a strong CYP450 3A4 inhibitor. Similarly, letermovir and cyclosporine may demonstrate some additive effects on OATP1B1 inhibition, although cyclosporine by itself is already a strong OATP1B1/3 inhibitor.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190909/', '[1] "Product Information. Prevymis (letermovir)." Merck & Company Inc, Whitehouse Station, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190682, 'Flurazepam', 'Levobupivacaine', 'Moderate', 'The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.', NULL, 'Caution is advised during concurrent use.', NULL, 'Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190910/', '[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190683, 'Flurazepam', 'Levacetylmethadol', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', NULL, 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', NULL, 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190911/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190684, 'Flurazepam', 'Lonafarnib', 'Moderate', 'Coadministration with lonafarnib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Lonafarnib is a potent CYP450 3A time-dependent and mechanism-based inhibitor in vitro.', NULL, 'Caution is advised when lonafarnib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when lonafarnib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lonafarnib is added to or withdrawn from therapy. Patients should be monitored for the development of adverse effects. The prescribing information recommends avoiding concomitant use of lonafarnib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges when possible. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190912/', '[1] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.[2] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190685, 'Flurazepam', 'Magaldrate', 'Minor', 'number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190913/', '[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI "Diazepam absorption: effect of antacids and food." Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP "Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics." Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J "Absorption rate, blood concentrations, and early response to oral chlordiazepoxide." Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS "Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids." Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J "Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption." Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP "Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics." Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ "The influence of three antacids on the absorption and clinical action of oral diazepam." Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD "Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide." Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[13] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190686, 'Flurazepam', 'Magnesium carbonate', 'Minor', 'number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190914/', '[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI "Diazepam absorption: effect of antacids and food." Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP "Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics." Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J "Absorption rate, blood concentrations, and early response to oral chlordiazepoxide." Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS "Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids." Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J "Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption." Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP "Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics." Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ "The influence of three antacids on the absorption and clinical action of oral diazepam." Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD "Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide." Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[13] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190687, 'Flurazepam', 'Magnesium hydroxide', 'Minor', 'number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190915/', '[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI "Diazepam absorption: effect of antacids and food." Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP "Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics." Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J "Absorption rate, blood concentrations, and early response to oral chlordiazepoxide." Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS "Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids." Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J "Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption." Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP "Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics." Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ "The influence of three antacids on the absorption and clinical action of oral diazepam." Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD "Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide." Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[13] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190688, 'Flurazepam', 'Melatonin', 'Minor', 'The concomitant use of melatonin and benzodiazepines or nonbenzodiazepine hypnotics may result in a transient enhancement of sedation and impairment of memory, coordination, and attention within 1 hour of coadministration.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190916/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[6] Hartter S, Nordmark A, Rose DM, Bertilsson L, Tybring G, Laine K "Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity." Br J Clin Pharmacol 56 (2003): 679-682', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190689, 'Flurazepam', 'Mephenytoin', 'Moderate', 'Coadministration with some benzodiazepines may alter the serum concentrations of phenytoin. Phenytoin toxicity has been reported in patients treated with various benzodiazepines, including clobazam, chlordiazepoxide, clonazepam, and diazepam. Conversely, phenytoin may reduce the plasma concentrations of some benzodiazepines by inducing their metabolism via hepatic microsomal enzymes.', NULL, 'Pharmacologic response and serum hydantoin levels should be monitored more closely whenever a benzodiazepine is added to or withdrawn from therapy, and the hydantoin dosage adjusted as necessary.', NULL, 'Pharmacologic response and serum hydantoin levels should be monitored more closely whenever a benzodiazepine is added to or withdrawn from therapy, and the hydantoin dosage adjusted as necessary. Patients should be advised to contact their physician if they experience symptoms of hydantoin toxicity such as nausea, vomiting, tremors, ataxia, lethargy, slurred speech, visual disturbances, or changes in mental status. The potential for diminished or inadequate benzodiazepine effects should be considered during concomitant use with phenytoin.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190917/', '[1] Murphy A, Wilbur K "Phenytoin-diazepam interaction." Ann Pharmacother 37 (2003): 659-63[2] Sennoune S, Mesdjian E, Bonneton J, et al "Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy." Ther Drug Monit 14 (1992): 269-74[3] Scott AK, Khir AS, Steele WH, et al "Oxazepam pharmacokinetics in patients with epilepsy treated long-term with phenytoin alone or in combination with phenobarbitone." Br J Clin Pharmacol 16 (1983): 441-4[4] Shuttleworth E, Wise G, Paulson G "Choreoathetosis and diphenylhydantoin intoxication." JAMA 230 (1974): 1170-1[5] Windorfer A Jr, Sauer W "Drug interactions during anticonvulsant therapy in childhood: diphenylhydantoin, primidone, phenobarbitone, clonazepam, nitrazepam, carbamazepin and dipropylacetate." Neuropadiatrie 8 (1977): 29-41[6] Saavedra IN, Aguilera LI, Faure E, Galdames DG "Phenytoin/clonazepam interaction." Ther Drug Monit 7 (1985): 481-4[7] Johannessen SI, Strandjord RE, Munthe-Kaas AW "Lack of effect of clonazepam on serum levels of diphenylhydantoin, phenobarbital and carbamazepine." Acta Neurol Scand 55 (1977): 506-12[8] Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7[9] Zifkin B, Sherwin A, Andermann F "Phenytoin toxicity due to interaction with clobazam." Neurology 41 (1991): 313-4[10] Vajda FJ, Prineas RJ, Lovell RR "Interaction between phenytoin and the benzodiazepines." Br Med J 1 (1971): 346[11] Siris JH, Pippenger CE, Werner WL, Masland RL "Anticonvulsant drug-serum levels in psychiatric patients with seizure disorders. Effects of certain psychotropic drugs." N Y State J Med 74 (1974): 1554-6[12] Kutt H "Interactions of antiepileptic drugs." Epilepsia 16 (1975): 393-402[13] Khoo KC, Mendels J, Rothbart M, et al "Influence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam." Clin Pharmacol Ther 28 (1980): 368-75[14] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[15] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[17] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[18] Cerner Multum, Inc. "Australian Product Information." O 0[19] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[20] Fleisher D, Sheth N, Kou JH "Phenytoin interaction with enteral feedings administered through nasogastric tubes." JPEN J Parenter Enteral Nutr 14 (1990): 513-6[21] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM "Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability." Epilepsia 28 (1987): 706-12[22] Haley CJ, Nelson J "Phenytoin-enteral feeding interaction." DICP 23 (1989): 796-8[23] Faraji B, Yu PP "Serum phenytoin levels of patients on gastrostomy tube feeding." J Neurosci Nurs 30 (1998): 55-9[24] Au Yeung SC, Ensom MH "Phenytoin and enteral feedings: does evidence support an interaction?" Ann Pharmacother 34 (2000): 896-905[25] Sandor P, Sellers EM, Dumbrell M, Khouw V "Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics." Clin Pharmacol Ther 30 (1981): 390-7[26] Ozuna J, Friel P "Effect of enteral tube feeding on serum phenytoin levels." J Neurosurg Nurs 16 (1984): 289-91[27] Guidry JR, Eastwood TF, Curry SC "Phenytoin absorption in volunteers receiving selected enteral feedings." West J Med 150 (1989): 659-61[28] Marvel ME, Bertino JS "Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension." JPEN J Parenter Enteral Nutr 15 (1991): 316-8[29] "Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.[30] Doak KK, Haas CE, Dunnigan KJ, et al. "Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings." Pharmacotherapy 18 (1998): 637-45[31] Rodman DP, Stevenson TL, Ray TR "Phenytoin malabsorption after jejunostomy tube delivery." Pharmacotherapy 15 (1995): 801-5[32] Sellers EM, Holloway MR "Drug kinetics and alcohol ingestion." Clin Pharmacokinet 3 (1978): 440-52[33] Holtz L, Milton J, Sturek JK "Compatibility of medications with enteral feedings." JPEN J Parenter Enteral Nutr 11 (1987): 183-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190690, 'Flurazepam', 'Meprobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190918/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190691, 'Flurazepam', 'Mesoridazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190919/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190692, 'Flurazepam', 'Methdilazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190920/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190693, 'Flurazepam', 'Methoxyflurane', 'Minor', 'Benzodiazepines may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required. In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique.', NULL, '-', NULL, '-', 'Others', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190921/', '[1] "Product Information. Ultane (sevoflurane)." Abbott Pharmaceutical, Abbott Park, IL.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190694, 'Flurazepam', 'Metocurine', 'Moderate', 'Benzodiazepines may have variable effects on nondepolarizing muscle relaxants. Potentiation, attenuation, and no effect have all been reported.', NULL, 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', NULL, 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190922/', '[1] Feldman SA, Crawley BE "Diazepam and muscle relaxants." Br Med J 1 (1970): 691[2] Driessen JJ, Crul JF, Vree TB, van Egmond J, Booij LH "Benzodiazepines and neuromuscular blocking drugs in patients." Acta Anaesthesiol Scand 30 (1986): 642-6[3] Driessen JJ, Vree TB, van Egmond J, Booij LH, Crul JF "In vitro interaction of diazepam and oxazepam with pancuronium and suxamethonium." Br J Anaesth 56 (1984): 1131-8[4] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[5] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190695, 'Flurazepam', 'Morphine (liposomal)', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', NULL, 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', NULL, 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190923/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190696, 'Flurazepam', 'Oxazepam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190924/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190697, 'Flurazepam', 'Oxtriphylline', 'Minor', 'Methylxanthines may antagonize the sedative effects of benzodiazepines. Aminophylline in particular has been demonstrated to attenuate the sedative effects of diazepam. The mechanism of this interaction may be related to competitive binding to intracerebral adenosine receptors.', NULL, '-', NULL, '-', 'Antagonism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190925/', '[1] Tuncok Y, Akpinar O, Guven H, Akkoclu A "The effects of theophylline on serum alprazolam levels." Int J Clin Pharmacol Ther 32 (1994): 642-5[2] Gallen JS "Aminophylline reversal of midazolam sedation." Anesth Analg 69 (1989): 268[3] Bonfiglio MF, Dasta JF "Clinical significance of the benzodiazepine-theophylline interaction." Pharmacotherapy 11 (1991): 85-7[4] Upton RA "Pharmacokinetic interactions between theophylline and other medication (Part II)." Clin Pharmacokinet 20 (1991): 135-50[5] Stirt JA "Aminophylline is a diazepam antagonist." Anesth Analg 60 (1981): 767-8[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190698, 'Flurazepam', 'Pancuronium', 'Moderate', 'Benzodiazepines may have variable effects on nondepolarizing muscle relaxants. Potentiation, attenuation, and no effect have all been reported.', NULL, 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', NULL, 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190926/', '[1] Feldman SA, Crawley BE "Diazepam and muscle relaxants." Br Med J 1 (1970): 691[2] Driessen JJ, Crul JF, Vree TB, van Egmond J, Booij LH "Benzodiazepines and neuromuscular blocking drugs in patients." Acta Anaesthesiol Scand 30 (1986): 642-6[3] Driessen JJ, Vree TB, van Egmond J, Booij LH, Crul JF "In vitro interaction of diazepam and oxazepam with pancuronium and suxamethonium." Br J Anaesth 56 (1984): 1131-8[4] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[5] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190699, 'Flurazepam', 'Paramethadione', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190927/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190700, 'Flurazepam', 'Penbutolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190928/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190701, 'Flurazepam', 'Perphenazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190929/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190702, 'Flurazepam', 'Phenacemide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190930/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190703, 'Flurazepam', 'Phenindamine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190931/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190704, 'Flurazepam', 'Phensuximide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190932/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190705, 'Flurazepam', 'Pipecuronium', 'Moderate', 'Benzodiazepines may have variable effects on nondepolarizing muscle relaxants. Potentiation, attenuation, and no effect have all been reported.', NULL, 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', NULL, 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190933/', '[1] Feldman SA, Crawley BE "Diazepam and muscle relaxants." Br Med J 1 (1970): 691[2] Driessen JJ, Crul JF, Vree TB, van Egmond J, Booij LH "Benzodiazepines and neuromuscular blocking drugs in patients." Acta Anaesthesiol Scand 30 (1986): 642-6[3] Driessen JJ, Vree TB, van Egmond J, Booij LH, Crul JF "In vitro interaction of diazepam and oxazepam with pancuronium and suxamethonium." Br J Anaesth 56 (1984): 1131-8[4] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[5] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190706, 'Flurazepam', 'Polythiazide', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190934/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190707, 'Flurazepam', 'Procaine', 'Moderate', 'The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.', NULL, 'Caution is advised during concurrent use.', NULL, 'Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190935/', '[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190708, 'Flurazepam', 'Promazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190936/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190709, 'Flurazepam', 'Propiomazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190937/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190710, 'Flurazepam', 'Rapacuronium', 'Moderate', 'Benzodiazepines may have variable effects on nondepolarizing muscle relaxants. Potentiation, attenuation, and no effect have all been reported.', NULL, 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', NULL, 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190938/', '[1] Feldman SA, Crawley BE "Diazepam and muscle relaxants." Br Med J 1 (1970): 691[2] Driessen JJ, Crul JF, Vree TB, van Egmond J, Booij LH "Benzodiazepines and neuromuscular blocking drugs in patients." Acta Anaesthesiol Scand 30 (1986): 642-6[3] Driessen JJ, Vree TB, van Egmond J, Booij LH, Crul JF "In vitro interaction of diazepam and oxazepam with pancuronium and suxamethonium." Br J Anaesth 56 (1984): 1131-8[4] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[5] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190711, 'Flurazepam', 'Reserpine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190939/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190712, 'Flurazepam', 'Sibutramine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190940/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190713, 'Iodide I-123', 'Flurazepam', 'Moderate', 'INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.', NULL, 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.', NULL, 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190941/', '[1] "Product Information. Sodium Iodide I-123 (sodium iodide I-123)." GE Healthcare, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190714, 'Flurazepam', 'Somapacitan', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190942/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Humatrope (somatropin)." Lilly, Eli and Company, Indianapolis, IN.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190715, 'Flurazepam', 'Somatrem', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190943/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Humatrope (somatropin)." Lilly, Eli and Company, Indianapolis, IN.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190716, 'Flurazepam', 'St. John''s Wort', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190944/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190717, 'Flurazepam', 'Thiethylperazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190945/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190718, 'Flurazepam', 'Thioridazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190946/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190719, 'Flurazepam', 'Trichlormethiazide', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190947/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190720, 'Flurazepam', 'Trifluoperazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190948/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190721, 'Flurazepam', 'Triflupromazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190949/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190722, 'Flurazepam', 'Trihexyphenidyl', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190950/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190723, 'Flurazepam', 'Alimemazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190951/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190724, 'Flurazepam', 'Trimethadione', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190952/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190725, 'Flurazepam', 'Trimethaphan', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190953/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190726, 'Flurazepam', 'Tripelennamine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190954/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190727, 'Flurazepam', 'Troleandomycin', 'Moderate', 'Macrolide antibiotics may increase and prolong the CNS effects of certain benzodiazepines. The mechanism is inhibition of CYP450 3A4 hepatic oxidation of the benzodiazepines.', NULL, 'Patients receiving this combination should be monitored for excessive or prolonged sedation.', NULL, 'Patients receiving this combination should be monitored for excessive or prolonged sedation. Non-interacting benzodiazepines or antimicrobials may be considered as alternatives.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190955/', '[1] Warot D, Bergougnan L, Lamiable D, et al "Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation." Eur J Clin Pharmacol 32 (1987): 389-93[2] Yeates RA, Laufen H, Zimmermann T, Schumacher T "Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin clarithromycin, and the azalide azithromycin." Int J Clin Pharmacol Ther 35 (1997): 577-9[3] Mattila MJ, Idanpaanheikkila JJ, Tornwall M, Vanakoski J "Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance." Pharmacol Toxicol 73 (1993): 180-5[4] Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A "Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam." Arzneimittelforschung 46 (1996): 213-7[5] Yasui N, Otani K, Kaneko S, et al "A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3a4 in alprazolam metabolism." Clin Pharmacol Ther 59 (1996): 514-9[6] Yeates RA, Laufen H, Zimmermann T "Interaction between midazolam and clarithromycin: comparison with azithromycin." Int J Clin Pharmacol Ther 34 (1996): 400-5[7] Gorski JC, Jones DR, HaehnerDaniels BD, Hamman MA, OMara EM, Hall SD "The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin." Clin Pharmacol Ther 64 (1998): 133-43[8] Phillips JP, Antal EJ, Smith RB "A pharmacokinetic drug interaction between erythromycin and triazolam." J Clin Psychopharmacol 6 (1986): 297-9[9] Wrighton SA, Ring BJ "Inhibition of human CYP3A catalyzed 1''-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine." Pharm Res 11 (1994): 921-4[10] Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y "Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4." Pharmaceut Res 17 (2000): 419-26[11] Ito K, Ogihara K, Kanamitsu SI, Itoh T "Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes." Drug Metab Dispos 31 (2003): 945-954[12] Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17[13] Luurila H, Olkkola KT, Neuvonen PJ "Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam." Pharmacol Toxicol 78 (1996): 117-22[14] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[15] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[17] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190728, 'Flurazepam', 'Tubocurarine', 'Moderate', 'Benzodiazepines may have variable effects on nondepolarizing muscle relaxants. Potentiation, attenuation, and no effect have all been reported.', NULL, 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', NULL, 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190956/', '[1] Feldman SA, Crawley BE "Diazepam and muscle relaxants." Br Med J 1 (1970): 691[2] Driessen JJ, Crul JF, Vree TB, van Egmond J, Booij LH "Benzodiazepines and neuromuscular blocking drugs in patients." Acta Anaesthesiol Scand 30 (1986): 642-6[3] Driessen JJ, Vree TB, van Egmond J, Booij LH, Crul JF "In vitro interaction of diazepam and oxazepam with pancuronium and suxamethonium." Br J Anaesth 56 (1984): 1131-8[4] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[5] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190729, 'Flurazepam', 'Valerian', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190957/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190730, 'Flurazepam', 'Vecuronium', 'Moderate', 'Benzodiazepines may have variable effects on nondepolarizing muscle relaxants. Potentiation, attenuation, and no effect have all been reported.', NULL, 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', NULL, 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190958/', '[1] Feldman SA, Crawley BE "Diazepam and muscle relaxants." Br Med J 1 (1970): 691[2] Driessen JJ, Crul JF, Vree TB, van Egmond J, Booij LH "Benzodiazepines and neuromuscular blocking drugs in patients." Acta Anaesthesiol Scand 30 (1986): 642-6[3] Driessen JJ, Vree TB, van Egmond J, Booij LH, Crul JF "In vitro interaction of diazepam and oxazepam with pancuronium and suxamethonium." Br J Anaesth 56 (1984): 1131-8[4] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[5] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190731, 'Fosnetupitant', 'Abemaciclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of abemaciclib and its pharmacologically active metabolites, all of which are substrates of the isoenzyme.', NULL, 'Caution is advised when abemaciclib is used with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised when abemaciclib is used with moderate CYP450 3A4 inhibitors. Dosage adjustments for abemaciclib in 50 mg decrements may be necessary and should be done in accordance with the product labeling. Patients should be monitored for potentially increased adverse effects such as nausea, vomiting, diarrhea, stomatitis, venous thromboembolism, hepatotoxicity, anemia, neutropenia, and thrombocytopenia.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190959/', '[1] "Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company, Indianapolis, IN.[2] "Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company, Indianapolis, IN.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190732, 'Acalabrutinib', 'Fosnetupitant', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized by the isoenzyme. Increased acalabrutinib exposure may potentiate the risk of toxicities such as hemorrhage, infection, cytopenias, malignancies, and atrial fibrillation or flutter.', NULL, 'The dosage of acalabrutinib should be reduced to 100 mg once daily when coadministered with moderate CYP450 3A4 inhibitors.', NULL, 'The dosage of acalabrutinib should be reduced to 100 mg once daily when coadministered with moderate CYP450 3A4 inhibitors.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190960/', '[1] "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190733, 'Fosnetupitant', 'Albendazole', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190961/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190734, 'Fosnetupitant', 'Aliskiren', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and P-glycoprotein may increase the plasma concentrations and pharmacologic effects of aliskiren, which is a substrate of both the isoenzyme and efflux transporter. According to the product labeling, plasma levels of aliskiren were increased approximately 80% by the potent CYP450 3A4 and moderate P-gp inhibitor ketoconazole at a dosage of 200 mg twice daily.', NULL, 'Pharmacologic response to aliskiren should be monitored more closely whenever a CYP450 3A4 and/or P-gp inhibitor is added to or withdrawn from therapy, and the aliskiren dosage adjusted if necessary.', NULL, 'Pharmacologic response to aliskiren should be monitored more closely whenever a CYP450 3A4 and/or P-gp inhibitor is added to or withdrawn from therapy, and the aliskiren dosage adjusted if necessary. Patients should be advised to notify their physician if they experience excessive adverse effects of aliskiren such as dizziness, lightheadedness, diarrhea, abdominal pain, and gastroesophageal reflux.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190962/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Tapaninen T, Backman JT, Kurkinen K, Neuvonen P, Niemi M "Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren." J Clin Pharmacol 51 (2011): 359-67[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Tekturna (aliskiren)." Novartis Pharmaceuticals, East Hanover, NJ.[5] Tapaninen T, Neuvonen PJ, Niemi M "Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren." Clin Pharmacol Ther 88 (2010): 339-42[6] Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP "Clinical pharmacokinetics and pharmacodynamics of aliskiren." Clin Pharmacokinet 47 (2008): 515-31[7] Tapaninen T, Neuvonen PJ, Niemi M "Orange and apple juices greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren." Br J Clin Pharmacol 71 (2010): 718-26[8] "Product Information. Tekturna (aliskiren)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190735, 'Fosnetupitant', 'Alpelisib', 'Moderate', 'Coadministration of inhibitors of the breast cancer resistance protein (BCRP) transporter with alpelisib may increase the plasma concentrations and risk of adverse effects of alpelisib, which is a substrate of this efflux transporter. Alpelisib has been identified as a substrate of BCRP in in vitro studies. However, clinical data are not available.', NULL, 'If coadministration with BCRP inhibitors is required, patients should be closely monitored for alpelisib-related adverse reactions, including hyperglycaemia, diarrhea, rash, acute kidney injury, abdominal pain, and anemia.', NULL, 'If coadministration with BCRP inhibitors is required, patients should be closely monitored for alpelisib-related adverse reactions, including hyperglycaemia, diarrhea, rash, acute kidney injury, abdominal pain, and anemia. Some authorities recommend coadministration of alpelisib with BCRP inhibitors be avoided whenever possible (US).', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190963/', '[1] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190736, 'Fosnetupitant', 'Alprazolam', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190964/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190737, 'Amlodipine', 'Fosnetupitant', 'Moderate', 'Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of amlodipine, which is a substrate of the isoenzyme.', NULL, 'Close monitoring of clinical response and tolerance is recommended if amlodipine is prescribed with potent or moderate CYP450 3A4 inhibitors.', NULL, 'Close monitoring of clinical response and tolerance is recommended if amlodipine is prescribed with potent or moderate CYP450 3A4 inhibitors. Dosage reduction may be required for amlodipine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190965/', '[1] Sasaki M, Maeda A, Fujimura A "Influence of diltiazem on the pharmacokinetics of amlodipine in elderly hypertensive patients." Eur J Clin Pharmacol 57 (2001): 85-6[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] "Product Information. Norvasc (amlodipine)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190738, 'Amprenavir', 'Fosnetupitant', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of netupitant. When a single 300 mg-0.5 mg dose of netupitant-palonosetron was administered following 400 mg once daily administration of the potent CYP450 3A4 inhibitor ketoconazole for 12 days, mean netupitant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 25% and 140%, respectively, while mean Cmax and AUC of palonosetron increased by 15% and 10%, respectively. No dosage adjustment is necessary for single-dose administration of netupitant-palonosetron when used with potent CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190966/', '[1] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190739, 'Fosnetupitant', 'Apalutamide', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190967/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190740, 'Fosnetupitant', 'Apixaban', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of apixaban, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'No dosage adjustment for apixaban is required during concomitant therapy with lone inhibitors of CYP450 3A4 or P-gp, or moderate or weak dual inhibitors of both CYP450 3A4 and P-gp.', NULL, 'No dosage adjustment for apixaban is required during concomitant therapy with lone inhibitors of CYP450 3A4 or P-gp, or moderate or weak dual inhibitors of both CYP450 3A4 and P-gp. However, caution may be advisable. Closer monitoring of the pharmacologic effects of apixaban may be appropriate whenever a CYP450 3A4 or P-gp inhibitor is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190968/', '[1] "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb Canada Inc, Montreal, IN.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190741, 'Fosnetupitant', 'Aprepitant', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190969/', '[1] "Product Information. Emend for Injection (fosaprepitant)." Merck & Company Inc, West Point, PA.[2] "Product Information. Emend (aprepitant)." Merck & Company Inc, West Point, PA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190742, 'Fosnetupitant', 'Armodafinil', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are both partially metabolized by the isoenzyme. Conversely, the plasma levels of some of these inhibitors may decrease, since many of them are also substrates of CYP450 3A4, and modafinil and armodafinil have been found to be modest inducers of CYP450 3A4. The clinical significance of this potential interaction is unknown. Clinical monitoring for altered effects of modafinil and armodafinil as well as the CYP450 3A4 inhibitor may be appropriate following addition or withdrawal of one or the other drug.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190970/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Nuvigil (armodafinil)." Cephalon Inc, West Chester, PA.[3] "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.[4] "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.[5] "Product Information. Nuvigil (armodafinil)." Cephalon Inc, West Chester, PA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190743, 'Fosnetupitant', 'Atazanavir', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of netupitant. When a single 300 mg-0.5 mg dose of netupitant-palonosetron was administered following 400 mg once daily administration of the potent CYP450 3A4 inhibitor ketoconazole for 12 days, mean netupitant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 25% and 140%, respectively, while mean Cmax and AUC of palonosetron increased by 15% and 10%, respectively. No dosage adjustment is necessary for single-dose administration of netupitant-palonosetron when used with potent CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190971/', '[1] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190744, 'Fosnetupitant', 'Atorvastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', NULL, 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', NULL, 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190972/', '[1] Yeo KR, Yeo WW, Wallis EJ, Ramsay LE "Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients." Br J Clin Pharmacol 48 (1999): 610-5[2] Andreou ER, Ledger S "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis." Can J Clin Pharmacol 10 (2003): 172-4[3] Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3[4] "Product Information. Zocor (simvastatin)." Merck & Co, Inc, West Point, PA.[5] Neuvonen PJ, Backman JT, Niemi M "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." Clin Pharmacokinet 47 (2008): 463-74[6] Norman DJ, Illingworth DR, Munson J, Hosenpud J "Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin." N Engl J Med 318 (1988): 46-7[7] Williams D, Feely J "Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors." Clin Pharmacokinet 41 (2002): 343-70[8] Dallaire M, Chamberland M "Severe rhabdomyolysis in a patient receiving lovastatin, danazol and doxycycline." Can Med Assoc J 150 (1994): 1991-4[9] Malaty LI, Kuper JJ "Drug interactions of HIV protease inhibitors." Drug Safety 20 (1999): 147-69[10] Kivisto KT, Kantola T, Neuvonen PJ "Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin." Br J Clin Pharmacol 46 (1998): 49-53[11] Huynh T, Cordato D, Yang F, et al. "HMG coA reductase-inhibitor-related myopathy and the influence of drug interactions." Intern Med J 32(9-10) (2002): 486-90[12] Neuvonen PJ, Jalava KM "Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 60 (1996): 54-61[13] Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F "New insights into the pharmacodynamic and pharmacokinetic properties of statins." Pharmacol Ther 84 (1999): 413-28[14] Amsden GW, Kuye O, Wei GC "A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers." J Clin Pharmacol 42 (2002): 444-9[15] Neuvonen PJ, Kantola T, Kivisto KT "Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole." Clin Pharmacol Ther 63 (1998): 332-41[16] Omar MA, Wilson JP "FDA adverse event reports on statin-associated rhabdomyolysis." Ann Pharmacother 36 (2002): 288-95[17] Spach DH, Bauwens JE, Clark CD, Burke WG "Rhabdomyolysis associated with lovastatin and erythromycin use." West J Med 154 (1991): 213-5[18] Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG "Rhabdomyolysis in association with simvastatin and amiodarone." Ann Pharmacother 38 (2004): 978-81[19] Jacobson RH, Wang P, Glueck CJ "Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone." JAMA 277 (1997): 296[20] Chouhan UM, Chakrabarti S, Millward LJ "Simvastatin interaction with clarithromycin and amiodarone causing myositis." Ann Pharmacother 39 (2005): 1760-1[21] Thompson M, Samuels S "Rhabdomyolysis with simvastatin and nefazodone." Am J Psychiatry 159 (2002): 1607[22] Grunden JW, Fisher KA "Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin." Ann Pharmacother 31 (1997): 859-63[23] Kantola T, Kivisto KT, Neuvonen PJ "Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations." Clin Pharmacol Ther 64 (1998): 177-82[24] "Product Information. Mevacor (lovastatin)." Merck & Co, Inc, West Point, PA.[25] Garnett WR "Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors." Am J Health Syst Pharm 52 (1995): 1639-45[26] "Product Information. Baycol (cerivastatin)." Bayer, West Haven, CT.[27] Gullestad L, Nordal KP, Berg KJ, Cheng H, Schwartz MS, Simonsen S "Interaction between lovastatin and cyclosporine A after heart and kidney transplantation." Transplant Proc 31 (1999): 2163-5[28] Yeo KR, Yeo WW "Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes." Br J Clin Pharmacol 51 (2001): 461-70[29] Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304[30] "Product Information. Lipitor (atorvastatin)." Parke-Davis, Morris Plains, NJ.[31] East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA "Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation." N Engl J Med 318 (1988): 47-8[32] Westphal JF "Macrolide - induced clinically relevant drug interactions with cytochrome P-450 (CYP) 3A4: an update focused on clarithromycin, azithromycin, and dirithromycin." Br J Clin Pharmacol 50 (2000): 285-95[33] Jacobson TA "Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors." Am J Cardiol 94 (2004): 1140-6[34] Sipe BE, Jones RJ, Bokhart GH "Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction." Ann Pharmacother 37 (2003): 808-11[35] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[36] Kantola T, Kivisto KT, Neuvonen PJ "Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations." Clin Pharmacol Ther 64 (1998): 177-82[37] Lee AJ, Maddix DS "Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin." Ann Pharmacother 35 (2001): 26-31[38] Zhou LX, Finley DK, Hassell AE, Holtzman JL "Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers." J Pharmacol Exp Ther 273 (1995): 121-7[39] Kantola T, Kivisto KT, Neuvonen PJ "Effect of itraconazole on the pharmacokinetics of atorvastatin." Clin Pharmacol Ther 64 (1998): 58-65[40] Karnik NS, Maldonado JR "Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis." Psychosomatics 46 (2005): 565-8[41] de Denus S, Spinler SA "Amiodarone''s role in simvastatin-associated rhabdomyolysis." Am J Health Syst Pharm 60 (2003): 1791; author reply 1791-2[42] Maltz HC, Balog DL, Cheigh JS "Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine." Ann Pharmacother 33 (1999): 1176-9[43] Mousa O, Brater DC, Sundblad KJ, Hall SD "The interaction of diltiazem with simvastatin." Clin Pharmacol Ther 67 (2000): 267-74[44] Wong PW, Dillard TA, Kroenke K "Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy." South Med J 91 (1998): 202-5[45] Campana C, Iacona I, Regassi MB, et al. "Efficacy and pharmacokinetics of simvastatin in heart transplant recipients." Ann Pharmacother 29 (1995): 235-9[46] Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA "Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin." Am J Cardiol 84 (1999): 811-5[47] Paoletti R, Corsini A, Bellosta S "Pharmacological interactions of statins." Atheroscler Suppl 3 (2002): 35-40[48] Azie NE, Brater DC, Becker PA, Jones DR, Hall SD "The interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 64 (1998): 369-77[49] Kantola T, Kivisto KT, Neuvonen PJ "Effect of itraconazole on cerivastatin pharmacokinetics." Eur J Clin Pharmacol 54 (1999): 851-5[50] Kusus M, Stapleton DD, Lertora JJL, Simon EE, Dreisbach AW "Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions." Am J Med Sci 320 (2000): 394-7[51] Corpier CL, Jones PH, Suki WN, et al. "Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients." JAMA 260 (1988): 239-41[52] Jody DN "Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone." JAMA 277 (1997): 296-7[53] Arnadottir M, Eriksson LO, Thysell H, Karkas JD "Plasma concentration profiles of simvastatin 3-hydroxy- 3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin." Nephron 65 (1993): 410-3[54] Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. "Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047." AIDS 16 (2002): 569-577[55] Skrabal MZ, Stading JA, Monaghan MS "Rhabdomyolysis associated with simvastatin-nefazodone therapy." South Med J 96 (2003): 1034-5[56] Jardine A, Holdaas H "Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience." J Clin Pharm Ther 24 (1999): 397-408[57] Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201[58] Siedlik PH, Olson SC, Yang BB, Stern RH "Erythromycin coadministration increases plasma atorvastatin concentrations." J Clin Pharmacol 39 (1999): 501-4[59] Gilad R, Lampl Y "Rhabdomyolysis induced by simvastatin and ketoconazole treatment." Clin Neuropharmacol 22 (1999): 295-7[60] Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3[61] Lomaestro BM, Piatek MA "Update on drug interactions with azole antifungal agents." Ann Pharmacother 32 (1998): 915-28[62] Rodriguez JA, CrespoLeiro MG, Paniagua MJ, Cuenca JJ, Hermida LF, Juffe A, CastroBeiras A "Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine." Transplant Proc 31 (1999): 2522-3[63] Lees RS, Lees AM "Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole." N Engl J Med 333 (1995): 664-5[64] Horn M "Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals." Arch Dermatol 132 (1996): 1254[65] Richter WO, Jacob BG, Schwandt P "Interaction between fibre and lovastatin." Lancet 338 (1991): 706[66] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[67] Neuvonen PJ, Backman JT, Niemi M "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." Clin Pharmacokinet 47 (2008): 463-74[68] "Product Information. Lipitor (atorvastatin)." Parke-Davis, Morris Plains, NJ.[69] McMillan K "Considerations in the formulary selection of hydroxymethylglutaryl coenzyme a reductase inhibitors." Am J Health Syst Pharm 53 (1996): 2206-14[70] Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M "Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P45 isozymes involved." Drug Metab Dispos 25 (1997): 321-31[71] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190745, 'Fosnetupitant', 'Avanafil', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme.', NULL, 'The dosage of avanafil should not exceed 50 mg once every 24 hours when used in combination with moderate CYP450 3A4 inhibitors.', NULL, 'The dosage of avanafil should not exceed 50 mg once every 24 hours when used in combination with moderate CYP450 3A4 inhibitors.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190973/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[3] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[4] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[5] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190746, 'Fosnetupitant', 'Avapritinib', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9. Increased exposure to avapritinib may increase the risk and/or severity of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils, and platelets.', NULL, 'Concomitant use of avapritinib with moderate CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of avapritinib with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends reducing the starting dosage of avapritinib from 300 mg orally once daily to 100 mg orally once daily.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190974/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Ayvakit (avapritinib)." Blueprint Medicines Corporation, Cambridge, MA.[3] "Product Information. Ayvakit (avapritinib)." Blueprint Medicines Corporation, Cambridge, MA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190747, 'Fosnetupitant', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190975/', '[1] "Product Information. Inlyta (axitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Inlyta (axitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190748, 'Fosnetupitant', 'Betamethasone', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190976/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190749, 'Fosnetupitant', 'Bexarotene', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may theoretically increase the plasma concentrations of bexarotene. In vitro studies suggest that bexarotene is metabolized by CYP450 3A4. However, concomitant administration with multiple doses of ketoconazole, a potent CYP450 3A4 inhibitor, did not alter bexarotene plasma concentrations, which would imply that bexarotene elimination is not substantially dependent on CYP450 3A4 metabolism in vivo. Conversely, bexarotene appears to be an inducer of CYP450 3A4 and may reduce the plasma concentrations of CYP450 3A4 inhibitors that are also substrates of the isoenzyme, such as azole antifungals, macrolides, some calcium channel blockers, mifepristone, and nefazodone.', NULL, '-', NULL, '-', 'Others', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190977/', '[1] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[2] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190750, 'Fosnetupitant', 'Binimetinib', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp), uridine diphosphate glucuronosyltransferase (UGT) 1A1 or 2B7, and/or breast cancer resistance protein (BCRP) may increase the plasma levels and risk of adverse effects of binimetinib. The proposed mechanism involves the reduced metabolic clearance of binimetinib through inhibition of P-gp, UGT 1A1, UGT 2B7, and/or BCRP.', NULL, 'Until further information is available, caution is recommended if binimetinib must be used concomitantly with P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitors.', NULL, 'Until further information is available, caution is recommended if binimetinib must be used concomitantly with P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitors. Binimetinib should be monitored more closely whenever a P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitor is added to or withdrawn from therapy, and the binimetinib dosage adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190978/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Mektovi (binimetinib)." Array BioPharma Inc., Boulder, CO.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190751, 'Fosnetupitant', 'Boceprevir', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of netupitant. When a single 300 mg-0.5 mg dose of netupitant-palonosetron was administered following 400 mg once daily administration of the potent CYP450 3A4 inhibitor ketoconazole for 12 days, mean netupitant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 25% and 140%, respectively, while mean Cmax and AUC of palonosetron increased by 15% and 10%, respectively. No dosage adjustment is necessary for single-dose administration of netupitant-palonosetron when used with potent CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190979/', '[1] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190752, 'Fosnetupitant', 'Bosentan', 'Moderate', 'Coadministration of bosentan with a drug that is both a substrate as well as inhibitor of CYP450 2C9 and/or 3A4 may result in increased plasma concentrations of bosentan and decreased plasma concentrations of the other drug. Bosentan itself is a substrate and inducer of both CYP450 2C9 and 3A4. Theoretically, bosentan may induce metabolism of the coadministered drug while its own metabolism may be inhibited by the coadministered drug.', NULL, 'When a drug that is both a substrate as well as inhibitor of CYP450 2C9 and/or 3A4 is coadministered with bosentan, the possibility of diminished therapeutic response to the coadministered drug should be considered.', NULL, 'When a drug that is both a substrate as well as inhibitor of CYP450 2C9 and/or 3A4 is coadministered with bosentan, the possibility of diminished therapeutic response to the coadministered drug should be considered. Clinical and/or laboratory monitoring may be appropriate whenever bosentan is added to or withdrawn from therapy, and the dosage of the concomitant drug adjusted as necessary. The possibility of prolonged and/or increased pharmacologic effects of bosentan, including serious adverse effects such as hepatotoxicity, should also be considered. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. Concomitant administration of bosentan with both a potent CYP450 2C9 inhibitor (e.g., fluconazole, amiodarone) and a potent CYP450 3A4 inhibitor (e.g., ketoconazole, itraconazole, ritonavir) is not recommended. Concomitant administration with combination CYP450 2C9/3A4 inhibitors (e.g., delavirdine, imatinib, miconazole, mifepristone, voriconazole) should probably be avoided also, if possible.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190980/', '[1] "Product Information. Tracleer (bosentan)." Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190753, 'Fosnetupitant', 'Bosutinib', 'Major', 'Coadministration with potent and moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of bosutinib, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of bosutinib with potent or moderate CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of bosutinib with potent or moderate CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of bosutinib during and for 2 weeks after treatment with itraconazole. If use of a potent or moderate CYP450 3A4 inhibitor is required, an interruption or a dosage reduction of bosutinib therapy should be considered.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190981/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Abbas R, Hug BA, Leister C, Sonnichsen D "A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects." Int J Cancer 131 (2012): Epub[7] "Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190754, 'Fosnetupitant', 'Brexpiprazole', 'Major', 'Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may significantly increase the plasma concentrations of brexpiprazole, which is metabolized by these isoenzymes.', NULL, 'The manufacturer recommends that the brexpiprazole dosage be reduced as follows during concomitant administration of CYP450 inhibitors.', NULL, 'The manufacturer recommends that the brexpiprazole dosage be reduced as follows during concomitant administration of CYP450 inhibitors. The brexpiprazole dosage should be increased to the original level if these agents are discontinued. It is advisable to monitor patients for clinical response.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190982/', '[1] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190755, 'Fosnetupitant', 'Brigatinib', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of brigatinib, which is partially metabolized by the isoenzyme.', NULL, 'Concomitant use of moderate CYP450 3A4 inhibitors should generally be avoided during therapy with brigatinib.', NULL, 'Concomitant use of moderate CYP450 3A4 inhibitors should generally be avoided during therapy with brigatinib. If coadministration is required, the brigatinib dose should be reduced by approximately 40% (i.e., from 180 mg to 120 mg, 120 mg to 90 mg, or from 90 mg to 60 mg). There are authorities (AU and UK) that state that no dose adjustment is required, however, patients should be closely monitored. Patients should be monitored for increased brigatinib adverse reactions such as nausea, vomiting, diarrhea, hypertension, bradycardia, hyperglycaemia, visual disturbances, lymphopenia, anemia, and elevations in pancreatic enzymes and creatine phosphokinase. If a dose adjustment is made, the brigatinib dose that was tolerated previously may be resumed following discontinuation of the CYP450 3A4 inhibitor.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190983/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Alunbrig (brigatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA.[4] "Product Information. Alunbrig (brigatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190756, 'Fosnetupitant', 'Bromocriptine', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190984/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190757, 'Fosnetupitant', 'Budesonide', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic metabolism via intestinal and hepatic CYP450 3A4. In pharmacokinetic studies, 6- to 8-fold increases in budesonide systemic exposure (AUC) have been observed during coadministration of the potent CYP450 3A4 inhibitor ketoconazole with different oral formulations of budesonide.', NULL, 'The possibility of increased systemic adverse effects of budesonide should be considered during coadministration with CYP450 3A4 inhibitors.', NULL, 'The possibility of increased systemic adverse effects of budesonide should be considered during coadministration with CYP450 3A4 inhibitors. If concomitant use cannot be avoided, the dosing times between budesonide and the CYP450 3A4 inhibitor should be separated by as much as possible. In addition, the lowest effective dosage of budesonide should be prescribed, and further adjustments made as necessary according to therapeutic response and tolerance.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190985/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Daveluy A, Raignoux C, Miremont-Salame G, et al. "Drug interactions between inhaled corticosteroids and enzymatic inhibitors." Eur J Clin Pharmacol (2009):[5] "Product Information. Entocort (budesonide)." AstraZeneca Pharma Inc, Mississauga, ON.[6] "Product Information. Victrelis (boceprevir)." Schering-Plough Corporation, Kenilworth, NJ.[7] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[8] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[9] Molimard M, Girodet PO, Pollet C, et al. "Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation." Drug Saf 31 (2008): 769-74[10] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[11] De Wachter E, Malfroot A, De Schutter I, Vanbesien J, De Schepper J "Inhaled budesonide induced Cushing''s syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450." J Calif Dent Assoc 2 (2003): 72-5[12] "Product Information. Incivek (telaprevir)." Vertex Pharmaceuticals, Cambridge, MA.[13] Kedem E, Shahar E, Hassoun G, Pollack S "Iatrogenic Cushing''s syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient." J Asthma 47 (2010): 830-1[14] Jonsson G, Astrom A, Andersson P "Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver." Drug Metab Dispos 23 (1995): 137-42[15] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[16] De Wachter E, Vanbesien J, De Schutter I, Malfroot A, De Schepper J "Rapidly developing Cushing syndrome in a 4-year-old patient during combined treatment with itraconazole and inhaled budesonide." Eur J Pediatr (2003):[17] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190758, 'Fosnetupitant', 'Budesonide (nasal)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic metabolism via intestinal and hepatic CYP450 3A4. In pharmacokinetic studies, 6- to 8-fold increases in budesonide systemic exposure (AUC) have been observed during coadministration of the potent CYP450 3A4 inhibitor ketoconazole with different oral formulations of budesonide.', NULL, 'The possibility of increased systemic adverse effects of budesonide should be considered during coadministration with CYP450 3A4 inhibitors.', NULL, 'The possibility of increased systemic adverse effects of budesonide should be considered during coadministration with CYP450 3A4 inhibitors. If concomitant use cannot be avoided, the dosing times between budesonide and the CYP450 3A4 inhibitor should be separated by as much as possible. In addition, the lowest effective dosage of budesonide should be prescribed, and further adjustments made as necessary according to therapeutic response and tolerance.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190986/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Daveluy A, Raignoux C, Miremont-Salame G, et al. "Drug interactions between inhaled corticosteroids and enzymatic inhibitors." Eur J Clin Pharmacol (2009):[5] "Product Information. Entocort (budesonide)." AstraZeneca Pharma Inc, Mississauga, ON.[6] "Product Information. Victrelis (boceprevir)." Schering-Plough Corporation, Kenilworth, NJ.[7] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[8] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[9] Molimard M, Girodet PO, Pollet C, et al. "Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation." Drug Saf 31 (2008): 769-74[10] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[11] De Wachter E, Malfroot A, De Schutter I, Vanbesien J, De Schepper J "Inhaled budesonide induced Cushing''s syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450." J Calif Dent Assoc 2 (2003): 72-5[12] "Product Information. Incivek (telaprevir)." Vertex Pharmaceuticals, Cambridge, MA.[13] Kedem E, Shahar E, Hassoun G, Pollack S "Iatrogenic Cushing''s syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient." J Asthma 47 (2010): 830-1[14] Jonsson G, Astrom A, Andersson P "Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver." Drug Metab Dispos 23 (1995): 137-42[15] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[16] De Wachter E, Vanbesien J, De Schutter I, Malfroot A, De Schepper J "Rapidly developing Cushing syndrome in a 4-year-old patient during combined treatment with itraconazole and inhaled budesonide." Eur J Pediatr (2003):[17] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190759, 'Fosnetupitant', 'Butorphanol', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of butorphanol according to the product labeling. Increased butorphanol concentrations could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Conversely, discontinuation of a CYP450 3A4 inhibitor could decrease butorphanol plasma concentrations, decrease opioid efficacy, and possibly even lead to a withdrawal syndrome in patients who had developed physical dependence to butorphanol.', NULL, 'Patients receiving butorphanol with potent or moderate CYP450 3A4 inhibitors should be carefully monitored, and dosage adjustments made accordingly as needed.', NULL, 'Patients receiving butorphanol with potent or moderate CYP450 3A4 inhibitors should be carefully monitored, and dosage adjustments made accordingly as needed. Patients and/or their caregivers should be advised to seek medical attention if potential signs and symptoms of toxicity occur, such as dizziness, confusion, fainting, extreme sedation, unresponsiveness, bradycardia, slow or difficult breathing, and shortness of breath. When discontinuing CYP450 3A4 inhibitors, monitor patients closely at frequent intervals and consider increasing the opioid dosage if needed to maintain adequate analgesia or if symptoms of opioid withdrawal occur.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190987/', '[1] "Product Information. Butorphanol Tartrate (butorphanol)." Apotex Corporation, Weston, FL.[2] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190760, 'Fosnetupitant', 'Cabazitaxel', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of cabazitaxel, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if cabazitaxel is prescribed with CYP450 3A4 inhibitors.', NULL, 'Caution is advised if cabazitaxel is prescribed with CYP450 3A4 inhibitors. Pharmacologic response to cabazitaxel should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the cabazitaxel dosage adjusted as necessary. Regular monitoring of peripheral blood counts between treatment cycles is recommended, and patients should be advised to contact their physician if they experience potential signs and symptoms of cabazitaxel toxicity such as infection, fever, chills, diarrhea, unusual bruising or bleeding, and burning, tingling, or numbness in the hands and feet.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190988/', '[1] "Product Information. Jevtana (cabazitaxel)." sanofi-aventis , Bridgewater, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190761, 'Fosnetupitant', 'Cannabidiol', 'Minor', 'Cannabidiol is a substrate for CYP450 3A4 and CYP450 2C19. Cannabidiol is metabolized in the liver and the gut (primarily in the liver) by CYP450 2C19 and CYP450 3A4 enzymes, and UGT1A7, UGT1A9, and UGT2B7 isoforms.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190989/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences Inc, Carlsbad, CA.[3] "Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences Inc, Carlsbad, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190762, 'Fosnetupitant', 'Capmatinib', 'Moderate', 'Coadministration of capmatinib with moderate CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung disease, pneumonitis, and hepatotoxicity. The proposed mechanism is decreased clearance due to inhibition of CYP450 3A4, which is one of the primary enzymes responsible for the metabolic clearance of capmatinib.', NULL, 'Close monitoring is recommended whenever capmatinib is used with a moderate CYP450 3A4 inhibitor.', NULL, 'Close monitoring is recommended whenever capmatinib is used with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy with capmatinib, and the dosage adjusted as necessary based on clinical response and toxicity. Patients should be monitored for the development of adverse effects.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190990/', '[1] "Product Information. Tabrecta (capmatinib)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190763, 'Fosnetupitant', 'Carbamazepine', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190991/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190764, 'Fosnetupitant', 'Cariprazine', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of cariprazine and its major active metabolite, didesmethyl cariprazine (DDCAR), both of which are primarily metabolized by the isoenzyme.', NULL, 'Caution is advised when cariprazine is prescribed with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised when cariprazine is prescribed with moderate CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as extrapyramidal symptoms, cognitive and motor impairment, hyperglycemia, dyslipidemia, weight gain, orthostatic hypotension, leukopenia, neutropenia, seizures and dysphagia, and the dosage of cariprazine adjusted as necessary in accordance with the product labeling.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190992/', '[1] "Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc., Parsippany, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190765, 'Fosnetupitant', 'Cerivastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', NULL, 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', NULL, 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190993/', '[1] Yeo KR, Yeo WW, Wallis EJ, Ramsay LE "Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients." Br J Clin Pharmacol 48 (1999): 610-5[2] Andreou ER, Ledger S "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis." Can J Clin Pharmacol 10 (2003): 172-4[3] Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3[4] "Product Information. Zocor (simvastatin)." Merck & Co, Inc, West Point, PA.[5] Neuvonen PJ, Backman JT, Niemi M "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." Clin Pharmacokinet 47 (2008): 463-74[6] Norman DJ, Illingworth DR, Munson J, Hosenpud J "Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin." N Engl J Med 318 (1988): 46-7[7] Williams D, Feely J "Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors." Clin Pharmacokinet 41 (2002): 343-70[8] Dallaire M, Chamberland M "Severe rhabdomyolysis in a patient receiving lovastatin, danazol and doxycycline." Can Med Assoc J 150 (1994): 1991-4[9] Malaty LI, Kuper JJ "Drug interactions of HIV protease inhibitors." Drug Safety 20 (1999): 147-69[10] Kivisto KT, Kantola T, Neuvonen PJ "Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin." Br J Clin Pharmacol 46 (1998): 49-53[11] Huynh T, Cordato D, Yang F, et al. "HMG coA reductase-inhibitor-related myopathy and the influence of drug interactions." Intern Med J 32(9-10) (2002): 486-90[12] Neuvonen PJ, Jalava KM "Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 60 (1996): 54-61[13] Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F "New insights into the pharmacodynamic and pharmacokinetic properties of statins." Pharmacol Ther 84 (1999): 413-28[14] Amsden GW, Kuye O, Wei GC "A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers." J Clin Pharmacol 42 (2002): 444-9[15] Neuvonen PJ, Kantola T, Kivisto KT "Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole." Clin Pharmacol Ther 63 (1998): 332-41[16] Omar MA, Wilson JP "FDA adverse event reports on statin-associated rhabdomyolysis." Ann Pharmacother 36 (2002): 288-95[17] Spach DH, Bauwens JE, Clark CD, Burke WG "Rhabdomyolysis associated with lovastatin and erythromycin use." West J Med 154 (1991): 213-5[18] Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG "Rhabdomyolysis in association with simvastatin and amiodarone." Ann Pharmacother 38 (2004): 978-81[19] Jacobson RH, Wang P, Glueck CJ "Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone." JAMA 277 (1997): 296[20] Chouhan UM, Chakrabarti S, Millward LJ "Simvastatin interaction with clarithromycin and amiodarone causing myositis." Ann Pharmacother 39 (2005): 1760-1[21] Thompson M, Samuels S "Rhabdomyolysis with simvastatin and nefazodone." Am J Psychiatry 159 (2002): 1607[22] Grunden JW, Fisher KA "Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin." Ann Pharmacother 31 (1997): 859-63[23] Kantola T, Kivisto KT, Neuvonen PJ "Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations." Clin Pharmacol Ther 64 (1998): 177-82[24] "Product Information. Mevacor (lovastatin)." Merck & Co, Inc, West Point, PA.[25] Garnett WR "Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors." Am J Health Syst Pharm 52 (1995): 1639-45[26] "Product Information. Baycol (cerivastatin)." Bayer, West Haven, CT.[27] Gullestad L, Nordal KP, Berg KJ, Cheng H, Schwartz MS, Simonsen S "Interaction between lovastatin and cyclosporine A after heart and kidney transplantation." Transplant Proc 31 (1999): 2163-5[28] Yeo KR, Yeo WW "Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes." Br J Clin Pharmacol 51 (2001): 461-70[29] Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304[30] "Product Information. Lipitor (atorvastatin)." Parke-Davis, Morris Plains, NJ.[31] East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA "Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation." N Engl J Med 318 (1988): 47-8[32] Westphal JF "Macrolide - induced clinically relevant drug interactions with cytochrome P-450 (CYP) 3A4: an update focused on clarithromycin, azithromycin, and dirithromycin." Br J Clin Pharmacol 50 (2000): 285-95[33] Jacobson TA "Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors." Am J Cardiol 94 (2004): 1140-6[34] Sipe BE, Jones RJ, Bokhart GH "Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction." Ann Pharmacother 37 (2003): 808-11[35] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[36] Kantola T, Kivisto KT, Neuvonen PJ "Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations." Clin Pharmacol Ther 64 (1998): 177-82[37] Lee AJ, Maddix DS "Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin." Ann Pharmacother 35 (2001): 26-31[38] Zhou LX, Finley DK, Hassell AE, Holtzman JL "Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers." J Pharmacol Exp Ther 273 (1995): 121-7[39] Kantola T, Kivisto KT, Neuvonen PJ "Effect of itraconazole on the pharmacokinetics of atorvastatin." Clin Pharmacol Ther 64 (1998): 58-65[40] Karnik NS, Maldonado JR "Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis." Psychosomatics 46 (2005): 565-8[41] de Denus S, Spinler SA "Amiodarone''s role in simvastatin-associated rhabdomyolysis." Am J Health Syst Pharm 60 (2003): 1791; author reply 1791-2[42] Maltz HC, Balog DL, Cheigh JS "Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine." Ann Pharmacother 33 (1999): 1176-9[43] Mousa O, Brater DC, Sundblad KJ, Hall SD "The interaction of diltiazem with simvastatin." Clin Pharmacol Ther 67 (2000): 267-74[44] Wong PW, Dillard TA, Kroenke K "Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy." South Med J 91 (1998): 202-5[45] Campana C, Iacona I, Regassi MB, et al. "Efficacy and pharmacokinetics of simvastatin in heart transplant recipients." Ann Pharmacother 29 (1995): 235-9[46] Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA "Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin." Am J Cardiol 84 (1999): 811-5[47] Paoletti R, Corsini A, Bellosta S "Pharmacological interactions of statins." Atheroscler Suppl 3 (2002): 35-40[48] Azie NE, Brater DC, Becker PA, Jones DR, Hall SD "The interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 64 (1998): 369-77[49] Kantola T, Kivisto KT, Neuvonen PJ "Effect of itraconazole on cerivastatin pharmacokinetics." Eur J Clin Pharmacol 54 (1999): 851-5[50] Kusus M, Stapleton DD, Lertora JJL, Simon EE, Dreisbach AW "Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions." Am J Med Sci 320 (2000): 394-7[51] Corpier CL, Jones PH, Suki WN, et al. "Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients." JAMA 260 (1988): 239-41[52] Jody DN "Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone." JAMA 277 (1997): 296-7[53] Arnadottir M, Eriksson LO, Thysell H, Karkas JD "Plasma concentration profiles of simvastatin 3-hydroxy- 3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin." Nephron 65 (1993): 410-3[54] Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. "Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047." AIDS 16 (2002): 569-577[55] Skrabal MZ, Stading JA, Monaghan MS "Rhabdomyolysis associated with simvastatin-nefazodone therapy." South Med J 96 (2003): 1034-5[56] Jardine A, Holdaas H "Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience." J Clin Pharm Ther 24 (1999): 397-408[57] Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201[58] Siedlik PH, Olson SC, Yang BB, Stern RH "Erythromycin coadministration increases plasma atorvastatin concentrations." J Clin Pharmacol 39 (1999): 501-4[59] Gilad R, Lampl Y "Rhabdomyolysis induced by simvastatin and ketoconazole treatment." Clin Neuropharmacol 22 (1999): 295-7[60] Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3[61] Lomaestro BM, Piatek MA "Update on drug interactions with azole antifungal agents." Ann Pharmacother 32 (1998): 915-28[62] Rodriguez JA, CrespoLeiro MG, Paniagua MJ, Cuenca JJ, Hermida LF, Juffe A, CastroBeiras A "Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine." Transplant Proc 31 (1999): 2522-3[63] Lees RS, Lees AM "Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole." N Engl J Med 333 (1995): 664-5[64] Horn M "Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals." Arch Dermatol 132 (1996): 1254[65] Richter WO, Jacob BG, Schwandt P "Interaction between fibre and lovastatin." Lancet 338 (1991): 706[66] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[67] Neuvonen PJ, Backman JT, Niemi M "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." Clin Pharmacokinet 47 (2008): 463-74[68] "Product Information. Lipitor (atorvastatin)." Parke-Davis, Morris Plains, NJ.[69] McMillan K "Considerations in the formulary selection of hydroxymethylglutaryl coenzyme a reductase inhibitors." Am J Health Syst Pharm 53 (1996): 2206-14[70] Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M "Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P45 isozymes involved." Drug Metab Dispos 25 (1997): 321-31[71] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190766, 'Fosnetupitant', 'Cevimeline', 'Moderate', 'Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of cevimeline, which is metabolized by these isoenzymes.', NULL, 'Dosage adjustments and clinical monitoring may be appropriate whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy.', NULL, 'Dosage adjustments and clinical monitoring may be appropriate whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to notify their physician if they experience excessive adverse cholinergic effects of cevimeline such as nausea, vomiting, diarrhea, sweating, salivation, urinary frequency, visual disturbance, confusion, tremor, palpitations, or irregular heartbeat.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190994/', '[1] "Product Information. Evoxac (cevimeline)" Daiichi Pharmaceuticals, Fort lee, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190767, 'Fosnetupitant', 'Cilostazol', 'Major', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C19 may increase the plasma concentrations of cilostazol and or its pharmacologically active metabolites, which are substrates of these isoenzymes. The possibility of prolonged and/or increased pharmacologic effects of cilostazol should be considered.', NULL, 'A 50% dosage reduction of cilostazol (i.', NULL, 'A 50% dosage reduction of cilostazol (i.e., 50 mg twice a day) should be considered when used with potent or moderate CYP450 3A4 and/or 2C19 inhibitors. Close clinical and laboratory monitoring is advised whenever the inhibitor is added to or withdrawn from therapy, and the cilostazol dosage adjusted as necessary. Patients should be advised to contact their physician if they experience adverse effects of cilostazol such as dizziness, nausea, diarrhea, bleeding, or irregular heartbeat.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190995/', '[1] Suri A, Bramer SL "Effect of omeprazole on the metabolism of cilostazol." Clin Pharmacokinet 37 (1999): 53-9[2] Suri A, Forbes WP, Bramer SL "Effects of CYP3A inhibition on the metabolism of cilostazol." Clin Pharmacokinet 37 (1999): 61-8[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals, Rockville, MD.[5] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[6] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[7] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[8] Cerner Multum, Inc. "Australian Product Information." O 0[9] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[10] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[11] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[12] "Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals, Rockville, MD.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190768, 'Fosnetupitant', 'Clonazepam', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190996/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190769, 'Fosnetupitant', 'Clorazepic acid', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190997/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190770, 'Fosnetupitant', 'Cobicistat', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of netupitant. When a single 300 mg-0.5 mg dose of netupitant-palonosetron was administered following 400 mg once daily administration of the potent CYP450 3A4 inhibitor ketoconazole for 12 days, mean netupitant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 25% and 140%, respectively, while mean Cmax and AUC of palonosetron increased by 15% and 10%, respectively. No dosage adjustment is necessary for single-dose administration of netupitant-palonosetron when used with potent CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190998/', '[1] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190771, 'Fosnetupitant', 'Cobimetinib', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of cobimetinib, which is primarily metabolized by the isoenzyme. The risk and/or severity of adverse effects such as diarrhea, nausea, vomiting, stomatitis, hemorrhage, cardiomyopathy, rash, photosensitivity, retinopathy, retinal vein occlusion, liver enzyme abnormalities, and rhabdomyolysis may be increased.', NULL, 'Concomitant use of cobimetinib with moderate CYP450 3A4 inhibitors should be avoided whenever possible.', NULL, 'Concomitant use of cobimetinib with moderate CYP450 3A4 inhibitors should be avoided whenever possible. If short-term (14 days or less) use of a moderate CYP450 3A4 inhibitor is required during treatment with cobimetinib 60 mg once daily, the manufacturer suggests reducing the cobimetinib dose to 20 mg. Following discontinuation of the moderate CYP450 3A4 inhibitor, the previous dose of 60 mg may be resumed. An alternative to the moderate CYP450 3A4 inhibitor should be used in patients who are already taking a reduced dose of cobimetinib (40 or 20 mg daily).', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/190999/', '[1] "Product Information. Cotellic (cobimetinib)." Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Cotellic (cobimetinib)." Genentech, South San Francisco, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190772, 'Fosnetupitant', 'Colchicine', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may significantly increase the serum concentrations of colchicine, which is primarily metabolized by the isoenzyme. Clinical toxicity including myopathy, neuropathy, multiorgan failure, and pancytopenia may occur.', NULL, 'Caution is advised if colchicine is prescribed in combination with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised if colchicine is prescribed in combination with moderate CYP450 3A4 inhibitors. In patients with normal renal and hepatic function, the dosage of colchicine should be reduced when used with moderate CYP450 3A4 inhibitors or within 14 days of using them. For the treatment of acute gout flares, the adjusted dosage recommended is 1.2 mg for one dose. Administration should not be repeated for at least three days. For the prophylaxis of gout flares, the adjusted dosage should be 0.3 mg twice a day (or 0.6 mg once a day) if the original regimen was 0.6 mg twice a day, and 0.3 mg once a day if the original regimen was 0.6 once a day. For the treatment of familial Mediterranean fever, the maximum dosage of colchicine is 1.2 mg/day (may be given as 0.6 mg twice a day) when used in the presence of moderate CYP450 3A4 inhibitors. Other significant inhibitors of CYP450 3A4 include amiodarone, dronedarone, imatinib, posaconazole, and quinupristin-dalfopristin, although the extent to which they may interact with colchicine is unknown. A similar dosage adjustment may be required. Patients should be advised to contact their physician if they experience symptoms of toxicity such as abdominal pain, nausea, vomiting, diarrhea, fatigue, myalgia, asthenia, hyporeflexia, paresthesia, and numbness.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191000/', '[1] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ "Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation." Biochem Pharmacol 53 (1996): 111-6[2] "Severe colchicine-macrolide interactions." Prescrire Int 12 (2003): 18-9[3] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C "Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration." Clin Nephrol 55 (2001): 181-2[4] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7[5] "Colchicine: serious interactions." Prescrire Int 17 (2008): 151-3[6] van der Velden W, Huussen J, Ter Laak H, de Sevaux R "Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin." Neth J Med 66 (2008): 204-6[7] "Product Information. Colcrys (colchicine)." AR Scientific Inc, Philadelphia, PA.[8] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[9] Cheng VC, Ho PL, Yuen KY "Two probable cases of serious drug interaction between clarithromycin and colchicine." South Med J 98 (2005): 811-3[10] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E "Acute colchicine intoxication: possible role of erythromycin administration." J Rheumatol 19 (1992): 494-6[11] Schiff D, Drislane FW "Rapid-onset colchicine myoneuropathy." Arthritis Rheum 35 (1992): 1535-6[12] McKinnell J, Tayek JA "Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis." J Clin Rheumatol 15 (2009): 303-5[13] Putterman C, Ben-Chetrit E, Caraco Y, Levy M "Colchicine intoxication: clinical pharmacology, risk factors, features, and management." Semin Arthritis Rheum 21 (1991): 143-55[14] Wilbur K, Makowsky M "Colchicine myotoxicity: case reports and literature review." Pharmacotherapy 24 (2004): 1784-92[15] Hung IF, Wu AK, Cheng VC, et al. "Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study." Clin Infect Dis 41 (2005): 291-300[16] Boomershine KH "Colchicine-induced rhabdomyolysis." Ann Pharmacother 36 (2002): 824-6[17] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P "Acute colchicine intoxication during clarithromycin administration." Ann Pharmacother 38 (2004): 2074-7[18] Goldbart A, Press J, Sofer S, Kapelushnik J "Near fatal acute colchicine intoxication in a child. A case report." Eur J Pediatr 159 (2000): 895-7[19] "Colchicine: serious interactions." Prescrire Int 17 (2008): 151-3[20] Wilbur K, Makowsky M "Colchicine myotoxicity: case reports and literature review." Pharmacotherapy 24 (2004): 1784-92[21] Schiff D, Drislane FW "Rapid-onset colchicine myoneuropathy." Arthritis Rheum 35 (1992): 1535-6[22] Putterman C, Ben-Chetrit E, Caraco Y, Levy M "Colchicine intoxication: clinical pharmacology, risk factors, features, and management." Semin Arthritis Rheum 21 (1991): 143-55[23] "Product Information. Colcrys (colchicine)." AR Scientific Inc, Philadelphia, PA.[24] Hung IF, Wu AK, Cheng VC, et al. "Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study." Clin Infect Dis 41 (2005): 291-300[25] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P "Acute colchicine intoxication during clarithromycin administration." Ann Pharmacother 38 (2004): 2074-7[26] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7[27] "Severe colchicine-macrolide interactions." Prescrire Int 12 (2003): 18-9[28] Boomershine KH "Colchicine-induced rhabdomyolysis." Ann Pharmacother 36 (2002): 824-6[29] van der Velden W, Huussen J, Ter Laak H, de Sevaux R "Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin." Neth J Med 66 (2008): 204-6[30] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C "Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration." Clin Nephrol 55 (2001): 181-2[31] Pettinger WA "Clonidine, a new antihypertensive drug." N Engl J Med 293 (1975): 1179-80[32] Dahan A, Amidon GL "Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein." Pharm Res 26 (2009): 883-92[33] McKinnell J, Tayek JA "Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis." J Clin Rheumatol 15 (2009): 303-5[34] Cheng VC, Ho PL, Yuen KY "Two probable cases of serious drug interaction between clarithromycin and colchicine." South Med J 98 (2005): 811-3[35] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E "Acute colchicine intoxication: possible role of erythromycin administration." J Rheumatol 19 (1992): 494-6[36] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ "Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation." Biochem Pharmacol 53 (1996): 111-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190773, 'Fosnetupitant', 'Conivaptan', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of netupitant. When a single 300 mg-0.5 mg dose of netupitant-palonosetron was administered following 400 mg once daily administration of the potent CYP450 3A4 inhibitor ketoconazole for 12 days, mean netupitant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 25% and 140%, respectively, while mean Cmax and AUC of palonosetron increased by 15% and 10%, respectively. No dosage adjustment is necessary for single-dose administration of netupitant-palonosetron when used with potent CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191001/', '[1] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190774, 'Fosnetupitant', 'Conjugated estrogens', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191002/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190775, 'Fosnetupitant', 'Conjugated estrogens (topical)', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191003/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190776, 'Fosnetupitant', 'Copanlisib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and P-glycoprotein (P-gp) may increase the plasma concentrations of copanlisib, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'Caution is advised when copanlisib is used with CYP450 3A4 inhibitors.', NULL, 'Caution is advised when copanlisib is used with CYP450 3A4 inhibitors. Patients should be monitored for potentially increased adverse effects such as nausea, vomiting, diarrhea, stomatitis, hyperglycemia, hypertension, noninfectious pneumonitis, cutaneous reactions (e.g., exfoliative dermatitis, maculopapular rash), anemia, neutropenia, thrombocytopenia, and infections. Dosage adjustments for copanlisib may be necessary and should be done in accordance with the product labeling.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191004/', '[1] "Product Information. Aliqopa (copanlisib)." Bayer Pharmaceutical Inc, West Haven, CT.[2] "Product Information. Aliqopa (copanlisib)." Bayer Pharmaceutical Inc, West Haven, CT.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190777, 'Fosnetupitant', 'Cyclophosphamide', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191005/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190778, 'Fosnetupitant', 'Cyclosporine', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191006/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190779, 'Fosnetupitant', 'Daclatasvir', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required.', NULL, 'Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191007/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb, Princeton, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190780, 'Fosnetupitant', 'Darifenacin', 'Moderate', 'Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes.', NULL, 'Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary.', NULL, 'Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary. Patients should be advised to contact their physician if they experience undue adverse effects of darifenacin such as severe abdominal pain or constipation for 3 or more days.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191008/', '[1] "Product Information. Enablex (darifenacin)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190781, 'Fosnetupitant', 'Darolutamide', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter. Caution is advised when darolutamide is used with CYP450 3A4 or P-gp inhibitors. Patients should be monitored more frequently for adverse effects such as fatigue, hypertension, neutropenia and abnormal liver function tests, and the darolutamide dosage adjusted as necessary in accordance with the product labeling.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191009/', '[1] "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.[2] "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190782, 'Fosnetupitant', 'Darunavir', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191010/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190783, 'Fosnetupitant', 'Deflazacort', 'Major', 'Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of 21-desdeflazacort, the active metabolite of deflazacort that is formed by esterases after oral administration and further metabolized by CYP450 3A4 to several inactive metabolites.', NULL, 'The manufacturer suggests using one-third of the recommended dosage of deflazacort when coadministered with potent or moderate CYP450 3A4 inhibitors.', NULL, 'The manufacturer suggests using one-third of the recommended dosage of deflazacort when coadministered with potent or moderate CYP450 3A4 inhibitors. Some authorities recommend avoiding concomitant use of deflazacort and CYP450 3A inhibitors unless the benefit outweighs the risk, in which case patients should be monitored for systemic corticosteroid side effects.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191011/', '[1] "Product Information. Emflaza (deflazacort)." Marathon Pharmaceuticals, Deerfield, IL.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190784, 'Fosnetupitant', 'Delavirdine', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of netupitant. When a single 300 mg-0.5 mg dose of netupitant-palonosetron was administered following 400 mg once daily administration of the potent CYP450 3A4 inhibitor ketoconazole for 12 days, mean netupitant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 25% and 140%, respectively, while mean Cmax and AUC of palonosetron increased by 15% and 10%, respectively. No dosage adjustment is necessary for single-dose administration of netupitant-palonosetron when used with potent CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191012/', '[1] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190785, 'Fosnetupitant', 'Dexamethasone', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may significantly increase the plasma concentrations of dexamethasone. The proposed mechanism is netupitant inhibition of dexamethasone metabolism via CYP450 3A4.', NULL, 'Dexamethasone should be administered at a reduced dosage when used with netupitant or fosnetupitant.', NULL, 'Dexamethasone should be administered at a reduced dosage when used with netupitant or fosnetupitant. For the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, dexamethasone should be dosed according to the product labeling for netupitant-palonosetron or fosnetupitant-palonosetron.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191013/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190786, 'Fosnetupitant', 'Diazepam', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191014/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190787, 'Fosnetupitant', 'Dienestrol (topical)', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191015/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190788, 'Fosnetupitant', 'Dihydroergotamine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.', NULL, 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191016/', '[1] Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6[2] Horowitz RS, Dart RC, Gomez HF "Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction." Arch Intern Med 156 (1996): 456-8[3] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W "Cerebral ergotism under treatment with ergotamine and ritonavir." Neurology 57 (2001): 743-4[4] Mortier E, Pouchet J, Vinceneux P, Lalande M "Ergotism related to interaction between nelfinavir and ergotamine." Am J Med 110 (2001): 594[5] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F "Clinical ergotism induced by ritonavir." Scand J Infect Dis 33 (2001): 788-9[6] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP "Ergotism related to concurrent administration of ergotamine tartrate and indinavir." JAMA 281 (1999): 987[7] Hayton AC "Precipitation of acute ergotism by triacetyloleandomycin." N Z Med J 69 (1969): 42[8] Liaudet L "Severe ergotism associated with interaction between ritonavir and ergotamine." BMJ 318 (1999): 771[9] Matthews NT, Havill JH "Ergotism with therapeutic doses of ergotamine tartrate." N Z Med J 89 (1979): 476-7[10] Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3[11] Baldwin ZK, Ceraldi CC "Ergotism associated with HIV antiviral protease inhibitor therapy." J Vasc Surg 37 (2003): 676-8[12] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[13] Eadie MJ "Clinically significant drug interactions with agents specific for migraine attacks." Cns Drugs 15 (2001): 105-18[14] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[15] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW "Fatal ergotism induced by an HIV protease inhibitor." Headache 42 (2002): 694-5[16] Bird PA, Sturgess AD "Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction." Aust N Z J Med 30 (2000): 635-6[17] Liaudet L, Buclin T, Jaccard C, Eckert P "Severe ergotism associated with interaction between ritonavir and ergotamine." Br Med J 318 (1999): 771[18] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother 41 (1997): 1207[19] Montero A, Giovannoni AG, Tvrde PL "Leg ischemia in a patient receiving ritonavir and ergotamine." Ann Intern Med 130 (1999): 329[20] Srisuma S, Lavonas EJ, Wananukul W "Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors." Clin Toxicol (Phila) (2014): 1-4[21] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7[22] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R "Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy." Ann Vasc Surg 7 (1993): 291-6[23] "Product Information. Migranal (dihydroergotamine nasal)." Novartis Pharmaceuticals, East Hanover, NJ.[24] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C "Dihydroergotamine-erythromycin-induced ergotism." Ann Intern Med 109 (1988): 249[25] "Product Information. Cafergot (caffeine-ergotamine)." Novartis Pharmaceuticals, East Hanover, NJ.[26] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[27] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[28] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[29] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[30] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[32] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[33] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[34] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[35] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[36] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[37] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[38] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[39] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[40] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[41] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[42] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[43] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[44] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[45] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[46] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[47] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[48] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[49] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[50] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[51] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[52] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[53] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[54] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[55] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[56] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[57] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190789, 'Fosnetupitant', 'Diltiazem', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191017/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190790, 'Fosnetupitant', 'Docetaxel', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 or dual CYP450 3A4 and P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of docetaxel, which is a substrate of both CYP450 3A4 and P-gp.', NULL, 'Caution is advised if docetaxel is prescribed in combination with CYP450 3A4 inhibitors or dual CYP450 3A4 and P-gp inhibitors.', NULL, 'Caution is advised if docetaxel is prescribed in combination with CYP450 3A4 inhibitors or dual CYP450 3A4 and P-gp inhibitors. Patients should be closely monitored for the development of docetaxel toxicity such as myelosuppression, stomatitis, neurotoxicity (e.g., paresthesia, dysesthesia, pain), myalgia, asthenia, fluid retention, nausea, vomiting, and diarrhea. Dosage reduction of docetaxel may be required if an interaction is suspected.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191018/', '[1] Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27[2] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91[3] "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] McInnes GT, Brodie MJ "Drug interactions that matter: a critical reappraisal." Drugs 36 (1988): 83-110[7] Yong WP, Wang LZ, Tham LS, et al. "A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers." Cancer Chemother Pharmacol 62 (2008): 243-51[8] Vodovar D, Arnaout M, Mongardon N, et al. "Severe docetaxel overdose induced by pharmacokinetic interaction with dronedarone." J Clin Oncol 29 (2011): e694-5[9] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J "Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel." Cancer Biol Ther 5 (2006): 833-9[10] McInnes GT, Brodie MJ "Drug interactions that matter: a critical reappraisal." Drugs 36 (1988): 83-110[11] Cerner Multum, Inc. "Australian Product Information." O 0[12] Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27[13] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J "Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel." Cancer Biol Ther 5 (2006): 833-9[14] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91[15] Yong WP, Wang LZ, Tham LS, et al. "A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers." Cancer Chemother Pharmacol 62 (2008): 243-51[16] "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.[17] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[18] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ "Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report." Br J Clin Pharmacol (2011):', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190791, 'Fosnetupitant', 'Doravirine', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of doravirine, which is primarily metabolized by the isoenzyme.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191019/', '[1] "Product Information. Pifeltro (doravirine)." Merck & Company Inc, Whitehouse Station, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190792, 'Fosnetupitant', 'Dutasteride', 'Moderate', 'Based on in vitro data, coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of dutasteride, which is metabolized by the isoenzyme.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of dutasteride should be considered during concomitant therapy with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of dutasteride should be considered during concomitant therapy with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191020/', '[1] "Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare, Pittsburgh, PA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190793, 'Fosnetupitant', 'Duvelisib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of duvelisib, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised when duvelisib is used with CYP450 3A4 inhibitors.', NULL, 'Caution is advised when duvelisib is used with CYP450 3A4 inhibitors. Patients should be monitored for the development of toxicities such as diarrhea, colitis, neutropenia, thrombocytopenia, pneumonitis, infections, cutaneous reactions and hepatotoxicity, and the dosing adjusted or discontinued in accordance with the duvelisib product labeling.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191021/', '[1] "Product Information. Copiktra (duvelisib)." Verastem, Inc., Needham, MA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190794, 'Fosnetupitant', 'Echinacea', 'Moderate', 'Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.', NULL, 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.', NULL, 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191022/', '[1] Gorski JC, Huang SM, Pinto A, et al. "The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo." Clin Pharmacol Ther 75 (2004): 89-100[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190795, 'Fosnetupitant', 'Elagolix', 'Moderate', 'Coadministration with inhibitors of the OATP 1B1 hepatic uptake transporter, CYP450 3A4 metabolic isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of elagolix. The effect of P-gp inhibitors on the pharmacokinetics of elagolix has not been studied, but some increases in elagolix exposure may occur, as it is a P-gp substrate. Increased exposure to elagolix may increase the risk of serious adverse effects such as bone loss, suicidal ideation and behavior, exacerbation of mood disorders, and hepatic transaminase elevations.', NULL, 'Caution is advised when elagolix is used with OATP 1B1, CYP450 3A4, and/or P-gp inhibitors.', NULL, 'Caution is advised when elagolix is used with OATP 1B1, CYP450 3A4, and/or P-gp inhibitors. Patients should be monitored for potentially altered effects of elagolix following the initiation or discontinuation of these inhibitors, and the elagolix dosage adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191023/', '[1] "Product Information. Orilissa (elagolix)." AbbVie US LLC, North Chicago, IL.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190796, 'Fosnetupitant', 'Eliglustat', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.', NULL, 'The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs).', NULL, 'The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs). In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a moderate CYP450 3A4 inhibitor. However, eliglustat should not be used with a moderate CYP450 3A4 inhibitor in CYP450 2D6 IMs or poor metabolizers (PMs). Moderate CYP450 3A4 inhibitors include aprepitant, ciprofloxacin, clotrimazole, crizotinib, darunavir, diltiazem, dronedarone, fluconazole, fusidic acid, imatinib, isavuconazonium, miconazole, mifepristone, netupitant, quinupristin-dalfopristin, ranolazine, stiripentol, and verapamil. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, duloxetine, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propoxyphene, quinidine, ranolazine, sertraline, stiripentol, and terbinafine.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191024/', '[1] "Product Information. Cerdelga (eliglustat)." Genzyme Corporation, Cambridge, MA.[2] "Product Information. Cerdelga (eliglustat)." Genzyme Corporation, Cambridge, MA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190797, 'Fosnetupitant', 'Encorafenib', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of encorafenib, which is primarily metabolized by the isoenzyme. Increased exposure to encorafenib may increase the risk of serious and life-threatening adverse effects such as hemorrhage, uveitis, QT prolongation, hepatotoxicity, dermatologic reactions, and new malignancies.', NULL, 'Concomitant use of encorafenib with moderate CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of encorafenib with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends reducing the encorafenib dose to one-half of the dose used prior to addition of the moderate CYP450 3A4 inhibitor. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, the encorafenib dose that was taken prior to initiating the inhibitor may be resumed.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191025/', '[1] "Product Information. Braftovi (encorafenib)." Array BioPharma Inc., Boulder, CO.[2] "Product Information. Braftovi (encorafenib)." Array BioPharma Inc., Boulder, CO.[3] "Product Information. Braftovi (encorafenib)." Array BioPharma Inc., Boulder, CO.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190798, 'Fosnetupitant', 'Enfortumab vedotin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of enfortumab vedotin. Enfortumab vedotin is an antibody-drug conjugate (ADC) that releases MMAE via proteolytic cleavage, and MMAE has been shown in vitro to be primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when enfortumab vedotin is used concomitantly with CYP450 3A4 inhibitors.', NULL, 'Caution is advised when enfortumab vedotin is used concomitantly with CYP450 3A4 inhibitors. Patients should be closely monitored for development or exacerbation of toxicities such as peripheral neuropathy, hyperglycaemia, dermatologic reactions (maculopapular rash, pruritus, symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), bullous dermatitis, exfoliative dermatitis, palmar-plantar erythrodysesthesia), and ocular disorders (dry eyes, keratitis, blurred vision, limbal stem cell deficiency), and the dosing of enfortumab vedotin adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191026/', '[1] Han TH, Gopal AK, Ramchandren R, et al. "CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies." J Clin Pharmacol 53 (2013): 866-77[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Padcev (enfortumab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190799, 'Fosnetupitant', 'Entrectinib', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of entrectinib, which is primarily metabolized by the isoenzyme. Increased exposure to entrectinib may increase the risk and/or severity of adverse effects such as cognitive impairment, mood disorders, dizziness, sleep disturbances, liver enzyme elevations, hyperuricemia, congestive heart failure, edema, myocarditis, QT prolongation, vision problems, anemia, and neutropenia.', NULL, 'Concomitant use of entrectinib with moderate CYP450 3A4 inhibitors should be avoided when possible.', NULL, 'Concomitant use of entrectinib with moderate CYP450 3A4 inhibitors should be avoided when possible. If coadministration is necessary, the dosage of entrectinib should be reduced to 100 mg once daily for adults and pediatrics patients (12 years and older) with a body surface area (BSA) greater than 1.5 m2. Following discontinuation, and after an appropriate washout period of the CYP450 3A4 inhibitor (i.e., 3 to 5 half-lives), the entrectinib dosage taken prior to initiating the CYP450 3A4 inhibitor may be resumed. For pediatric patients with a body surface area of 1.5 m2 or less, concomitant use of entrectinib with moderate CYP450 3A4 inhibitors should be avoided.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191027/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.[3] "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.[4] "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190800, 'Fosnetupitant', 'Enzalutamide', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191028/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190801, 'Fosnetupitant', 'Eplerenone', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of eplerenone, which is primarily metabolized by the isoenzyme.', NULL, 'When used with moderate CYP450 3A4 inhibitors, the initial dosage of eplerenone should be reduced to 25 mg once daily for the treatment of hypertension.', NULL, 'When used with moderate CYP450 3A4 inhibitors, the initial dosage of eplerenone should be reduced to 25 mg once daily for the treatment of hypertension. Patients already on eplerenone who start treatment with a moderate CYP450 3A4 inhibitor should have serum potassium and creatinine checked in 3 to 7 days.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191029/', '[1] "Product Information. Inspra (eplerenone)." Searle, Chicago, IL.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190802, 'Fosnetupitant', 'Ergometrine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.', NULL, 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191030/', '[1] Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6[2] Horowitz RS, Dart RC, Gomez HF "Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction." Arch Intern Med 156 (1996): 456-8[3] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W "Cerebral ergotism under treatment with ergotamine and ritonavir." Neurology 57 (2001): 743-4[4] Mortier E, Pouchet J, Vinceneux P, Lalande M "Ergotism related to interaction between nelfinavir and ergotamine." Am J Med 110 (2001): 594[5] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F "Clinical ergotism induced by ritonavir." Scand J Infect Dis 33 (2001): 788-9[6] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP "Ergotism related to concurrent administration of ergotamine tartrate and indinavir." JAMA 281 (1999): 987[7] Hayton AC "Precipitation of acute ergotism by triacetyloleandomycin." N Z Med J 69 (1969): 42[8] Liaudet L "Severe ergotism associated with interaction between ritonavir and ergotamine." BMJ 318 (1999): 771[9] Matthews NT, Havill JH "Ergotism with therapeutic doses of ergotamine tartrate." N Z Med J 89 (1979): 476-7[10] Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3[11] Baldwin ZK, Ceraldi CC "Ergotism associated with HIV antiviral protease inhibitor therapy." J Vasc Surg 37 (2003): 676-8[12] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[13] Eadie MJ "Clinically significant drug interactions with agents specific for migraine attacks." Cns Drugs 15 (2001): 105-18[14] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[15] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW "Fatal ergotism induced by an HIV protease inhibitor." Headache 42 (2002): 694-5[16] Bird PA, Sturgess AD "Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction." Aust N Z J Med 30 (2000): 635-6[17] Liaudet L, Buclin T, Jaccard C, Eckert P "Severe ergotism associated with interaction between ritonavir and ergotamine." Br Med J 318 (1999): 771[18] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother 41 (1997): 1207[19] Montero A, Giovannoni AG, Tvrde PL "Leg ischemia in a patient receiving ritonavir and ergotamine." Ann Intern Med 130 (1999): 329[20] Srisuma S, Lavonas EJ, Wananukul W "Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors." Clin Toxicol (Phila) (2014): 1-4[21] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7[22] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R "Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy." Ann Vasc Surg 7 (1993): 291-6[23] "Product Information. Migranal (dihydroergotamine nasal)." Novartis Pharmaceuticals, East Hanover, NJ.[24] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C "Dihydroergotamine-erythromycin-induced ergotism." Ann Intern Med 109 (1988): 249[25] "Product Information. Cafergot (caffeine-ergotamine)." Novartis Pharmaceuticals, East Hanover, NJ.[26] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[27] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[28] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[29] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[30] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[32] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[33] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[34] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[35] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[36] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[37] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[38] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[39] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[40] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[41] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[42] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[43] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[44] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[45] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[46] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[47] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[48] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[49] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[50] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[51] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[52] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[53] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[54] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[55] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[56] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[57] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190803, 'Fosnetupitant', 'Ergotamine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.', NULL, 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191031/', '[1] Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6[2] Horowitz RS, Dart RC, Gomez HF "Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction." Arch Intern Med 156 (1996): 456-8[3] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W "Cerebral ergotism under treatment with ergotamine and ritonavir." Neurology 57 (2001): 743-4[4] Mortier E, Pouchet J, Vinceneux P, Lalande M "Ergotism related to interaction between nelfinavir and ergotamine." Am J Med 110 (2001): 594[5] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F "Clinical ergotism induced by ritonavir." Scand J Infect Dis 33 (2001): 788-9[6] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP "Ergotism related to concurrent administration of ergotamine tartrate and indinavir." JAMA 281 (1999): 987[7] Hayton AC "Precipitation of acute ergotism by triacetyloleandomycin." N Z Med J 69 (1969): 42[8] Liaudet L "Severe ergotism associated with interaction between ritonavir and ergotamine." BMJ 318 (1999): 771[9] Matthews NT, Havill JH "Ergotism with therapeutic doses of ergotamine tartrate." N Z Med J 89 (1979): 476-7[10] Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3[11] Baldwin ZK, Ceraldi CC "Ergotism associated with HIV antiviral protease inhibitor therapy." J Vasc Surg 37 (2003): 676-8[12] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[13] Eadie MJ "Clinically significant drug interactions with agents specific for migraine attacks." Cns Drugs 15 (2001): 105-18[14] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[15] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW "Fatal ergotism induced by an HIV protease inhibitor." Headache 42 (2002): 694-5[16] Bird PA, Sturgess AD "Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction." Aust N Z J Med 30 (2000): 635-6[17] Liaudet L, Buclin T, Jaccard C, Eckert P "Severe ergotism associated with interaction between ritonavir and ergotamine." Br Med J 318 (1999): 771[18] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother 41 (1997): 1207[19] Montero A, Giovannoni AG, Tvrde PL "Leg ischemia in a patient receiving ritonavir and ergotamine." Ann Intern Med 130 (1999): 329[20] Srisuma S, Lavonas EJ, Wananukul W "Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors." Clin Toxicol (Phila) (2014): 1-4[21] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7[22] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R "Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy." Ann Vasc Surg 7 (1993): 291-6[23] "Product Information. Migranal (dihydroergotamine nasal)." Novartis Pharmaceuticals, East Hanover, NJ.[24] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C "Dihydroergotamine-erythromycin-induced ergotism." Ann Intern Med 109 (1988): 249[25] "Product Information. Cafergot (caffeine-ergotamine)." Novartis Pharmaceuticals, East Hanover, NJ.[26] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[27] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[28] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[29] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[30] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[32] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[33] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[34] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[35] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[36] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[37] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[38] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[39] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[40] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[41] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[42] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[43] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[44] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[45] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[46] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[47] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[48] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[49] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[50] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[51] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[52] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[53] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[54] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[55] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[56] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[57] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190804, 'Fosnetupitant', 'Erlotinib', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191032/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190805, 'Fosnetupitant', 'Estazolam', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191033/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190806, 'Fosnetupitant', 'Esterified estrogens', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191034/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190807, 'Fosnetupitant', 'Estradiol', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191035/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190808, 'Fosnetupitant', 'Estradiol (topical)', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191036/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190809, 'Fosnetupitant', 'Estrone', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191037/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190810, 'Fosnetupitant', 'Estrone sulfate', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191038/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190811, 'Fosnetupitant', 'Estrone sulfate (topical)', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191039/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190812, 'Fosnetupitant', 'Eszopiclone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of both zopiclone and its pharmacologically active S(-) enantiomer, eszopiclone. Zopiclone has been shown in vitro to be metabolized by CYP450 3A4 and CYP450 2C8, while eszopiclone is primarily metabolized by CYP450 3A4 and 2E1 via demethylation and oxidation.', NULL, 'Caution is advised when zopiclone or eszopiclone is coadministered with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised when zopiclone or eszopiclone is coadministered with moderate CYP450 3A4 inhibitors. A dosage reduction may be required if an interaction is suspected. Patients should be advised to avoid driving or operating hazardous machinery until they know how these medications affect them, preferably at least 12 hours after administration of the hypnotic.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191040/', '[1] Becquemont L, Mouajjah S, Escaffre O, Beaune P, Funck-Bretano C, Jaillon P "Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism." Drug Metab Dispos 27 (1999): 1068-73[2] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[3] "Product Information. Imovane (zopiclone)." Rhone-Poulenc Rorer Canada Inc, Laval, IN.[4] Aranko K, Luurila H, Backman JT, Neuvonen PJ, Olkkola KT "The effect of erythromycin on the pharmacokinetics and pharmacodymanics of zopiclone." Br J Clin Pharmacol 38 (1994): 363-7[5] "Product Information. Lunesta (eszopiclone)." Sepracor Inc, Marlborough, MA.[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Alderman CP, Gebauer MG, Gilbert AL, Condon JT "Possible interaction of zopiclone and nefazodone." Ann Pharmacother 35 (2001): 1378-80[8] "Product Information. Lunesta (eszopiclone)." Sepracor Inc, Marlborough, MA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190813, 'Fosnetupitant', 'Ethosuximide', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191041/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190814, 'Fosnetupitant', 'Etonogestrel', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191042/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190815, 'Fosnetupitant', 'Etoposide', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191043/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190816, 'Fosnetupitant', 'Etravirine', 'Moderate', 'Coadministration of etravirine with a drug that is both a substrate as well as inhibitor of CYP450 3A4 may result in increased plasma concentrations of etravirine and decreased plasma concentrations of the other drug. Etravirine itself is a substrate and inducer of CYP450 3A4. Theoretically, etravirine may induce metabolism of the coadministered drug while its own metabolism may be inhibited by the coadministered drug.', NULL, 'Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with a drug that is an inhibitor of CYP450 3A4.', NULL, 'Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with a drug that is an inhibitor of CYP450 3A4. In addition, dosage adjustments may be required for the coadministered drug if it is also a substrate of CYP450 3A4.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191044/', '[1] "Product Information. Intelence (etravirine)." Ortho Biotech Inc, Bridgewater, NJ.[2] "Product Information. Intelence (etravirine)." Ortho Biotech Inc, Bridgewater, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190817, 'Fosnetupitant', 'Everolimus', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 and P-glycoprotein may significantly increase the plasma concentrations of everolimus following oral administration. Everolimus is a substrate of both the CYP450 3A4 isoenzyme and P-glycoprotein drug efflux transporter, thus their inhibition in the intestine can enhance the absorption of everolimus. The risk of side effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycaemia, and hyperlipidemia may be increased.', NULL, 'Blood trough levels should be closely monitored, and the dosage adjusted accordingly during concomitant administration and after discontinuation of moderate CYP450 3A4 and P-glycoprotein inhibitors.', NULL, 'Blood trough levels should be closely monitored, and the dosage adjusted accordingly during concomitant administration and after discontinuation of moderate CYP450 3A4 and P-glycoprotein inhibitors. The manufacturer''s drug product labeling should be consulted for specific recommendations.', 'Metabolism, Absorption', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191045/', '[1] "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.[2] "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190818, 'Fosnetupitant', 'Fedratinib', 'Minor', 'Coadministration of fedratinib with moderate CYP450 3A4 inhibitors may increase the plasma concentrations and the risk of adverse effects of fedratinib, which is a substrate of the isoenzyme. However, clinical data are not available. Until further information is available, caution and monitoring for adverse effects including anemia, thrombocytopenia, gastrointestinal toxicity, and hepatic and pancreatic enzyme elevations is advised if fedratinib is used with moderate CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191046/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[6] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[9] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[10] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[11] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[12] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[13] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[14] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[18] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[19] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[20] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[21] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[22] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[23] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[24] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[26] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[27] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[28] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[29] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[30] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[31] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[32] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[33] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190819, 'Fosnetupitant', 'Felodipine', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191047/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190820, 'Fosnetupitant', 'Fesoterodine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fesoterodine''s active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of fesoterodine should be considered. Because 5-hydroxymethyl tolterodine is also metabolized by CYP450 2D6, the clinical significance of the interaction may be greater in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 (approximately 7% of Caucasians and less than 2% of Asians and individuals of African descent) who may rely more on the 3A4 metabolic pathway for clearance of the drug.', NULL, 'Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from fesoterodine therapy, and the dosage adjusted if necessary.', NULL, 'Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from fesoterodine therapy, and the dosage adjusted if necessary. Patients should be advised to notify their physician if they experience potential adverse effects of fesoterodine such as irregular heartbeat, blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, gastrointestinal upset, or constipation.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191048/', '[1] "Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] "Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190821, 'Fosnetupitant', 'Flibanserin', 'Major', 'Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C19. High plasma levels of flibanserin may increase the risk of severe hypotension, syncope, and central nervous system depression.', NULL, 'Concomitant use of flibanserin with moderate or potent CYP450 3A4 inhibitors is considered contraindicated.', NULL, 'Concomitant use of flibanserin with moderate or potent CYP450 3A4 inhibitors is considered contraindicated. When initiating flibanserin following treatment with a moderate or potent CYP450 3A4 inhibitor, the manufacturer recommends waiting until 2 weeks after the last dose of CYP450 3A4 inhibitor. Conversely, if a moderate or potent CYP450 3A4 inhibitor is required during flibanserin therapy, flibanserin should be discontinued at least 2 days before starting the CYP450 3A4 inhibitor.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191049/', '[1] "Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals, Raleigh, NC.[2] "Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals, Raleigh, NC.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190822, 'Fosnetupitant', 'Fludrocortisone', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191050/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190823, 'Fosnetupitant', 'Flurazepam', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191051/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190824, 'Fosnetupitant', 'Fluticasone', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the systemic exposure to fluticasone following intranasal administration or oral inhalation. Fluticasone undergoes extensive first-pass and systemic metabolism via CYP450 3A4, thus inhibition of the isoenzyme may significantly increase systemic bioavailability of the drug. However, the extent of interaction may depend on the route of fluticasone administration and the specific formulation.', NULL, 'Monitor for signs and symptoms of hypercorticism if intranasal or orally inhaled fluticasone is coadministered with a moderate inhibitor of CYP450 3A4.', NULL, 'Monitor for signs and symptoms of hypercorticism if intranasal or orally inhaled fluticasone is coadministered with a moderate inhibitor of CYP450 3A4. Signs and symptoms of hypercorticism include acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Signs and symptoms of adrenal insufficiency include anorexia, hypoglycemia, nausea, vomiting, weight loss, muscle wasting, fatigue, weakness, dizziness, postural hypotension, depression, and adrenal crisis manifested as inability to respond to stress (e.g., illness, infection, surgery, trauma). Systemic glucocorticoids may be necessary until adrenal function recovers.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191052/', '[1] St Clair K, Maguire JD "Role of fluconazole in a case of rapid onset ritonavir and inhaled fluticasone-associated secondary adrenal insufficiency." Int J STD AIDS 23 (2012): 371-2[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Imbruvica (ibrutinib)." Pharmacyclics Inc, Sunnyvale, CA.[4] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Hoover WC, Britton LJ, Gardner J, Jackson T, Gutierrez H "Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor." Ann Pharmacother 45 (2011): e38[7] "Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190825, 'Fosnetupitant', 'Fluticasone (nasal)', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the systemic exposure to fluticasone following intranasal administration or oral inhalation. Fluticasone undergoes extensive first-pass and systemic metabolism via CYP450 3A4, thus inhibition of the isoenzyme may significantly increase systemic bioavailability of the drug. However, the extent of interaction may depend on the route of fluticasone administration and the specific formulation.', NULL, 'Monitor for signs and symptoms of hypercorticism if intranasal or orally inhaled fluticasone is coadministered with a moderate inhibitor of CYP450 3A4.', NULL, 'Monitor for signs and symptoms of hypercorticism if intranasal or orally inhaled fluticasone is coadministered with a moderate inhibitor of CYP450 3A4. Signs and symptoms of hypercorticism include acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Signs and symptoms of adrenal insufficiency include anorexia, hypoglycemia, nausea, vomiting, weight loss, muscle wasting, fatigue, weakness, dizziness, postural hypotension, depression, and adrenal crisis manifested as inability to respond to stress (e.g., illness, infection, surgery, trauma). Systemic glucocorticoids may be necessary until adrenal function recovers.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191053/', '[1] St Clair K, Maguire JD "Role of fluconazole in a case of rapid onset ritonavir and inhaled fluticasone-associated secondary adrenal insufficiency." Int J STD AIDS 23 (2012): 371-2[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Imbruvica (ibrutinib)." Pharmacyclics Inc, Sunnyvale, CA.[4] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Hoover WC, Britton LJ, Gardner J, Jackson T, Gutierrez H "Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor." Ann Pharmacother 45 (2011): e38[7] "Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190826, 'Fosnetupitant', 'Fosamprenavir', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of netupitant. When a single 300 mg-0.5 mg dose of netupitant-palonosetron was administered following 400 mg once daily administration of the potent CYP450 3A4 inhibitor ketoconazole for 12 days, mean netupitant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 25% and 140%, respectively, while mean Cmax and AUC of palonosetron increased by 15% and 10%, respectively. No dosage adjustment is necessary for single-dose administration of netupitant-palonosetron when used with potent CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191054/', '[1] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190827, 'Fosnetupitant', 'Fosaprepitant', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191055/', '[1] "Product Information. Emend for Injection (fosaprepitant)." Merck & Company Inc, West Point, PA.[2] "Product Information. Emend (aprepitant)." Merck & Company Inc, West Point, PA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190828, 'Fosphenytoin', 'Fosnetupitant', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191056/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190829, 'Fostamatinib', 'Fosnetupitant', 'Moderate', 'Coadministration of fostamatinib with inhibitors of CYP450 3A4 may increase exposure to the active metabolite known as R406, the predominant moiety in the systemic circulation following fostamatinib administration. Fostamatinib is metabolized in the gut by alkaline phosphatase to R406, which then undergoes oxidation via CYP450 3A4 and glucuronidation via UGT1A9. In vitro, R406 is also a substrate of the P-glycoprotein (P-gp) efflux transporter.', NULL, 'Patients should be monitored for toxicities of fostamatinib during concomitant use of potent or moderate CYP450 3A4 inhibitors or dual CYP450 3A4/P-gp inhibitors, and the fostamatinib dosage adjusted as necessary in accordance with the product labeling.', NULL, 'Patients should be monitored for toxicities of fostamatinib during concomitant use of potent or moderate CYP450 3A4 inhibitors or dual CYP450 3A4/P-gp inhibitors, and the fostamatinib dosage adjusted as necessary in accordance with the product labeling.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191057/', '[1] "Product Information. Tavalisse (fostamatinib)." Rigel Pharmaceuticals, South San Francisco, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190830, 'Gefitinib', 'Fosnetupitant', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of gefitinib, which is primarily metabolized by the isoenzyme. According to the product labeling, administration of gefitinib (250 mg single dose) with the potent inhibitor itraconazole (200 mg once a day for 12 days) increased the mean gefitinib systemic exposure (AUC) by 88% in healthy male volunteers.', NULL, 'Caution is advised if gefitinib is administered with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.', NULL, 'Caution is advised if gefitinib is administered with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors. Pharmacologic response to gefitinib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be advised to contact their physician if they experience possible symptoms of gefitinib toxicity such as severe diarrhea, nausea, dyspnea, cough, and fever.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191058/', '[1] Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7[2] "Product Information. Iressa (gefitinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190831, 'Granisetron', 'Fosnetupitant', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191059/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190832, 'Guanfacine', 'Fosnetupitant', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of guanfacine, which is primarily metabolized by the isoenzyme. The risk of adverse reactions such as hypotension, bradycardia, and sedation may increase.', NULL, 'Caution and dosage adjustment are advised when guanfacine is administered with potent and moderate CYP450 3A4 inhibitors.', NULL, 'Caution and dosage adjustment are advised when guanfacine is administered with potent and moderate CYP450 3A4 inhibitors. For extended-release guanfacine, the manufacturers recommend reducing the dosage to half the recommended level during concomitant use . Further dosage adjustments may be required based on patient tolerance and response.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191060/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Intuniv (guanfacine)." Shire US Inc, Florence, KY.[3] "Product Information. Tenex (guanfacine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Intuniv (guanfacine)." Shire US Inc, Florence, KY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190833, 'Hydrocodone', 'Fosnetupitant', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme. Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.', NULL, 'Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.', NULL, 'Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine). A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone. Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension. Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191061/', '[1] "Product Information. Zohydro ER (HYDROcodone)." Zogenix, Inc, San Diego, CA.[2] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97[3] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919[4] Das PK, Warkentin DI, Hewko R, Forrest DL "Serotonin syndrome after concomitant treatment with linezolid and meperidine." Clin Infect Dis 46 (2008): 264-5[5] Mittino D, Mula M, Monaco F "Serotonin syndrome associated with tramadol-sertraline coadministration." Clin Neuropharmacol 27 (2004): 150-1[6] Gillman PK "Possible serotonin syndrome with moclobemide and pethidine." Med J Aust 162 (1995): 554[7] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[8] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[9] Kesavan S, Sobala GM "Serotonin syndrome with fluoxetine plus tramadol." J R Soc Med 92 (1999): 474-5[10] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[11] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[12] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[13] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[14] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[15] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[16] Meyer D, Halfin V "Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review." J Clin Psychopharmacol 1 (1981): 319-21[17] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[18] Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):[19] US Food and Drug Administration (FDA) "FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Available from: URL: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf." ([2016, Mar 22]):[20] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K "Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology." J Clin Psychopharmacol 22 (2002): 440-1[21] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA "Mania and tramadol-fluoxetine combination." Am J Psychiatry 158 (2001): 964-5[22] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[23] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F "Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database." J Clin Psychopharmacol (2015):[24] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[25] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[26] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE "Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil." J Clin Anesth 25 (2013): 52-4[27] Shakoor M, Ayub S, Ahad A, Ayub Z "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor." Am J Case Rep 15 (2014): 562-4[28] Lantz MS, Buchalter EN, Giambanco V "Serotonin syndrome following the administration of tramadol with paroxetine." Int J Geriatr Psychiatry 13 (1998): 343-5[29] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[30] "Venlafaxine + tramadol: serotonin syndrome." Prescrire Int 13 (2004): 57[31] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB "Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?" J Am Med Dir Assoc 6 (2005): 265-9[32] Houlihan DJ "Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine." Ann Pharmacother 38 (2004): 411-3[33] Hillman AD, Witenko CJ, Sultan SM, Gala G "Serotonin syndrome caused by fentanyl and methadone in a burn injury." Pharmacotherapy 35 (2015): 112-7[34] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[35] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[36] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL "Meperidine-induced serotonin syndrome in a susceptible patient." Br J Anaesth (2009):[37] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H "Serotonin Syndrome Probably Triggered by a Morphine-Phenelzine Interaction." Pharmacotherapy (2015):[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Kitson R, Carr B "Tramadol and severe serotonin syndrome." Anaesthesia 60 (2005): 934-5[40] Zornberg GL, Bodkin JA, Cohen BM "Severe adverse interaction between pethidine and selegiline." Lancet 337 (1991): 246[41] Mahlberg R, Kunz D, Sasse J, Kirchheiner J "Serotonin syndrome with tramadol and citalopram." Am J Psychiatry 161 (2004): 1129[42] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J "Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy." J Clin Anesth 27 (2015): 247-51[43] "Product Information. Zohydro ER (HYDROcodone)." Zogenix, Inc, San Diego, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190834, 'Hydrocortisone', 'Fosnetupitant', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191062/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190835, 'Idelalisib', 'Fosnetupitant', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of netupitant. When a single 300 mg-0.5 mg dose of netupitant-palonosetron was administered following 400 mg once daily administration of the potent CYP450 3A4 inhibitor ketoconazole for 12 days, mean netupitant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 25% and 140%, respectively, while mean Cmax and AUC of palonosetron increased by 15% and 10%, respectively. No dosage adjustment is necessary for single-dose administration of netupitant-palonosetron when used with potent CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191063/', '[1] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190836, 'Ifosfamide', 'Fosnetupitant', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191064/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190837, 'Imatinib', 'Fosnetupitant', 'Moderate', 'Imatinib is a substrate of the CYP450 3A4 isoenzyme as well as a potent competitive inhibitor of the CYP450 2C9, 2D6 and 3A4 isoenzymes. Some drugs that are known inhibitors of CYP450 3A4 are also metabolized by one or more of the isoenzymes inhibited by imatinib. Theoretically, coadministration of imatinib with those drugs may result in mutually elevated plasma drug concentrations due to competitive and noncompetitive inhibition of CYP450 activities.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of imatinib, including serious adverse effects such as edema, hematologic toxicity and immunosuppression, should be considered during concomitant therapy, particularly with potent CYP450 3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, nefazodone, and erythromycin.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of imatinib, including serious adverse effects such as edema, hematologic toxicity and immunosuppression, should be considered during concomitant therapy, particularly with potent CYP450 3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, nefazodone, and erythromycin. In addition, clinical and laboratory monitoring for potentially increased pharmacologic effects of coadministered medications is recommended, especially those with a narrow therapeutic range.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191065/', '[1] "Product Information. Gleevec (imatinib mesylate)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Gleevec (imatinib mesylate)." Novartis Pharmaceuticals, East Hanover, NJ.[4] Cerner Multum, Inc. "Australian Product Information." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190838, 'Indinavir', 'Fosnetupitant', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of netupitant. When a single 300 mg-0.5 mg dose of netupitant-palonosetron was administered following 400 mg once daily administration of the potent CYP450 3A4 inhibitor ketoconazole for 12 days, mean netupitant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 25% and 140%, respectively, while mean Cmax and AUC of palonosetron increased by 15% and 10%, respectively. No dosage adjustment is necessary for single-dose administration of netupitant-palonosetron when used with potent CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191066/', '[1] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190839, 'Irinotecan', 'Fosnetupitant', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.', NULL, 'Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.', NULL, 'Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191067/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Corona G, Vaccher E, Sandron S, et al. "Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi''s sarcoma." Clin Pharmacol Ther 83 (2008): 601-6[4] "Product Information. Onivyde (irinotecan liposomal)." Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Phansalker S, Desai AA, Bell D, et al "High-priority drug-drug interactions for use in electronic health records." J Am Med Inform Assoc 19 (2012): 735-43[7] "Product Information. Camptosar (irinotecan)." Pharmacia and Upjohn, Kalamazoo, MI.[8] "Product Information. Juxtapid (lomitapide)." Aegerion Pharmaceuticals Inc, Cambridge, MA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190840, 'Irinotecan (liposomal)', 'Fosnetupitant', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.', NULL, 'Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.', NULL, 'Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191068/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Corona G, Vaccher E, Sandron S, et al. "Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi''s sarcoma." Clin Pharmacol Ther 83 (2008): 601-6[4] "Product Information. Onivyde (irinotecan liposomal)." Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Phansalker S, Desai AA, Bell D, et al "High-priority drug-drug interactions for use in electronic health records." J Am Med Inform Assoc 19 (2012): 735-43[7] "Product Information. Camptosar (irinotecan)." Pharmacia and Upjohn, Kalamazoo, MI.[8] "Product Information. Juxtapid (lomitapide)." Aegerion Pharmaceuticals Inc, Cambridge, MA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190841, 'Isavuconazonium', 'Fosnetupitant', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).', NULL, 'Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors.', NULL, 'Caution is advised when isavuconazonium sulfate is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as nausea, vomiting, diarrhea, peripheral edema, hypokalemia, hypomagnesemia, and hepatotoxicity. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored, as isavuconazole itself is reportedly a moderate CYP450 3A4 inhibitor.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191069/', '[1] "Product Information. Cresemba (isavuconazonium)." Astellas Pharma US, Inc, Deerfield, IL.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190842, 'Isradipine', 'Fosnetupitant', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191070/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190843, 'Istradefylline', 'Fosnetupitant', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191071/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190844, 'Itraconazole', 'Fosnetupitant', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of netupitant. When a single 300 mg-0.5 mg dose of netupitant-palonosetron was administered following 400 mg once daily administration of the potent CYP450 3A4 inhibitor ketoconazole for 12 days, mean netupitant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 25% and 140%, respectively, while mean Cmax and AUC of palonosetron increased by 15% and 10%, respectively. No dosage adjustment is necessary for single-dose administration of netupitant-palonosetron when used with potent CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191072/', '[1] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190845, 'Ivacaftor', 'Fosnetupitant', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.', NULL, 'Please consult manufacturer''s product labeling for complete dosing information.', NULL, 'Please consult manufacturer''s product labeling for complete dosing information.For ivacaftor - For patients aged 6 months and older the frequency of dosing should be reduced to 1 tablet or packet once a day when coadministered with moderate CYP450 3A4 inhibitors. Patients should continue to receive the same tablet or oral granule packet strength, but instead of dosing twice a day, the frequency should be reduced to once a day. For example, ivacaftor 150 mg twice a day should be 150 mg once a day, ivacaftor 50 mg twice a day should be 50 mg once a day, etc. Use of ivacaftor with moderate or strong CYP450 3A4 inhibitors is not recommended in patients less than 6 months of age. For lumacaftor/ivacaftor - No dosage adjustment is necessary when coadministered with moderate CYP450 3A4 inhibitors. For tezacaftor/ivacaftor - The frequency of dosing should be reduced to a single morning dose of one tezacaftor/ivacaftor tablet alternating with one ivacaftor tablet every other morning during treatment with moderate CYP450 3A4 inhibitors. The evening dose of ivacaftor should not be taken. For elexacaftor/tezacaftor/ivacaftor - The frequency of dosing should be reduced to a single morning dose of two elexacaftor /tezacaftor /ivacaftor tablets alternating with one ivacaftor tablet every other day during treatment with moderate CYP450 3A4 inhibitors. The evening dose of ivacaftor should not be taken.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191073/', '[1] "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[2] "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[3] "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[4] "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[7] "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[8] "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[9] "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190846, 'Ivermectin', 'Fosnetupitant', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191074/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190847, 'Fosnetupitant', 'Ixabepilone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ixabepilone, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised when ixabepilone is prescribed with CYP450 3A4 inhibitors.', NULL, 'Caution is advised when ixabepilone is prescribed with CYP450 3A4 inhibitors. Pharmacologic response to ixabepilone should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the ixabepilone dosage adjusted as necessary. Frequent monitoring of peripheral blood counts between treatment cycles is recommended, and patients should be advised to contact their physician if they experience signs and symptoms of ixabepilone toxicities such as infection or burning, tingling, or numbness in the hands and feet.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191075/', '[1] "Product Information. Ixempra (ixabepilone)." Bristol-Myers Squibb, Princeton, NJ.[2] "Product Information. Ixempra (ixabepilone)." Bristol-Myers Squibb, Princeton, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190848, 'Fosnetupitant', 'Ketamine', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191076/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190849, 'Fosnetupitant', 'Larotrectinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4, P-glycoprotein (P-gp), and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of larotrectinib.', NULL, 'Caution is advised when larotrectinib is used with CYP450 3A4, P-gp, and/or BCRP inhibitors.', NULL, 'Caution is advised when larotrectinib is used with CYP450 3A4, P-gp, and/or BCRP inhibitors. Patients should be monitored for adverse effects such as neurotoxicity (delirium, dysarthria, dizziness, gait disturbance, paraesthesia, encephalopathy, memory impairment, tremor) and hepatotoxicity (elevations in liver transaminases), and the larotrectinib dosage adjusted as necessary in accordance with the product labeling.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191077/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Vitrakvi (larotrectinib)." Bayer Pharmaceutical Inc, West Haven, CT.[4] "Product Information. Vitrakvi (larotrectinib)." Bayer Pharmaceutical Inc, West Haven, CT.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190850, 'Fosnetupitant', 'Lemborexant', 'Major', 'Coadministration with potent or moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of lemborexant, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of lemborexant with potent or moderate CYP450 3A4 inhibitors should be avoided.', NULL, 'Concomitant use of lemborexant with potent or moderate CYP450 3A4 inhibitors should be avoided.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191078/', '[1] "Product Information. Dayvigo (lemborexant)." Eisai Inc, Woodcliff Lake, NJ.[2] "Product Information. Dayvigo (lemborexant)." Eisai Inc, Woodcliff Lake, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190851, 'Fosnetupitant', 'Letermovir', 'Moderate', 'Coadministration with letermovir may increase the plasma concentrations of drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or organic anion transporting polypeptide protein (OATP) 1B1 and 1B3. Letermovir has been shown to be a reversible inhibitor of CYP450 2C8 in vitro, although its effect on CYP450 2C8 substrates has not been evaluated clinically. Letermovir is also a time-dependent inhibitor and inducer of CYP450 3A4 in vitro.', NULL, 'Caution is advised when letermovir is used concurrently with drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or OATP 1B1 and 1B3, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when letermovir is used concurrently with drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or OATP 1B1 and 1B3, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever letermovir is added to or withdrawn from therapy. Moreover, clinicians should be aware that the magnitude of CYP450 3A- and OATP1B1/3-mediated drug interactions with coadministered drugs may be different when letermovir is used with cyclosporine. The combined effect of the two drugs on CYP450 3A4 may be similar to that of a strong CYP450 3A4 inhibitor, hence clinicians should refer to the prescribing information for dosing recommendations of the CYP450 3A4 substrate with a strong CYP450 3A4 inhibitor. Similarly, letermovir and cyclosporine may demonstrate some additive effects on OATP1B1 inhibition, although cyclosporine by itself is already a strong OATP1B1/3 inhibitor.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191079/', '[1] "Product Information. Prevymis (letermovir)." Merck & Company Inc, Whitehouse Station, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190852, 'Fosnetupitant', 'Letrozole', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191080/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190853, 'Fosnetupitant', 'Levamlodipine', 'Moderate', 'Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of amlodipine, which is a substrate of the isoenzyme.', NULL, 'Close monitoring of clinical response and tolerance is recommended if amlodipine is prescribed with potent or moderate CYP450 3A4 inhibitors.', NULL, 'Close monitoring of clinical response and tolerance is recommended if amlodipine is prescribed with potent or moderate CYP450 3A4 inhibitors. Dosage reduction may be required for amlodipine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191081/', '[1] Sasaki M, Maeda A, Fujimura A "Influence of diltiazem on the pharmacokinetics of amlodipine in elderly hypertensive patients." Eur J Clin Pharmacol 57 (2001): 85-6[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] "Product Information. Norvasc (amlodipine)." Pfizer US Pharmaceuticals, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190854, 'Fosnetupitant', 'Levobupivacaine', 'Moderate', 'Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.', NULL, 'Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.', NULL, 'Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.g., quinolones, deferasirox, mexiletine, propafenone, ticlopidine, zileuton) or CYP450 3A4 (e.g., azole antifungals, macrolide antibiotics, protease inhibitors, kinase inhibitors, aprepitant, conivaptan, cyclosporine, delavirdine, diltiazem, nefazodone, verapamil). Particular caution and dosage adjustment of levobupivacaine may be warranted during concomitant use of both a CYP450 1A2 inhibitor and a CYP450 3A4 inhibitor, or a drug that inhibits both isoenzymes (e.g., fluvoxamine). Patients should be monitored for early signs and symptoms of central nervous system toxicity such as dizziness, drowsiness, lightheadedness, anxiety, restlessness, incoherent speech, tremors, twitching, numbness and tingling of the mouth and lips, metallic taste, tinnitus, and blurred vision, as well as more serious reactions including convulsions, hypotension, arrhythmias, and cardiorespiratory depression.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191082/', '[1] "Product Information. Chirocaine (levobupivacaine)" Organon, West Orange, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190855, 'Fosnetupitant', 'Levonorgestrel', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191083/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190856, 'Fosnetupitant', 'Lomitapide', 'Major', 'Coadministration with potent and moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lomitapide, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of lomitapide with potent or moderate inhibitors of CYP450 3A4 is considered contraindicated.', NULL, 'Concomitant use of lomitapide with potent or moderate inhibitors of CYP450 3A4 is considered contraindicated. Some authorities consider concomitant administration of lomitapide and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191084/', '[1] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[2] "Product Information. Juxtapid (lomitapide)." Aegerion Pharmaceuticals Inc, Cambridge, MA.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Juxtapid (lomitapide)." Aegerion Pharmaceuticals Inc, Cambridge, MA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190857, 'Fosnetupitant', 'Lonafarnib', 'Major', 'Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lonafarnib.', NULL, 'Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inhibitors is considered contraindicated.', NULL, 'Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inhibitors is considered contraindicated.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191085/', '[1] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.[2] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190858, 'Fosnetupitant', 'Loratadine', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191086/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190859, 'Fosnetupitant', 'Lorlatinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of lorlatinib, which has been found to be metabolized primarily by CYP450 3A4 and UGT1A4 in vitro. Increased exposure to lorlatinib may increase the risk of central nervous system adverse effects (e.g., seizures, hallucinations, changes in cognitive function, mood disorders, mental status changes, sleep impairment), hyperlipidemia (hypercholesterolemia and hypertriglyceridemia), PR interval prolongation and atrioventricular (AV) block, and interstitial lung disease/pneumonitis. The extent to which other, less potent CYP450 3A4 inhibitors may affect lorlatinib is unknown.', NULL, 'Caution is advised when lorlatinib is used with CYP450 3A4 inhibitors.', NULL, 'Caution is advised when lorlatinib is used with CYP450 3A4 inhibitors. Patients should be monitored for the development of central nervous system and other adverse effects, and the dosing adjusted or discontinued in accordance with the lorlatinib product labeling.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191087/', '[1] "Product Information. Lorbrena (lorlatinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Lorbrena (lorlatinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190860, 'Fosnetupitant', 'Lovastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', NULL, 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', NULL, 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191088/', '[1] Yeo KR, Yeo WW, Wallis EJ, Ramsay LE "Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients." Br J Clin Pharmacol 48 (1999): 610-5[2] Andreou ER, Ledger S "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis." Can J Clin Pharmacol 10 (2003): 172-4[3] Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3[4] "Product Information. Zocor (simvastatin)." Merck & Co, Inc, West Point, PA.[5] Neuvonen PJ, Backman JT, Niemi M "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." Clin Pharmacokinet 47 (2008): 463-74[6] Norman DJ, Illingworth DR, Munson J, Hosenpud J "Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin." N Engl J Med 318 (1988): 46-7[7] Williams D, Feely J "Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors." Clin Pharmacokinet 41 (2002): 343-70[8] Dallaire M, Chamberland M "Severe rhabdomyolysis in a patient receiving lovastatin, danazol and doxycycline." Can Med Assoc J 150 (1994): 1991-4[9] Malaty LI, Kuper JJ "Drug interactions of HIV protease inhibitors." Drug Safety 20 (1999): 147-69[10] Kivisto KT, Kantola T, Neuvonen PJ "Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin." Br J Clin Pharmacol 46 (1998): 49-53[11] Huynh T, Cordato D, Yang F, et al. "HMG coA reductase-inhibitor-related myopathy and the influence of drug interactions." Intern Med J 32(9-10) (2002): 486-90[12] Neuvonen PJ, Jalava KM "Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 60 (1996): 54-61[13] Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F "New insights into the pharmacodynamic and pharmacokinetic properties of statins." Pharmacol Ther 84 (1999): 413-28[14] Amsden GW, Kuye O, Wei GC "A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers." J Clin Pharmacol 42 (2002): 444-9[15] Neuvonen PJ, Kantola T, Kivisto KT "Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole." Clin Pharmacol Ther 63 (1998): 332-41[16] Omar MA, Wilson JP "FDA adverse event reports on statin-associated rhabdomyolysis." Ann Pharmacother 36 (2002): 288-95[17] Spach DH, Bauwens JE, Clark CD, Burke WG "Rhabdomyolysis associated with lovastatin and erythromycin use." West J Med 154 (1991): 213-5[18] Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG "Rhabdomyolysis in association with simvastatin and amiodarone." Ann Pharmacother 38 (2004): 978-81[19] Jacobson RH, Wang P, Glueck CJ "Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone." JAMA 277 (1997): 296[20] Chouhan UM, Chakrabarti S, Millward LJ "Simvastatin interaction with clarithromycin and amiodarone causing myositis." Ann Pharmacother 39 (2005): 1760-1[21] Thompson M, Samuels S "Rhabdomyolysis with simvastatin and nefazodone." Am J Psychiatry 159 (2002): 1607[22] Grunden JW, Fisher KA "Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin." Ann Pharmacother 31 (1997): 859-63[23] Kantola T, Kivisto KT, Neuvonen PJ "Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations." Clin Pharmacol Ther 64 (1998): 177-82[24] "Product Information. Mevacor (lovastatin)." Merck & Co, Inc, West Point, PA.[25] Garnett WR "Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors." Am J Health Syst Pharm 52 (1995): 1639-45[26] "Product Information. Baycol (cerivastatin)." Bayer, West Haven, CT.[27] Gullestad L, Nordal KP, Berg KJ, Cheng H, Schwartz MS, Simonsen S "Interaction between lovastatin and cyclosporine A after heart and kidney transplantation." Transplant Proc 31 (1999): 2163-5[28] Yeo KR, Yeo WW "Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes." Br J Clin Pharmacol 51 (2001): 461-70[29] Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304[30] "Product Information. Lipitor (atorvastatin)." Parke-Davis, Morris Plains, NJ.[31] East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA "Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation." N Engl J Med 318 (1988): 47-8[32] Westphal JF "Macrolide - induced clinically relevant drug interactions with cytochrome P-450 (CYP) 3A4: an update focused on clarithromycin, azithromycin, and dirithromycin." Br J Clin Pharmacol 50 (2000): 285-95[33] Jacobson TA "Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors." Am J Cardiol 94 (2004): 1140-6[34] Sipe BE, Jones RJ, Bokhart GH "Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction." Ann Pharmacother 37 (2003): 808-11[35] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[36] Kantola T, Kivisto KT, Neuvonen PJ "Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations." Clin Pharmacol Ther 64 (1998): 177-82[37] Lee AJ, Maddix DS "Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin." Ann Pharmacother 35 (2001): 26-31[38] Zhou LX, Finley DK, Hassell AE, Holtzman JL "Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers." J Pharmacol Exp Ther 273 (1995): 121-7[39] Kantola T, Kivisto KT, Neuvonen PJ "Effect of itraconazole on the pharmacokinetics of atorvastatin." Clin Pharmacol Ther 64 (1998): 58-65[40] Karnik NS, Maldonado JR "Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis." Psychosomatics 46 (2005): 565-8[41] de Denus S, Spinler SA "Amiodarone''s role in simvastatin-associated rhabdomyolysis." Am J Health Syst Pharm 60 (2003): 1791; author reply 1791-2[42] Maltz HC, Balog DL, Cheigh JS "Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine." Ann Pharmacother 33 (1999): 1176-9[43] Mousa O, Brater DC, Sundblad KJ, Hall SD "The interaction of diltiazem with simvastatin." Clin Pharmacol Ther 67 (2000): 267-74[44] Wong PW, Dillard TA, Kroenke K "Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy." South Med J 91 (1998): 202-5[45] Campana C, Iacona I, Regassi MB, et al. "Efficacy and pharmacokinetics of simvastatin in heart transplant recipients." Ann Pharmacother 29 (1995): 235-9[46] Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA "Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin." Am J Cardiol 84 (1999): 811-5[47] Paoletti R, Corsini A, Bellosta S "Pharmacological interactions of statins." Atheroscler Suppl 3 (2002): 35-40[48] Azie NE, Brater DC, Becker PA, Jones DR, Hall SD "The interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 64 (1998): 369-77[49] Kantola T, Kivisto KT, Neuvonen PJ "Effect of itraconazole on cerivastatin pharmacokinetics." Eur J Clin Pharmacol 54 (1999): 851-5[50] Kusus M, Stapleton DD, Lertora JJL, Simon EE, Dreisbach AW "Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions." Am J Med Sci 320 (2000): 394-7[51] Corpier CL, Jones PH, Suki WN, et al. "Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients." JAMA 260 (1988): 239-41[52] Jody DN "Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone." JAMA 277 (1997): 296-7[53] Arnadottir M, Eriksson LO, Thysell H, Karkas JD "Plasma concentration profiles of simvastatin 3-hydroxy- 3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin." Nephron 65 (1993): 410-3[54] Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. "Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047." AIDS 16 (2002): 569-577[55] Skrabal MZ, Stading JA, Monaghan MS "Rhabdomyolysis associated with simvastatin-nefazodone therapy." South Med J 96 (2003): 1034-5[56] Jardine A, Holdaas H "Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience." J Clin Pharm Ther 24 (1999): 397-408[57] Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201[58] Siedlik PH, Olson SC, Yang BB, Stern RH "Erythromycin coadministration increases plasma atorvastatin concentrations." J Clin Pharmacol 39 (1999): 501-4[59] Gilad R, Lampl Y "Rhabdomyolysis induced by simvastatin and ketoconazole treatment." Clin Neuropharmacol 22 (1999): 295-7[60] Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3[61] Lomaestro BM, Piatek MA "Update on drug interactions with azole antifungal agents." Ann Pharmacother 32 (1998): 915-28[62] Rodriguez JA, CrespoLeiro MG, Paniagua MJ, Cuenca JJ, Hermida LF, Juffe A, CastroBeiras A "Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine." Transplant Proc 31 (1999): 2522-3[63] Lees RS, Lees AM "Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole." N Engl J Med 333 (1995): 664-5[64] Horn M "Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals." Arch Dermatol 132 (1996): 1254[65] Richter WO, Jacob BG, Schwandt P "Interaction between fibre and lovastatin." Lancet 338 (1991): 706[66] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[67] Neuvonen PJ, Backman JT, Niemi M "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." Clin Pharmacokinet 47 (2008): 463-74[68] "Product Information. Lipitor (atorvastatin)." Parke-Davis, Morris Plains, NJ.[69] McMillan K "Considerations in the formulary selection of hydroxymethylglutaryl coenzyme a reductase inhibitors." Am J Health Syst Pharm 53 (1996): 2206-14[70] Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M "Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P45 isozymes involved." Drug Metab Dispos 25 (1997): 321-31[71] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190861, 'Fosnetupitant', 'Lumateperone', 'Major', 'Coadministration with strong or moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of lumateperone, which is metabolized by the isoenzyme in vitro.', NULL, 'Coadministration of strong or moderate CYP450 3A4 inhibitors with lumateperone should be avoided.', NULL, 'Coadministration of strong or moderate CYP450 3A4 inhibitors with lumateperone should be avoided.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191089/', '[1] "Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc., New York, NY.[2] "Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc., New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190862, 'Fosnetupitant', 'Lurasidone', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lurasidone and its active metabolite, both of which are primarily metabolized by the isoenzyme.', NULL, 'Lurasidone dosage should start at 20 mg/day and not exceed 80 mg/day when coadministered with moderate CYP450 3A4 inhibitors.', NULL, 'Lurasidone dosage should start at 20 mg/day and not exceed 80 mg/day when coadministered with moderate CYP450 3A4 inhibitors. If a moderate CYP450 3A4 inhibitor is added to existing lurasidone therapy, the lurasidone dosage should be reduced by half. Patients should be monitored for potentially increased adverse effects such as dizziness, drowsiness, dry mouth, increased appetite, weight gain, extrapyramidal symptoms, tardive dyskinesia, hyperglycaemia, dyslipidemia, hyperprolactinemia (galactorrhea, amenorrhea, gynecomastia), orthostatic hypotension, cognitive and motor impairment, seizures, dysphagia, and heat-related illnesses due to disruption of body temperature regulation.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191090/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc, Marlborough, MA.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc, Marlborough, MA.[7] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190863, 'Fosnetupitant', 'Lurbinectedin', 'Major', 'Coadministration with a moderate CYP450 3A4 inhibitor is predicted to increase lurbinectedin systemic exposure, which may increase the incidence and severity of adverse reactions to lurbinectedin, such as myelosuppression and hepatotoxicity. Concomitant use of lurbinectedin and moderate CYP450 3A4 inhibitors should generally be avoided. If the coadministration of lurbinectedin with a moderate CYP450 3A4 inhibitor cannot be avoided, a dose reduction for lurbinectedin may be considered.', NULL, 'Close clinical and laboratory monitoring is advised whenever a moderate inhibitor is added to or withdrawn from therapy.', NULL, 'Close clinical and laboratory monitoring is advised whenever a moderate inhibitor is added to or withdrawn from therapy. Patients should be advised to contact their physician if they experience symptoms suggestive of myelosuppression or hepatotoxicity, such as fever or any other signs of infection, unusual bruising or bleeding; nausea or vomiting, or pain on the right side of the abdomen.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191091/', '[1] "Product Information. Zepzelca (lurbinectedin)." Jazz Pharmaceuticals, Palo Alto, CA.[2] "Product Information. Zepzelca (lurbinectedin)." Jazz Pharmaceuticals, Palo Alto, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190864, 'Fosnetupitant', 'Lusutrombopag', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of lusutrombopag, which is a substrate of both efflux transporter proteins.', NULL, 'Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors.', NULL, 'Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors. Pharmacologic response to lusutrombopag should be monitored more closely following initiation, discontinuation, or change of dosage of the concomitant P-gp or BCRP inhibitor.', 'Distribution', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191092/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190865, 'Fosnetupitant', 'Macitentan', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of macitentan, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advisable if macitentan is used with inhibitors of CYP450 3A4.', NULL, 'Caution is advisable if macitentan is used with inhibitors of CYP450 3A4. The product labeling recommends avoiding concomitant use with potent inhibitors (e.g., protease inhibitors, clarithromycin, cobicistat, conivaptan, delavirdine, itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole), but no suggestions are given regarding use with less potent inhibitors. It may be reasonable to monitor therapeutic response to macitentan more closely.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191093/', '[1] "Product Information. Opsumit (macitentan)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190866, 'Fosnetupitant', 'Maraviroc', 'Moderate', 'Coadministration with inhibitors of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may increase the plasma concentrations of maraviroc, which is a substrate of both.', NULL, 'Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein.', NULL, 'Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein. Dosage adjustment for maraviroc may be necessary if an interaction is suspected.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191094/', '[1] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190867, 'Fosnetupitant', 'Medroxyprogesterone acetate', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191095/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190868, 'Fosnetupitant', 'Megestrol acetate', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191096/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190869, 'Fosnetupitant', 'Methylergometrine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.', NULL, 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191097/', '[1] Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6[2] Horowitz RS, Dart RC, Gomez HF "Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction." Arch Intern Med 156 (1996): 456-8[3] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W "Cerebral ergotism under treatment with ergotamine and ritonavir." Neurology 57 (2001): 743-4[4] Mortier E, Pouchet J, Vinceneux P, Lalande M "Ergotism related to interaction between nelfinavir and ergotamine." Am J Med 110 (2001): 594[5] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F "Clinical ergotism induced by ritonavir." Scand J Infect Dis 33 (2001): 788-9[6] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP "Ergotism related to concurrent administration of ergotamine tartrate and indinavir." JAMA 281 (1999): 987[7] Hayton AC "Precipitation of acute ergotism by triacetyloleandomycin." N Z Med J 69 (1969): 42[8] Liaudet L "Severe ergotism associated with interaction between ritonavir and ergotamine." BMJ 318 (1999): 771[9] Matthews NT, Havill JH "Ergotism with therapeutic doses of ergotamine tartrate." N Z Med J 89 (1979): 476-7[10] Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3[11] Baldwin ZK, Ceraldi CC "Ergotism associated with HIV antiviral protease inhibitor therapy." J Vasc Surg 37 (2003): 676-8[12] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[13] Eadie MJ "Clinically significant drug interactions with agents specific for migraine attacks." Cns Drugs 15 (2001): 105-18[14] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[15] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW "Fatal ergotism induced by an HIV protease inhibitor." Headache 42 (2002): 694-5[16] Bird PA, Sturgess AD "Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction." Aust N Z J Med 30 (2000): 635-6[17] Liaudet L, Buclin T, Jaccard C, Eckert P "Severe ergotism associated with interaction between ritonavir and ergotamine." Br Med J 318 (1999): 771[18] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother 41 (1997): 1207[19] Montero A, Giovannoni AG, Tvrde PL "Leg ischemia in a patient receiving ritonavir and ergotamine." Ann Intern Med 130 (1999): 329[20] Srisuma S, Lavonas EJ, Wananukul W "Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors." Clin Toxicol (Phila) (2014): 1-4[21] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7[22] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R "Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy." Ann Vasc Surg 7 (1993): 291-6[23] "Product Information. Migranal (dihydroergotamine nasal)." Novartis Pharmaceuticals, East Hanover, NJ.[24] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C "Dihydroergotamine-erythromycin-induced ergotism." Ann Intern Med 109 (1988): 249[25] "Product Information. Cafergot (caffeine-ergotamine)." Novartis Pharmaceuticals, East Hanover, NJ.[26] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[27] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[28] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[29] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[30] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[32] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[33] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[34] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[35] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[36] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[37] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[38] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[39] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[40] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[41] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[42] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[43] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[44] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[45] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[46] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[47] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[48] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[49] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[50] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[51] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[52] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[53] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[54] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[55] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[56] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[57] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190870, 'Fosnetupitant', 'Methylprednisolone', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191098/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190871, 'Fosnetupitant', 'Methysergide', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.', NULL, 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191099/', '[1] Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6[2] Horowitz RS, Dart RC, Gomez HF "Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction." Arch Intern Med 156 (1996): 456-8[3] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W "Cerebral ergotism under treatment with ergotamine and ritonavir." Neurology 57 (2001): 743-4[4] Mortier E, Pouchet J, Vinceneux P, Lalande M "Ergotism related to interaction between nelfinavir and ergotamine." Am J Med 110 (2001): 594[5] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F "Clinical ergotism induced by ritonavir." Scand J Infect Dis 33 (2001): 788-9[6] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP "Ergotism related to concurrent administration of ergotamine tartrate and indinavir." JAMA 281 (1999): 987[7] Hayton AC "Precipitation of acute ergotism by triacetyloleandomycin." N Z Med J 69 (1969): 42[8] Liaudet L "Severe ergotism associated with interaction between ritonavir and ergotamine." BMJ 318 (1999): 771[9] Matthews NT, Havill JH "Ergotism with therapeutic doses of ergotamine tartrate." N Z Med J 89 (1979): 476-7[10] Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3[11] Baldwin ZK, Ceraldi CC "Ergotism associated with HIV antiviral protease inhibitor therapy." J Vasc Surg 37 (2003): 676-8[12] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[13] Eadie MJ "Clinically significant drug interactions with agents specific for migraine attacks." Cns Drugs 15 (2001): 105-18[14] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[15] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW "Fatal ergotism induced by an HIV protease inhibitor." Headache 42 (2002): 694-5[16] Bird PA, Sturgess AD "Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction." Aust N Z J Med 30 (2000): 635-6[17] Liaudet L, Buclin T, Jaccard C, Eckert P "Severe ergotism associated with interaction between ritonavir and ergotamine." Br Med J 318 (1999): 771[18] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother 41 (1997): 1207[19] Montero A, Giovannoni AG, Tvrde PL "Leg ischemia in a patient receiving ritonavir and ergotamine." Ann Intern Med 130 (1999): 329[20] Srisuma S, Lavonas EJ, Wananukul W "Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors." Clin Toxicol (Phila) (2014): 1-4[21] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7[22] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R "Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy." Ann Vasc Surg 7 (1993): 291-6[23] "Product Information. Migranal (dihydroergotamine nasal)." Novartis Pharmaceuticals, East Hanover, NJ.[24] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C "Dihydroergotamine-erythromycin-induced ergotism." Ann Intern Med 109 (1988): 249[25] "Product Information. Cafergot (caffeine-ergotamine)." Novartis Pharmaceuticals, East Hanover, NJ.[26] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[27] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[28] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[29] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[30] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[32] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[33] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[34] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[35] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[36] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[37] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[38] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[39] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[40] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[41] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[42] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[43] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[44] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[45] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[46] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[47] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[48] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[49] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[50] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[51] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[52] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[53] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[54] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[55] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[56] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[57] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190872, 'Fosnetupitant', 'Midazolam', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191100/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190873, 'Fosnetupitant', 'Mirabegron', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme. However, in vivo results indicate that CYP450 3A4 may play a limited role in the overall elimination. No dosage adjustment is recommended when mirabegron is administered in combination with ketoconazole and probably other CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191101/', '[1] "Product Information. Myrbetriq (mirabegron)." Astellas Pharma US, Inc, Deerfield, IL.[2] "Product Information. Myrbetriq (mirabegron)." Astellas Pharma US, Inc, Deerfield, IL.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190874, 'Fosnetupitant', 'Mitotane', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191102/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190875, 'Fosnetupitant', 'Modafinil', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are both partially metabolized by the isoenzyme. Conversely, the plasma levels of some of these inhibitors may decrease, since many of them are also substrates of CYP450 3A4, and modafinil and armodafinil have been found to be modest inducers of CYP450 3A4. The clinical significance of this potential interaction is unknown. Clinical monitoring for altered effects of modafinil and armodafinil as well as the CYP450 3A4 inhibitor may be appropriate following addition or withdrawal of one or the other drug.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191103/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Nuvigil (armodafinil)." Cephalon Inc, West Chester, PA.[3] "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.[4] "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.[5] "Product Information. Nuvigil (armodafinil)." Cephalon Inc, West Chester, PA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190876, 'Fosnetupitant', 'Naldemedine', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 and/or moderate or potent inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of naldemedine, which is primarily metabolized by CYP450 3A4 to nor-naldemedine and to a minor extent by UGT1A3 to naldemedine 3-G. Both metabolites have demonstrated antagonistic activity for opioid receptors, but with less potency than the parent drug.', NULL, 'Caution is advised during concomitant use of naldemedine with moderate inhibitors of CYP450 3A4 and/or moderate or potent inhibitors of P-glycoprotein (P-gp).', NULL, 'Caution is advised during concomitant use of naldemedine with moderate inhibitors of CYP450 3A4 and/or moderate or potent inhibitors of P-glycoprotein (P-gp). Patients should be closely monitored for potential opioid withdrawal symptoms as well as other adverse effects of naldemedine.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191104/', '[1] "Product Information. Symproic (naldemedine)." Shionogi USA Inc, Florham Park, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Symproic (naldemedine)." Shionogi USA Inc, Florham Park, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190877, 'Fosnetupitant', 'Naloxegol', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of naloxegol, which is primarily metabolized by the isoenzyme. Increased exposure to naloxegol may precipitate opioid withdrawal symptoms such as hyperhidrosis, lacrimation, rhinorrhea, chills, diarrhea, abdominal pain, anxiety, insomnia, irritability, restlessness, and yawning.', NULL, 'Concomitant use of naloxegol with moderate CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of naloxegol with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the dosage of naloxegol should be reduced to 12.5 mg once daily and the patient closely monitored for opioid withdrawal symptoms.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191105/', '[1] "Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190878, 'Fosnetupitant', 'Nelfinavir', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of netupitant. When a single 300 mg-0.5 mg dose of netupitant-palonosetron was administered following 400 mg once daily administration of the potent CYP450 3A4 inhibitor ketoconazole for 12 days, mean netupitant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 25% and 140%, respectively, while mean Cmax and AUC of palonosetron increased by 15% and 10%, respectively. No dosage adjustment is necessary for single-dose administration of netupitant-palonosetron when used with potent CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191106/', '[1] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190879, 'Fosnetupitant', 'Neratinib', 'Major', 'Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of neratinib, which is primarily metabolized by the isoenzyme.', NULL, 'Given the potential for increased risk of toxicity, concomitant use of neratinib with potent or moderate inhibitors of CYP450 3A4 should generally be avoided.', NULL, 'Given the potential for increased risk of toxicity, concomitant use of neratinib with potent or moderate inhibitors of CYP450 3A4 should generally be avoided.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191107/', '[1] "Product Information. Nerlynx (neratinib)." Puma Biotechnology, Inc., Los Angeles, CA.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] "Product Information. Nerlynx (neratinib)." Puma Biotechnology, Inc., Los Angeles, CA.[6] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7[7] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190880, 'Fosnetupitant', 'Nevirapine', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191108/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190881, 'Fosnetupitant', 'Nicardipine', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191109/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190882, 'Fosnetupitant', 'Nifedipine', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191110/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190883, 'Fosnetupitant', 'Nimodipine', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191111/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190884, 'Fosnetupitant', 'Nisoldipine', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191112/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190885, 'Fosnetupitant', 'Nitisinone', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191113/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190886, 'Fosnetupitant', 'Norethisterone', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191114/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190887, 'Fosnetupitant', 'Norgestrel', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191115/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190888, 'Fosnetupitant', 'Olaparib', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme. Increased exposure to olaparib may increase the risk of adverse effects such as hematologic toxicity, nausea, vomiting, diarrhea, anorexia, dyspepsia, and abdominal pain or discomfort.', NULL, 'Concomitant use of olaparib with moderate CYP450 3A4 inhibitors should be avoided whenever possible.', NULL, 'Concomitant use of olaparib with moderate CYP450 3A4 inhibitors should be avoided whenever possible. If coadministration is required, dose reductions are recommended as follows: the olaparib tablet dosage should be reduced to 150 mg twice a day; the olaparib capsule dosage should be reduced to 200 mg twice a day. Specific dose recommendations for each formulation should be followed as the tablet and capsule formulations are not interchangeable due to differences in bioavailability. Once the CYP450 3A4 inhibitor has been discontinued for 3 to 5 elimination half-lives, the usual olaparib dose should be resumed.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191116/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190889, 'Fosnetupitant', 'Oxybutynin', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191117/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190890, 'Fosnetupitant', 'Oxycodone', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of oxycodone, which is substantially metabolized by the isoenzyme. Increased oxycodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Because oxycodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.', NULL, 'Extreme caution is advised if oxycodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.', NULL, 'Extreme caution is advised if oxycodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191118/', '[1] "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919[5] Das PK, Warkentin DI, Hewko R, Forrest DL "Serotonin syndrome after concomitant treatment with linezolid and meperidine." Clin Infect Dis 46 (2008): 264-5[6] Mittino D, Mula M, Monaco F "Serotonin syndrome associated with tramadol-sertraline coadministration." Clin Neuropharmacol 27 (2004): 150-1[7] Gillman PK "Possible serotonin syndrome with moclobemide and pethidine." Med J Aust 162 (1995): 554[8] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[9] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[10] Kesavan S, Sobala GM "Serotonin syndrome with fluoxetine plus tramadol." J R Soc Med 92 (1999): 474-5[11] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[12] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[13] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[14] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[15] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[16] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[17] Meyer D, Halfin V "Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review." J Clin Psychopharmacol 1 (1981): 319-21[18] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[19] Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):[20] US Food and Drug Administration (FDA) "FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Available from: URL: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf." ([2016, Mar 22]):[21] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K "Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology." J Clin Psychopharmacol 22 (2002): 440-1[22] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA "Mania and tramadol-fluoxetine combination." Am J Psychiatry 158 (2001): 964-5[23] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[24] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F "Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database." J Clin Psychopharmacol (2015):[25] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[26] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[27] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE "Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil." J Clin Anesth 25 (2013): 52-4[28] Shakoor M, Ayub S, Ahad A, Ayub Z "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor." Am J Case Rep 15 (2014): 562-4[29] Lantz MS, Buchalter EN, Giambanco V "Serotonin syndrome following the administration of tramadol with paroxetine." Int J Geriatr Psychiatry 13 (1998): 343-5[30] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[31] "Venlafaxine + tramadol: serotonin syndrome." Prescrire Int 13 (2004): 57[32] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB "Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?" J Am Med Dir Assoc 6 (2005): 265-9[33] Houlihan DJ "Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine." Ann Pharmacother 38 (2004): 411-3[34] Hillman AD, Witenko CJ, Sultan SM, Gala G "Serotonin syndrome caused by fentanyl and methadone in a burn injury." Pharmacotherapy 35 (2015): 112-7[35] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[36] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[37] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL "Meperidine-induced serotonin syndrome in a susceptible patient." Br J Anaesth (2009):[38] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H "Serotonin Syndrome Probably Triggered by a Morphine-Phenelzine Interaction." Pharmacotherapy (2015):[39] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[40] Kitson R, Carr B "Tramadol and severe serotonin syndrome." Anaesthesia 60 (2005): 934-5[41] Zornberg GL, Bodkin JA, Cohen BM "Severe adverse interaction between pethidine and selegiline." Lancet 337 (1991): 246[42] Mahlberg R, Kunz D, Sasse J, Kirchheiner J "Serotonin syndrome with tramadol and citalopram." Am J Psychiatry 161 (2004): 1129[43] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J "Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy." J Clin Anesth 27 (2015): 247-51[44] Nieminen TH, Hagelberg NM, Saari TI, et al "Grapefruit juice enhances the exposure to oral oxycodone." Basic Clin Pharmacol Toxicol 107 (2010): 782-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190891, 'Fosnetupitant', 'Paclitaxel', 'Moderate', 'Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate of these isoenzymes.', NULL, 'Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.', NULL, 'Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191119/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):[3] Bun SS, Ciccolini J, Bun H, Aubert C, Catalin J "Drug interactions of paclitaxel metabolism in human liver microsomes." J Chemother 15 (2003): 266-74[4] Spencer CM, Faulds D "Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer." Drugs 48 (1994): 794-847[5] "Product Information. Abraxane (paclitaxel protein-bound)." American Pharmaceutical Partners, Schaumberg, IL.[6] "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.[7] Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993[8] Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27[9] "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.[10] Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27[11] Cerner Multum, Inc. "Australian Product Information." O 0[12] Yong WP, Wang LZ, Tham LS, et al. "A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers." Cancer Chemother Pharmacol 62 (2008): 243-51[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91[15] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ "Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report." Br J Clin Pharmacol (2011):[16] McInnes GT, Brodie MJ "Drug interactions that matter: a critical reappraisal." Drugs 36 (1988): 83-110[17] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J "Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel." Cancer Biol Ther 5 (2006): 833-9', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190892, 'Fosnetupitant', 'Paclitaxel (protein-bound)', 'Moderate', 'Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate of these isoenzymes.', NULL, 'Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.', NULL, 'Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191120/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):[3] Bun SS, Ciccolini J, Bun H, Aubert C, Catalin J "Drug interactions of paclitaxel metabolism in human liver microsomes." J Chemother 15 (2003): 266-74[4] Spencer CM, Faulds D "Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer." Drugs 48 (1994): 794-847[5] "Product Information. Abraxane (paclitaxel protein-bound)." American Pharmaceutical Partners, Schaumberg, IL.[6] "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.[7] Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993[8] Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27[9] "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.[10] Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27[11] Cerner Multum, Inc. "Australian Product Information." O 0[12] Yong WP, Wang LZ, Tham LS, et al. "A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers." Cancer Chemother Pharmacol 62 (2008): 243-51[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91[15] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ "Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report." Br J Clin Pharmacol (2011):[16] McInnes GT, Brodie MJ "Drug interactions that matter: a critical reappraisal." Drugs 36 (1988): 83-110[17] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J "Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel." Cancer Biol Ther 5 (2006): 833-9', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190893, 'Fosnetupitant', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', NULL, 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors.', NULL, 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors. Dosage adjustment for palbociclib is not generally considered necessary for suspected interactions with mild to moderate inhibitors. However, patients should be monitored for increased adverse effects such as infections, neutropenia, leucopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, asthenia, peripheral neuropathy, and epistaxis.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191121/', '[1] "Product Information. Ibrance (palbociclib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Ibrance (palbociclib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190894, 'Fosnetupitant', 'Pemigatinib', 'Major', 'Coadministration with potent or moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of pemigatinib, which is primarily metabolized by the isoenzyme in vitro.', NULL, 'Concomitant use of pemigatinib with potent or moderate CYP450 3A4 inhibitors should be avoided.', NULL, 'Concomitant use of pemigatinib with potent or moderate CYP450 3A4 inhibitors should be avoided. If coadministration is required, a reduction in the dosage of pemigatinib is recommended.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191122/', '[1] "Product Information. Pemazyre (pemigatinib)." Incyte Corporation, Wilmington, DE.[2] "Product Information. Pemazyre (pemigatinib)." Incyte Corporation, Wilmington, DE.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190895, 'Fosnetupitant', 'Pexidartinib', 'Major', 'Coadministration of pexidartinib with moderate CYP450 3A4 inhibitors may significantly increase the plasma concentrations and the incidence and severity of adverse effects of pexidartinib, including potentially fatal hepatotoxicity. The proposed mechanism is inhibition of CYP450 3A4, the primary isoenzyme responsible for the metabolic clearance of pexidartinib.', NULL, 'The use of pexidartinib with a moderate CYP450 3A4 inhibitor should generally be avoided.', NULL, 'The use of pexidartinib with a moderate CYP450 3A4 inhibitor should generally be avoided. If concomitant use is required, the dose of pexidartinib should be reduced according to the manufacturer''s recommendations. If concomitant use of a moderate CYP450 3A4 inhibitor is discontinued, the dose of pexidartinib may be increased, after 3 plasma half-lives of the moderate CYP450 3A4 inhibitor, to the dose that was used prior to starting the moderate CYP450 3A4 inhibitor.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191123/', '[1] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.[2] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190896, 'Fosnetupitant', 'Phenobarbital', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191124/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190897, 'Fosnetupitant', 'Phenytoin', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191125/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190898, 'Fosnetupitant', 'Pimecrolimus (topical)', 'Minor', 'Theoretically, coadministration with CYP450 3A inhibitors may increase the plasma concentrations of pimecrolimus, which has been shown in vitro to undergo metabolism by this subfamily of hepatic microsomal enzymes. Although clinically significant drug interactions are not expected due to minimal systemic absorption of topically administered pimecrolimus, the possibility cannot be ruled out.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191126/', '[1] "Product Information. Elidel (pimecrolimus topical)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190899, 'Fosnetupitant', 'Polatuzumab vedotin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4.', NULL, 'Caution is advised when polatuzumab vedotin is used concomitantly with CYP450 3A4 inhibitors.', NULL, 'Caution is advised when polatuzumab vedotin is used concomitantly with CYP450 3A4 inhibitors. Patients should be monitored for development or exacerbation of toxicities such as peripheral neuropathy, myelosuppression, opportunistic infections, tumor lysis syndrome and hepatotoxicity, and the dosing of polatuzumab vedotin adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191127/', '[1] "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190900, 'Fosnetupitant', 'Pomalidomide', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191128/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190901, 'Fosnetupitant', 'Ponatinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ponatinib, which is a substrate of the isoenzyme.', NULL, 'Caution is advised if ponatinib is used in combination with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised if ponatinib is used in combination with moderate CYP450 3A4 inhibitors. Patients should be monitored for potentially increased side effects such as thromboembolism, ischemia, congestive heart failure, hypertension, hepatotoxicity, pancreatitis, myelosuppression, hemorrhage, and fluid retention.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191129/', '[1] "Product Information. Iclusig (ponatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA.[2] "Product Information. Iclusig (ponatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190902, 'Fosnetupitant', 'Pralsetinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of pralsetinib, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised when pralsetinib is used with CYP450 3A inhibitors.', NULL, 'Caution is advised when pralsetinib is used with CYP450 3A inhibitors. Monitor closely for adverse effects whenever a CYP450 3A4 inhibitor is added to therapy. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191130/', '[1] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation, Cambridge, MA.[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation, Cambridge, MA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190903, 'Fosnetupitant', 'Praziquantel', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191131/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190904, 'Fosnetupitant', 'Prednisolone', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191132/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190905, 'Fosnetupitant', 'Prednisone', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191133/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190906, 'Fosnetupitant', 'Primidone', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191134/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190907, 'Fosnetupitant', 'Progesterone', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191135/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190908, 'Fosnetupitant', 'Progesterone (topical)', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191136/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190909, 'Fosnetupitant', 'Quinestrol', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191137/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190910, 'Fosnetupitant', 'Ramelteon', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191138/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190911, 'Fosnetupitant', 'Ranolazine', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because ranolazine prolongs QT interval in a dose-dependent manner, high plasma levels of ranolazine may increase the risk of ventricular arrhythmias such as ventricular tachycardia, ventricular fibrillation, and torsade de pointes.', NULL, 'The dosage of ranolazine should not exceed 500 mg twice a day when coadministered with moderate inhibitors of CYP450 3A4, including but not limited to diltiazem, verapamil, aprepitant, erythromycin, fluconazole, and grapefruit juice.', NULL, 'The dosage of ranolazine should not exceed 500 mg twice a day when coadministered with moderate inhibitors of CYP450 3A4, including but not limited to diltiazem, verapamil, aprepitant, erythromycin, fluconazole, and grapefruit juice. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191139/', '[1] "Product Information. Ranexa (ranolazine)." Calmoseptine Inc, Huntington Beach, CA.[2] European Medicines Agency "CHMP Assessment Report for Latixa. International nonproprietary name: ranolazine. Procedure No. EMEA/H/C/805. Available from: URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/latixa/H-805-en6.pdf." ([cited 2008]):[3] "Product Information. Ranexa (ranolazine)." Calmoseptine Inc, Huntington Beach, CA.[4] "Product Information. Ranexa (ranolazine)." Calmoseptine Inc, Huntington Beach, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190912, 'Fosnetupitant', 'Repaglinide', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of repaglinide, which is partially metabolized by the isoenzyme.', NULL, 'Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, pharmacologic response to repaglinide should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.', NULL, 'Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, pharmacologic response to repaglinide should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191140/', '[1] Khamaisi M, Leitersdorf E "Severe hypoglycemia from clarithromycin-repaglinide drug interaction." Pharmacotherapy 28 (2008): 682-4[2] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[3] Hatorp V, Hansen KT, Thomsen MS "Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide." J Clin Pharmacol 43 (2003): 649-60[4] Niemi M, Backman JT, Neuvonen M, Neuvonen PJ "Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide." Diabetologia 46 (2003): 347-51[5] Niemi M, Neuvonen PJ, Kivisto KT "The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide." Clin Pharmacol Ther 70 (2001): 58-65[6] Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14[7] Tornio A, Niemi M, Neuvonen M, et al. "The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo." Clin Pharmacol Ther 84 (2008): 403-11[8] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[9] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[10] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[11] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[12] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[13] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[14] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[15] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[16] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[17] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[18] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[19] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[20] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[21] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[22] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[23] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[24] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[26] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[27] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[28] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[29] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[30] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[31] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[32] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[33] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[34] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[35] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[36] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[37] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[38] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[39] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190913, 'Fosnetupitant', 'Retapamulin (topical)', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of retapamulin, which is primarily metabolized by the isoenzyme. However, dosage adjustments are not necessary due to the low systemic exposure to retapamulin following topical application.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191141/', '[1] "Product Information. Altabax (retapamulin topical)." GlaxoSmithKline, Research Triangle Park, NC.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190914, 'Fosnetupitant', 'Rifabutin', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191142/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190915, 'Fosnetupitant', 'Rifampicin', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191143/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190916, 'Fosnetupitant', 'Rifapentine', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', NULL, 'Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191144/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190917, 'Fosnetupitant', 'Rimegepant', 'Moderate', 'INTERVAL: Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of rimegepant, which is primarily metabolized by the isoenzyme. Coadministration with a weak CYP450 3A4 inhibitor is not expected to have a clinically significant effect on rimegepant exposures.', NULL, 'Following concomitant administration with a moderate CYP450 3A4 inhibitor, the manufacturer recommends avoiding another dose of rimegepant within 48 hours.', NULL, 'Following concomitant administration with a moderate CYP450 3A4 inhibitor, the manufacturer recommends avoiding another dose of rimegepant within 48 hours.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191145/', '[1] "Product Information. Nurtec ODT (rimegepant)." Biohaven Pharmaceuticals, New Haven, CT.[2] "Product Information. Nurtec ODT (rimegepant)." Biohaven Pharmaceuticals, New Haven, CT.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190918, 'Fosnetupitant', 'Ripretinib', 'Moderate', 'Coadministration of CYP450 3A4 inhibitors with ripretinib may increase the plasma concentrations and the risk of adverse effects (e.g., palmar-plantar erythrodysesthesia, hypertension, cardiac dysfunction, arthralgia/myalgia) of ripretinib and its active metabolite (DP-5439). The proposed mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ripretinib and DP-5439.', NULL, 'Caution is recommended when ripretinib is used concomitantly with a CYP450 3A4 inhibitor.', NULL, 'Caution is recommended when ripretinib is used concomitantly with a CYP450 3A4 inhibitor. Clinical and laboratory monitoring should be considered whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy with ripretinib, and the dosage adjusted as necessary. Patients should be monitored for development of adverse effects.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191146/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Qinlock (ripretinib)." Deciphera Pharmaceuticals, Waltham, MA.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[5] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[10] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[13] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[15] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[17] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[18] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[19] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[20] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[21] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[22] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[23] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[25] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[28] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[29] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[30] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[31] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[32] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[33] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[34] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190919, 'Fosnetupitant', 'Ritonavir', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of netupitant. When a single 300 mg-0.5 mg dose of netupitant-palonosetron was administered following 400 mg once daily administration of the potent CYP450 3A4 inhibitor ketoconazole for 12 days, mean netupitant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 25% and 140%, respectively, while mean Cmax and AUC of palonosetron increased by 15% and 10%, respectively. No dosage adjustment is necessary for single-dose administration of netupitant-palonosetron when used with potent CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191147/', '[1] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190920, 'Fosnetupitant', 'Rivaroxaban', 'Moderate', 'Coadministration with moderate or potent inhibitors of CYP450 3A4 may increase the plasma concentrations of rivaroxaban, which is a substrate of the isoenzyme.', NULL, 'In patients with significant renal impairment, the use of rivaroxaban with moderate or potent inhibitors of CYP450 3A4 should be approached with caution.', NULL, 'In patients with significant renal impairment, the use of rivaroxaban with moderate or potent inhibitors of CYP450 3A4 should be approached with caution. Patients should be routinely evaluated for signs and symptoms suggesting blood loss such as a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress (in pregnant women). Renal function should also be assessed periodically, and treatment with rivaroxaban discontinued if acute renal failure develops. Due to the lack of clinical data, rivaroxaban is not recommended in patients with CrCl below 30 mL/min when used for the prophylaxis of deep vein thrombosis and in patients with CrCl below 15 mL/min when used for reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191148/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Xarelto (rivaroxaban)." Bayer Inc, Toronto, IA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190921, 'Fosnetupitant', 'Ropivacaine', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ropivacaine. Although ropivacaine is primarily metabolized by CYP450 1A2, it has been shown to undergo some metabolism via CYP450 3A4.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191149/', '[1] Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT "The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine." Anesth Analg 91 (2000): 1207-12[2] Ekstrom G, Gunnarsson UB "Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes." Drug Metab Dispos 24 (1996): 955-61[3] Arlander E, Ekstrom G, Alm C, Carrillo JA, Bielenstein M, Bottiger Y, Bertilsson L, Gustafsson LL "Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors." Clin Pharmacol Ther 64 (1998): 484-91[4] McClure JH "Ropivacaine." Br J Anaesth 76 (1996): 300-7[5] "Product Information. Naropin (ropivacaine)." Astra USA, Westborough, MA.[6] Halldin MM, Bredberg E, Angelin B, Arvidsson T, Askemark Y, Elofsson S, Widman M "Metabolism and excretion of ropivacaine in humans." Drug Metab Dispos 24 (1996): 962-8[7] Oda Y, Furuichi K, Tanaka K, Hiroi T, Imaoka S, Asada A, Fujimori M, Funae Y "Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450." Anesthesiology 82 (1995): 214-20', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190922, 'Fosnetupitant', 'Ruxolitinib', 'Minor', 'Coadministration with mild or moderate inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ruxolitinib, which is primarily metabolized by the isoenzyme. No dosage adjustment is recommended when ruxolitinib is coadministered with mild or moderate CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191150/', '[1] "Product Information. Jakafi (ruxolitinib)." Incyte Corporation, Wilmington, DE.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Jakafi (ruxolitinib)." Incyte Corporation, Wilmington, DE.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190923, 'Fosnetupitant', 'Saxagliptin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may alter the plasma concentrations of saxagliptin and its pharmacologically active metabolite, both of which are substrates of the isoenzyme.', NULL, 'Pharmacologic response to saxagliptin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.', NULL, 'Pharmacologic response to saxagliptin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations. The physician should be notified if an interaction is suspected.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191151/', '[1] "Product Information. Onglyza (saxagliptin)." Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[5] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[6] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[7] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[8] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[9] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[10] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[11] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190924, 'Fosnetupitant', 'Selumetinib', 'Major', 'Coadministration with potent or moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5. Selumetinib also undergoes glucuronidation by UGT1A1 and UGT1A3. When coadministered with itraconazole, a potent CYP450 3A4 inhibitor, selumetinib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 19% and 49%, respectively.', NULL, 'Concomitant use of selumetinib with potent or moderate CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of selumetinib with potent or moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, a reduction in the dosage of selumetinib is recommended.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191152/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] "Multum Information Services, Inc. Expert Review Panel"[3] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190925, 'Fosnetupitant', 'Sildenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sildenafil, which is primarily metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of sildenafil should be considered.', NULL, 'Caution is advised if sildenafil is coadministered with CYP450 3A4 inhibitors.', NULL, 'Caution is advised if sildenafil is coadministered with CYP450 3A4 inhibitors. Dosage adjustments may be appropriate for sildenafil whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy based on efficacy and side effects. Patients should be advised to promptly notify their physician if they experience pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191153/', '[1] "Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] Warrington JS, Shader RI, vonMoltke LL, Greenblatt DJ "In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions." Drug Metab Disposition 28 (2000): 392-7[4] Hyland R, Roe GH, Jones BC, Smith DA "Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil." Br J Clin Pharmaacol 51 (2001): 239-48[5] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190926, 'Fosnetupitant', 'Silodosin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of silodosin, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if silodosin is prescribed in combination with inhibitors of CYP450 3A4.', NULL, 'Caution is advised if silodosin is prescribed in combination with inhibitors of CYP450 3A4. Pharmacologic response to silodosin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the silodosin dosage adjusted as necessary. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191154/', '[1] "Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals, Corona, CA.[2] "Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals, Corona, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190927, 'Fosnetupitant', 'Simvastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', NULL, 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', NULL, 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191155/', '[1] Yeo KR, Yeo WW, Wallis EJ, Ramsay LE "Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients." Br J Clin Pharmacol 48 (1999): 610-5[2] Andreou ER, Ledger S "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis." Can J Clin Pharmacol 10 (2003): 172-4[3] Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3[4] "Product Information. Zocor (simvastatin)." Merck & Co, Inc, West Point, PA.[5] Neuvonen PJ, Backman JT, Niemi M "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." Clin Pharmacokinet 47 (2008): 463-74[6] Norman DJ, Illingworth DR, Munson J, Hosenpud J "Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin." N Engl J Med 318 (1988): 46-7[7] Williams D, Feely J "Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors." Clin Pharmacokinet 41 (2002): 343-70[8] Dallaire M, Chamberland M "Severe rhabdomyolysis in a patient receiving lovastatin, danazol and doxycycline." Can Med Assoc J 150 (1994): 1991-4[9] Malaty LI, Kuper JJ "Drug interactions of HIV protease inhibitors." Drug Safety 20 (1999): 147-69[10] Kivisto KT, Kantola T, Neuvonen PJ "Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin." Br J Clin Pharmacol 46 (1998): 49-53[11] Huynh T, Cordato D, Yang F, et al. "HMG coA reductase-inhibitor-related myopathy and the influence of drug interactions." Intern Med J 32(9-10) (2002): 486-90[12] Neuvonen PJ, Jalava KM "Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 60 (1996): 54-61[13] Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F "New insights into the pharmacodynamic and pharmacokinetic properties of statins." Pharmacol Ther 84 (1999): 413-28[14] Amsden GW, Kuye O, Wei GC "A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers." J Clin Pharmacol 42 (2002): 444-9[15] Neuvonen PJ, Kantola T, Kivisto KT "Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole." Clin Pharmacol Ther 63 (1998): 332-41[16] Omar MA, Wilson JP "FDA adverse event reports on statin-associated rhabdomyolysis." Ann Pharmacother 36 (2002): 288-95[17] Spach DH, Bauwens JE, Clark CD, Burke WG "Rhabdomyolysis associated with lovastatin and erythromycin use." West J Med 154 (1991): 213-5[18] Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG "Rhabdomyolysis in association with simvastatin and amiodarone." Ann Pharmacother 38 (2004): 978-81[19] Jacobson RH, Wang P, Glueck CJ "Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone." JAMA 277 (1997): 296[20] Chouhan UM, Chakrabarti S, Millward LJ "Simvastatin interaction with clarithromycin and amiodarone causing myositis." Ann Pharmacother 39 (2005): 1760-1[21] Thompson M, Samuels S "Rhabdomyolysis with simvastatin and nefazodone." Am J Psychiatry 159 (2002): 1607[22] Grunden JW, Fisher KA "Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin." Ann Pharmacother 31 (1997): 859-63[23] Kantola T, Kivisto KT, Neuvonen PJ "Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations." Clin Pharmacol Ther 64 (1998): 177-82[24] "Product Information. Mevacor (lovastatin)." Merck & Co, Inc, West Point, PA.[25] Garnett WR "Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors." Am J Health Syst Pharm 52 (1995): 1639-45[26] "Product Information. Baycol (cerivastatin)." Bayer, West Haven, CT.[27] Gullestad L, Nordal KP, Berg KJ, Cheng H, Schwartz MS, Simonsen S "Interaction between lovastatin and cyclosporine A after heart and kidney transplantation." Transplant Proc 31 (1999): 2163-5[28] Yeo KR, Yeo WW "Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes." Br J Clin Pharmacol 51 (2001): 461-70[29] Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304[30] "Product Information. Lipitor (atorvastatin)." Parke-Davis, Morris Plains, NJ.[31] East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA "Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation." N Engl J Med 318 (1988): 47-8[32] Westphal JF "Macrolide - induced clinically relevant drug interactions with cytochrome P-450 (CYP) 3A4: an update focused on clarithromycin, azithromycin, and dirithromycin." Br J Clin Pharmacol 50 (2000): 285-95[33] Jacobson TA "Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors." Am J Cardiol 94 (2004): 1140-6[34] Sipe BE, Jones RJ, Bokhart GH "Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction." Ann Pharmacother 37 (2003): 808-11[35] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[36] Kantola T, Kivisto KT, Neuvonen PJ "Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations." Clin Pharmacol Ther 64 (1998): 177-82[37] Lee AJ, Maddix DS "Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin." Ann Pharmacother 35 (2001): 26-31[38] Zhou LX, Finley DK, Hassell AE, Holtzman JL "Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers." J Pharmacol Exp Ther 273 (1995): 121-7[39] Kantola T, Kivisto KT, Neuvonen PJ "Effect of itraconazole on the pharmacokinetics of atorvastatin." Clin Pharmacol Ther 64 (1998): 58-65[40] Karnik NS, Maldonado JR "Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis." Psychosomatics 46 (2005): 565-8[41] de Denus S, Spinler SA "Amiodarone''s role in simvastatin-associated rhabdomyolysis." Am J Health Syst Pharm 60 (2003): 1791; author reply 1791-2[42] Maltz HC, Balog DL, Cheigh JS "Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine." Ann Pharmacother 33 (1999): 1176-9[43] Mousa O, Brater DC, Sundblad KJ, Hall SD "The interaction of diltiazem with simvastatin." Clin Pharmacol Ther 67 (2000): 267-74[44] Wong PW, Dillard TA, Kroenke K "Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy." South Med J 91 (1998): 202-5[45] Campana C, Iacona I, Regassi MB, et al. "Efficacy and pharmacokinetics of simvastatin in heart transplant recipients." Ann Pharmacother 29 (1995): 235-9[46] Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA "Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin." Am J Cardiol 84 (1999): 811-5[47] Paoletti R, Corsini A, Bellosta S "Pharmacological interactions of statins." Atheroscler Suppl 3 (2002): 35-40[48] Azie NE, Brater DC, Becker PA, Jones DR, Hall SD "The interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 64 (1998): 369-77[49] Kantola T, Kivisto KT, Neuvonen PJ "Effect of itraconazole on cerivastatin pharmacokinetics." Eur J Clin Pharmacol 54 (1999): 851-5[50] Kusus M, Stapleton DD, Lertora JJL, Simon EE, Dreisbach AW "Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions." Am J Med Sci 320 (2000): 394-7[51] Corpier CL, Jones PH, Suki WN, et al. "Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients." JAMA 260 (1988): 239-41[52] Jody DN "Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone." JAMA 277 (1997): 296-7[53] Arnadottir M, Eriksson LO, Thysell H, Karkas JD "Plasma concentration profiles of simvastatin 3-hydroxy- 3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin." Nephron 65 (1993): 410-3[54] Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. "Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047." AIDS 16 (2002): 569-577[55] Skrabal MZ, Stading JA, Monaghan MS "Rhabdomyolysis associated with simvastatin-nefazodone therapy." South Med J 96 (2003): 1034-5[56] Jardine A, Holdaas H "Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience." J Clin Pharm Ther 24 (1999): 397-408[57] Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201[58] Siedlik PH, Olson SC, Yang BB, Stern RH "Erythromycin coadministration increases plasma atorvastatin concentrations." J Clin Pharmacol 39 (1999): 501-4[59] Gilad R, Lampl Y "Rhabdomyolysis induced by simvastatin and ketoconazole treatment." Clin Neuropharmacol 22 (1999): 295-7[60] Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3[61] Lomaestro BM, Piatek MA "Update on drug interactions with azole antifungal agents." Ann Pharmacother 32 (1998): 915-28[62] Rodriguez JA, CrespoLeiro MG, Paniagua MJ, Cuenca JJ, Hermida LF, Juffe A, CastroBeiras A "Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine." Transplant Proc 31 (1999): 2522-3[63] Lees RS, Lees AM "Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole." N Engl J Med 333 (1995): 664-5[64] Horn M "Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals." Arch Dermatol 132 (1996): 1254[65] Richter WO, Jacob BG, Schwandt P "Interaction between fibre and lovastatin." Lancet 338 (1991): 706[66] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[67] Neuvonen PJ, Backman JT, Niemi M "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." Clin Pharmacokinet 47 (2008): 463-74[68] "Product Information. Lipitor (atorvastatin)." Parke-Davis, Morris Plains, NJ.[69] McMillan K "Considerations in the formulary selection of hydroxymethylglutaryl coenzyme a reductase inhibitors." Am J Health Syst Pharm 53 (1996): 2206-14[70] Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M "Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P45 isozymes involved." Drug Metab Dispos 25 (1997): 321-31[71] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190928, 'Fosnetupitant', 'Sirolimus', 'Moderate', 'Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the blood concentrations of the macrolide immunosuppressants sirolimus and tacrolimus, both of which are metabolized by the isoenzyme.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of macrolide immunosuppressant therapy should be considered, including adverse effects such as fever, infection, diarrhea, hypokalemia, anemia, thrombocytopenia, leukopenia, and hyperlipidemia.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of macrolide immunosuppressant therapy should be considered, including adverse effects such as fever, infection, diarrhea, hypokalemia, anemia, thrombocytopenia, leukopenia, and hyperlipidemia. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191156/', '[1] Christians U, Schmidt G, Bader A, et al "Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes." Br J Clin Pharmacol 41 (1996): 187-90[2] "Product Information. Parlodel (bromocriptine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Rapamune (sirolimus)" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] "Product Information. Rapamune (sirolimus)" Wyeth-Ayerst Laboratories, Philadelphia, PA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190929, 'Fosnetupitant', 'Sonidegib', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of sonidegib, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of sonidegib with moderate CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of sonidegib with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends limiting use of the moderate CYP450 3A4 inhibitor to less than 14 days and monitoring for adverse reactions, particularly musculoskeletal toxicity.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191157/', '[1] "Product Information. Odomzo (sonidegib)." Novartis Pharmaceuticals, East Hanover, NJ.[2] "Product Information. Odomzo (sonidegib)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190930, 'Fosnetupitant', 'Suvorexant', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of suvorexant, which is primarily metabolized by the isoenzyme.', NULL, 'The recommended dose of suvorexant is 5 mg when used with moderate CYP450 3A4 inhibitors, and generally should not exceed 10 mg.', NULL, 'The recommended dose of suvorexant is 5 mg when used with moderate CYP450 3A4 inhibitors, and generally should not exceed 10 mg.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191158/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190931, 'Fosnetupitant', 'Tadalafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of tadalafil should be considered.', NULL, 'Caution is advised if tadalafil is prescribed with CYP450 3A4 inhibitors.', NULL, 'Caution is advised if tadalafil is prescribed with CYP450 3A4 inhibitors. Dosage adjustments may be appropriate for tadalafil whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy based on efficacy and side effects. Tadalafil labeling recommends that the dosage not exceed 10 mg once every 72 hours in patients treated concomitantly with a potent CYP450 3A4 inhibitor, such as erythromycin, itraconazole, ketoconazole, protease inhibitors, and nefazodone. Patients should be advised to promptly notify their physician if they experience potential symptoms of PDE5 inhibitor toxicity such as pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191159/', '[1] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[2] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation, Silver Spring, MD.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190932, 'Fosnetupitant', 'Talazoparib', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of talazoparib, which has been shown in vitro to be a substrate of both efflux membrane transporters.', NULL, 'No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil.', NULL, 'No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil. However, patients should be closely monitored for adverse effects such as myelosuppression and myelodysplastic syndrome/acute myeloid leukemia, and dosage adjustments made or treatment withheld as needed in accordance with the product labeling.', 'Distribution', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191160/', '[1] "Product Information. Talzenna (talazoparib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190933, 'Fosnetupitant', 'Tamsulosin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may increase the plasma concentrations of tamsulosin, which is primarily metabolized in the liver by these isoenzymes.', NULL, 'Caution is advised if tamsulosin is used concomitantly with moderate CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised if tamsulosin is used concomitantly with moderate CYP450 3A4 inhibitors (e.g., amiodarone, aprepitant, diltiazem, dronedarone, erythromycin, fluconazole, fluvoxamine, fusidic acid, imatinib, isavuconazonium, verapamil) and/or moderate to potent CYP450 2D6 inhibitors (e.g., abiraterone, bupropion, celecoxib, cinacalcet, darifenacin, dronedarone, duloxetine, fluoxetine, lorcaserin, paroxetine, propafenone, quinidine, ranolazine, rolapitant, terbinafine), particularly at a dosage higher than 0.4 mg/day. The potential for increased risk of adverse effects such as postural hypotension, syncope, and priapism should be considered. It should be noted that rolapitant, a moderate CYP450 2D6 inhibitor, can increase plasma concentrations and the risk of adverse effects of tamsulosin for at least 28 days after administration of rolapitant. Patients should be advised to avoid rising abruptly from a sitting or recumbent position, and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery until they know how the medication affects them.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191161/', '[1] "Product Information. Varubi (rolapitant)." Tesaro Inc., Waltham, MA.[2] Kamimura H, Oishi S, Matsushima H, et al. "Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes." Xenobiotica 28 (1998): 909-22[3] "Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim, Ridgefield, CT.[4] Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88[5] "Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim, Ridgefield, CT.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190934, 'Fosnetupitant', 'Tasimelteon', 'Moderate', 'Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes.', NULL, 'Caution is advised if tasimelteon is prescribed in combination with inhibitors of CYP450 1A2 and/or 3A4.', NULL, 'Caution is advised if tasimelteon is prescribed in combination with inhibitors of CYP450 1A2 and/or 3A4. Patients should be monitored for excessive sedation and other side effects.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191162/', '[1] "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc, Rockville, MD.[2] "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc, Rockville, MD.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190935, 'Fosnetupitant', 'Tazemetostat', 'Major', 'Coadministration with moderate or potent CYP450 3A4 inhibitors may significantly increase the plasma concentrations of tazemetostat, which is primarily metabolized by the isoenzyme. Clinically, this interaction may result in an increased risk of the frequency or severity of adverse reactions due to tazemetostat such as secondary malignancies, hemorrhage, pleural effusion, skin infection, dyspnea, pain, and respiratory distress.', NULL, 'Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inhibitors should generally be avoided. Alternative therapeutic agents with less inhibitory potential should be considered whenever possible. If coadministration with a moderate CYP450 3A4 inhibitor is required and no other alternatives are possible, the dose of tazemetostat should be reduced as per manufacturer recommendations. After the inhibitor has been discontinued for 3 elimination half-lives, the tazemetostat dose that was taken prior to initiating the inhibitor may be resumed. Patients should be advised to notify their health care professional if they experience signs or symptoms of possible tazemetostat-related adverse effects including secondary malignancies, hemorrhage, pleural effusion, skin infection, dyspnea, pain, and respiratory distress.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191163/', '[1] "Product Information. Tazverik (tazemetostat)." Epizyme, Inc, Cambridge, MA.[2] "Product Information. Tazverik (tazemetostat)." Epizyme, Inc, Cambridge, MA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190936, 'Fosnetupitant', 'Telaprevir', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of netupitant. When a single 300 mg-0.5 mg dose of netupitant-palonosetron was administered following 400 mg once daily administration of the potent CYP450 3A4 inhibitor ketoconazole for 12 days, mean netupitant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 25% and 140%, respectively, while mean Cmax and AUC of palonosetron increased by 15% and 10%, respectively. No dosage adjustment is necessary for single-dose administration of netupitant-palonosetron when used with potent CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191164/', '[1] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190937, 'Fosnetupitant', 'Telotristat ethyl', 'Moderate', 'Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.', NULL, 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.', NULL, 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191165/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190938, 'Fosnetupitant', 'Temsirolimus', 'Moderate', 'Coadministration of temsirolimus with inhibitors of CYP450 3A4 may increase the plasma concentrations of sirolimus, a major active metabolite of temsirolimus and known substrate of CYP450 3A4.', NULL, 'Caution is advised if temsirolimus is prescribed in combination with CYP450 3A4 inhibitors.', NULL, 'Caution is advised if temsirolimus is prescribed in combination with CYP450 3A4 inhibitors. Pharmacologic response to temsirolimus should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the temsirolimus dosage adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191166/', '[1] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190939, 'Fosnetupitant', 'Teniposide', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191167/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190940, 'Fosnetupitant', 'Testosterone', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191168/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190941, 'Fosnetupitant', 'Testosterone (topical)', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191169/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190942, 'Fosnetupitant', 'Tiagabine', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191170/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190943, 'Fosnetupitant', 'Ticagrelor', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of ticagrelor, which is primarily metabolized by the isoenzyme.', NULL, 'Although administration with moderate CYP450 3A4 inhibitors is thought to be generally safe, it may be advisable to monitor pharmacologic response to ticagrelor more closely following the addition and withdrawal of these agents.', NULL, 'Although administration with moderate CYP450 3A4 inhibitors is thought to be generally safe, it may be advisable to monitor pharmacologic response to ticagrelor more closely following the addition and withdrawal of these agents. Discontinuation of the concomitant medication may be required if an interaction is suspected.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191171/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190944, 'Fosnetupitant', 'Tinidazole', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191172/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190945, 'Fosnetupitant', 'Tofacitinib', 'Moderate', 'Coadministration with one or more medications that may result in both moderate inhibition of CYP450 3A4 and potent inhibition of CYP450 2C19 may significantly increase the plasma concentrations of tofacitinib, which is primarily metabolized by the former isoenzyme with minor contribution from the latter. Side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased.', NULL, 'The dosage of tofacitinib should be reduced by 50% when used concomitantly with one or more medications that may result in both moderate inhibition of CYP450 3A4 and potent inhibition of CYP450 2C19.', NULL, 'The dosage of tofacitinib should be reduced by 50% when used concomitantly with one or more medications that may result in both moderate inhibition of CYP450 3A4 and potent inhibition of CYP450 2C19. For example, the dose for patients receiving 10 mg twice daily should be reduced to 5 mg twice daily and the dose for patients receiving 5 mg twice daily should be reduced to 5 mg once daily. For patients receiving 11 mg once daily of the extended-release formulation, the dose should be reduced to 5 mg once daily of the immediate-release formulation. The dose for patients receiving 3.2 mg twice daily should be reduced to 3.2 mg once daily and the dose for patients receiving 4 mg twice daily should be reduced to 4 mg once daily. Moderate inhibitors of CYP450 3A4 include amiodarone, aprepitant, ciprofloxacin, crizotinib, darunavir, dalfopristin-quinupristin, diltiazem, dronedarone, erythromycin, fluconazole, fusidic acid, grapefruit juice, imatinib, isavuconazonium, netupitant, and verapamil. Potent inhibitors of CYP450 2C19 include fluconazole, fluvoxamine, esomeprazole, lansoprazole, and omeprazole. Inhibitors of CYP450 2C19 alone are unlikely to substantially alter the pharmacokinetics of tofacitinib.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191173/', '[1] "Product Information. Xeljanz (tofacitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190946, 'Fosnetupitant', 'Tolterodine', 'Moderate', 'Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of tolterodine should be considered. Although tolterodine is primarily metabolized by CYP450 2D6, there is some evidence that CYP450 3A4 may play a minor role, thus any alteration in its activity levels could conceivably affect the metabolism of tolterodine.', NULL, 'The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors.', NULL, 'The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors. Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to notify their physician if they experience an irregular heartbeat, severe blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, or GI upset.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191174/', '[1] "Product Information. Detrol (tolterodine)." Pharmacia and Upjohn, Kalamazoo, MI.[2] Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190947, 'Fosnetupitant', 'Tolvaptan', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of tolvaptan, which is almost exclusively metabolized by the isoenzyme.', NULL, 'Concomitant use of tolvaptan with moderate CYP450 3A4 inhibitors should generally be avoided unless no alternatives exist and benefits outweigh potential risks.', NULL, 'Concomitant use of tolvaptan with moderate CYP450 3A4 inhibitors should generally be avoided unless no alternatives exist and benefits outweigh potential risks. A lower dosage of tolvaptan should be considered. Serum sodium concentration and neurologic status should be closely monitored during coadministration. Too rapid correction of hyponatremia increases the risk of osmotic demyelination syndrome, which is associated with dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, and death. Discontinuation or interruption of tolvaptan therapy should be considered in patients who develop too rapid a rise in serum sodium.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191175/', '[1] "Product Information. Samsca (tolvaptan)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[2] "Product Information. Samsca (tolvaptan)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190948, 'Fosnetupitant', 'Trabectedin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors.', NULL, 'Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191176/', '[1] "Product Information. Yondelis (trabectedin)." Janssen Pharmaceuticals, Titusville, NJ.[2] Machiels JP, Staddon A, Herremans C, et al. "Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies." Cancer Chemother Pharmacol 74 (2014): 729-37[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Yondelis (trabectedin)." Janssen Pharmaceuticals, Titusville, NJ.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190949, 'Fosnetupitant', 'Tretinoin', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191177/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190950, 'Fosnetupitant', 'Triamcinolone', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191178/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190951, 'Fosnetupitant', 'Triazolam', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191179/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190952, 'Fosnetupitant', 'Troglitazone', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191180/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190953, 'Fosnetupitant', 'Troleandomycin', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of netupitant. When a single 300 mg-0.5 mg dose of netupitant-palonosetron was administered following 400 mg once daily administration of the potent CYP450 3A4 inhibitor ketoconazole for 12 days, mean netupitant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 25% and 140%, respectively, while mean Cmax and AUC of palonosetron increased by 15% and 10%, respectively. No dosage adjustment is necessary for single-dose administration of netupitant-palonosetron when used with potent CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191181/', '[1] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190954, 'Fosnetupitant', 'Tucatinib', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of netupitant. When a single 300 mg-0.5 mg dose of netupitant-palonosetron was administered following 400 mg once daily administration of the potent CYP450 3A4 inhibitor ketoconazole for 12 days, mean netupitant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 25% and 140%, respectively, while mean Cmax and AUC of palonosetron increased by 15% and 10%, respectively. No dosage adjustment is necessary for single-dose administration of netupitant-palonosetron when used with potent CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191182/', '[1] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190955, 'Fosnetupitant', 'Ubrogepant', 'Moderate', 'Coadministration with moderate or weak inhibitors of CYP450 3A4 may increase the plasma concentrations of ubrogepant, which is primarily metabolized by the isoenzyme.', NULL, 'The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with moderate or weak CYP450 3A4 inhibitors.', NULL, 'The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with moderate or weak CYP450 3A4 inhibitors. If needed, a second ubrogepant dose should be avoided within 24 hours of the initial dose when used with moderate CYP450 3A4 inhibitors.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191183/', '[1] "Product Information. Ubrelvy (ubrogepant)." Allergan Inc, Irvine, CA.[2] "Product Information. Ubrelvy (ubrogepant)." Allergan Inc, Irvine, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190956, 'Fosnetupitant', 'Upadacitinib', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inhibitors. Pharmacologic effects of upadacitinib should be monitored more closely whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191184/', '[1] "Product Information. Rinvoq (upadacitinib)." AbbVie US LLC, North Chicago, IL.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190957, 'Fosnetupitant', 'Valdecoxib', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191185/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190958, 'Fosnetupitant', 'Venetoclax', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of venetoclax, which is a substrate of the isoenzyme.', NULL, 'Concomitant use of venetoclax with moderate CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of venetoclax with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends that venetoclax dosage be reduced by at least 50%. The dosage used prior to initiating the CYP450 3A4 inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191186/', '[1] "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190959, 'Fosnetupitant', 'Verapamil', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191187/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190960, 'Fosnetupitant', 'Vinblastine', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191188/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190961, 'Fosnetupitant', 'Vincristine', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191189/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190962, 'Fosnetupitant', 'Vincristine (liposome)', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191190/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190963, 'Fosnetupitant', 'Vinorelbine', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191191/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190964, 'Fosnetupitant', 'Voxelotor', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191192/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190965, 'Fosnetupitant', 'Zanubrutinib', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of zanubrutinib, which is primarily metabolized by the isoenzyme. Increased zanubrutinib exposure may potentiate the risk of toxicities such as hemorrhage, infection, cytopenias, malignancies, and atrial fibrillation or flutter.', NULL, 'The manufacturer recommends reducing the dosage of zanubrutinib to 80 mg twice daily when coadministered with moderate CYP450 3A4 inhibitors.', NULL, 'The manufacturer recommends reducing the dosage of zanubrutinib to 80 mg twice daily when coadministered with moderate CYP450 3A4 inhibitors. Patients should be closely monitored for development of zanubrutinib-related toxicities, and further dosage adjustments made or treatment withheld as needed in accordance with the product labeling. Following discontinuation of the CYP450 3A4 inhibitor, the previous dosage of zanubrutinib should be resumed.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191193/', '[1] "Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc, San Mateo, CA.[2] "Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc, San Mateo, CA.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190966, 'Fosnetupitant', 'Zolpidem', 'Moderate', 'Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191194/', '[1] "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.[2] "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190967, 'Fosnetupitant', 'Zonisamide', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of zonisamide, which is metabolized by the isoenzyme. While clinical data are lacking, the possibility of prolonged and/or increased pharmacologic effects of zonisamide should be considered.', NULL, 'Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.', NULL, 'Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to notify their physician if they experience symptoms such as severe drowsiness, confusion, loss of coordination, depression, aphasia, decreased sweating, fever, loss of seizure control, or slow pulse.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191195/', '[1] Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83[2] "Product Information. Zonegran (zonisamide)" Elan Pharmaceuticals, S. San Francisco, CA.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190968, 'Gallium chloride Ga-67', 'Ferumoxsil', 'Moderate', 'The concomitant use of certain medications (e.g., cytarabine, fluorouracil, methotrexate, and iron) may cause displacement of gallium citrate Ga-67 from plasma protein binding sites and interfere with test results.', NULL, 'Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.', NULL, 'Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.', 'Distribution', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191196/', '[1] "Product Information. Gallium Citrate Ga-67 (gallium citrate 67 Ga (gallium citrate 67Ga))." Bristol-Myers Squibb, Princeton, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190969, 'Iron protein succinylate', 'Gallium chloride Ga-67', 'Moderate', 'The concomitant use of certain medications (e.g., cytarabine, fluorouracil, methotrexate, and iron) may cause displacement of gallium citrate Ga-67 from plasma protein binding sites and interfere with test results.', NULL, 'Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.', NULL, 'Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.', 'Distribution', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191197/', '[1] "Product Information. Gallium Citrate Ga-67 (gallium citrate 67 Ga (gallium citrate 67Ga))." Bristol-Myers Squibb, Princeton, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190970, 'Gallium chloride Ga-67', 'Vincristine (liposome)', 'Moderate', 'The concomitant use of vincristine or mechlorethamine may alter the pharmacokinetics and pharmacodynamics of gallium citrate Ga-67 and increase its deposition in bone.', NULL, 'Clinicians should be aware of the potential for an interaction.', NULL, 'Clinicians should be aware of the potential for an interaction.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191198/', '[1] "Product Information. Gallium Citrate Ga-67 (gallium citrate 67 Ga (gallium citrate 67Ga))." Bristol-Myers Squibb, Princeton, NJ.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190971, 'Gonadorelin', 'Ganirelix', 'Moderate', 'Ganirelix can suppress the secretion of pituitary gonadotropins.', NULL, 'A dose adjustment may be necessary when exogenous gonadotropins are used during controlled ovarian hyperstimulation.', NULL, 'A dose adjustment may be necessary when exogenous gonadotropins are used during controlled ovarian hyperstimulation.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191199/', '[1] "Product Information. Antagon (ganirelix)" Organon, West Orange, NJ.[2] "Product Information. Trelstar (triptorelin)" Pharmacia and Upjohn, Kalamazoo, MI.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190972, 'Ganirelix', 'Urofollitropin', 'Moderate', 'Ganirelix can suppress the secretion of pituitary gonadotropins.', NULL, 'A dose adjustment may be necessary when exogenous gonadotropins are used during controlled ovarian hyperstimulation.', NULL, 'A dose adjustment may be necessary when exogenous gonadotropins are used during controlled ovarian hyperstimulation.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191200/', '[1] "Product Information. Antagon (ganirelix)" Organon, West Orange, NJ.[2] "Product Information. Trelstar (triptorelin)" Pharmacia and Upjohn, Kalamazoo, MI.', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190973, 'Garlic', 'Acetohexamide', 'Minor', 'Some authors suggest that garlic may potentiate the hypoglycemic effect of insulin and oral antidiabetic agents, although supportive evidence is scarce.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191201/', '[1] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[2] Aslam M, Stockley IH "Interaction between curry ingredient (karela) and drug (chlorpropamide)." Lancet I (1979): 607[3] Semaan N "Integration of complementary disciplines into the oncology clinic - Part III. Herbal medicine - Drug interactions: The role of the pharmacist." Curr Prob Cancer 24 (2000): 213-22[4] Mulrow C, Lawrence V, Ackermann R, et al. Agency for Healthcare Research and Quality "Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. Evidence Report/Technology Assessment Number 20. AHRQ Publication No. 01-E023 Available from: URL: http://www.ahrq.gov/clinics/garlicsum." ([2000 Oct]):[5] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[6] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[7] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[12] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[13] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190974, 'Anisindione', 'Garlic', 'Moderate', 'Garlic may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Garlic has been shown in some studies to have antithrombotic effects and may increase fibrinolysis, decrease platelet aggregation, and increase prothrombin time. Antiplatelet activity is present in garlic powder, aged garlic preparations, garlic oil, and fresh garlic (more so raw than when it is cooked). There have been isolated reports of bleeding complications associated with chronic, high dietary intake of garlic, as well as reports suggesting an interaction between warfarin and garlic resulting in increased INR.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine. In general, consumption of garlic supplements and large amounts of garlic should preferably be avoided during use of coagulation-modifying agents. In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191202/', '[1] Legnani C, Frascaro M, Guazzaloca G, Ludovici S, Cesarano G, Coccheri S "Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects." Arzneimittelforschung 43 (1993): 119-22[2] Steiner M, Lin RS "Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract." J Cardiovasc Pharmacol 31 (1998): 904-8[3] Burnham BE "Garlic as a possible risk for postoperative bleeding." Plast Reconstr Surg 95 (1995): 213[4] Chutani SK, Bordia A "The effect of fried versus raw garlic on fibrinolytic activity in man." Atherosclerosis 38 (1981): 417-21[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] Apitz-Castro R, Escalante J, Vargas R, Jain MK "Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory action of prostacyclin, forskolin, indomethacin and dypiridamole on human platelets." Thromb Res 42 (1986): 303-11[7] Mulrow C, Lawrence V, Ackermann R, et al. Agency for Healthcare Research and Quality "Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. Evidence Report/Technology Assessment Number 20. AHRQ Publication No. 01-E023 Available from: URL: http://www.ahrq.gov/clinics/garlicsum." ([2000 Oct]):[8] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[9] Evans V "Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use." J Neurosci Nurs 32 (2000): 229-32[10] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[11] German K, Kumar U, Blackford HN "Garlic and the risk of TURP bleeding." Br J Urol 76 (1996): 518[12] Vaes LP, Chyka PA "Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence." Ann Pharmacother 34 (2000): 1478-82[13] Kiesewetter H, Jung F, Jung EM, Mrowietz C, Kosciehlny J, Wenzel E "Effect of garlic on platelet aggregation in patients with increased risk of juvenile ischaemic attack." Eur J Clin Pharmacol 45 (1993): 333-6[14] Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[15] Morris J, Burke V, Mori TA, Vandongen R, Beilin LJ "Effects of garlic extract on platelet aggregation: a randomized placebo-controlled double-blind study." Clin Exp Pharmacol Physiol 22 (1995): 414-7', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190975, 'Anistreplase', 'Garlic', 'Moderate', 'Garlic may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Garlic has been shown in some studies to have antithrombotic effects and may increase fibrinolysis, decrease platelet aggregation, and increase prothrombin time. Antiplatelet activity is present in garlic powder, aged garlic preparations, garlic oil, and fresh garlic (more so raw than when it is cooked). There have been isolated reports of bleeding complications associated with chronic, high dietary intake of garlic, as well as reports suggesting an interaction between warfarin and garlic resulting in increased INR.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine. In general, consumption of garlic supplements and large amounts of garlic should preferably be avoided during use of coagulation-modifying agents. In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191203/', '[1] Legnani C, Frascaro M, Guazzaloca G, Ludovici S, Cesarano G, Coccheri S "Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects." Arzneimittelforschung 43 (1993): 119-22[2] Steiner M, Lin RS "Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract." J Cardiovasc Pharmacol 31 (1998): 904-8[3] Burnham BE "Garlic as a possible risk for postoperative bleeding." Plast Reconstr Surg 95 (1995): 213[4] Chutani SK, Bordia A "The effect of fried versus raw garlic on fibrinolytic activity in man." Atherosclerosis 38 (1981): 417-21[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] Apitz-Castro R, Escalante J, Vargas R, Jain MK "Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory action of prostacyclin, forskolin, indomethacin and dypiridamole on human platelets." Thromb Res 42 (1986): 303-11[7] Mulrow C, Lawrence V, Ackermann R, et al. Agency for Healthcare Research and Quality "Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. Evidence Report/Technology Assessment Number 20. AHRQ Publication No. 01-E023 Available from: URL: http://www.ahrq.gov/clinics/garlicsum." ([2000 Oct]):[8] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[9] Evans V "Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use." J Neurosci Nurs 32 (2000): 229-32[10] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[11] German K, Kumar U, Blackford HN "Garlic and the risk of TURP bleeding." Br J Urol 76 (1996): 518[12] Vaes LP, Chyka PA "Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence." Ann Pharmacother 34 (2000): 1478-82[13] Kiesewetter H, Jung F, Jung EM, Mrowietz C, Kosciehlny J, Wenzel E "Effect of garlic on platelet aggregation in patients with increased risk of juvenile ischaemic attack." Eur J Clin Pharmacol 45 (1993): 333-6[14] Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[15] Morris J, Burke V, Mori TA, Vandongen R, Beilin LJ "Effects of garlic extract on platelet aggregation: a randomized placebo-controlled double-blind study." Clin Exp Pharmacol Physiol 22 (1995): 414-7', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190976, 'Garlic', 'Ardeparin', 'Moderate', 'Garlic may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Garlic has been shown in some studies to have antithrombotic effects and may increase fibrinolysis, decrease platelet aggregation, and increase prothrombin time. Antiplatelet activity is present in garlic powder, aged garlic preparations, garlic oil, and fresh garlic (more so raw than when it is cooked). There have been isolated reports of bleeding complications associated with chronic, high dietary intake of garlic, as well as reports suggesting an interaction between warfarin and garlic resulting in increased INR.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine. In general, consumption of garlic supplements and large amounts of garlic should preferably be avoided during use of coagulation-modifying agents. In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191204/', '[1] Legnani C, Frascaro M, Guazzaloca G, Ludovici S, Cesarano G, Coccheri S "Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects." Arzneimittelforschung 43 (1993): 119-22[2] Steiner M, Lin RS "Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract." J Cardiovasc Pharmacol 31 (1998): 904-8[3] Burnham BE "Garlic as a possible risk for postoperative bleeding." Plast Reconstr Surg 95 (1995): 213[4] Chutani SK, Bordia A "The effect of fried versus raw garlic on fibrinolytic activity in man." Atherosclerosis 38 (1981): 417-21[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] Apitz-Castro R, Escalante J, Vargas R, Jain MK "Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory action of prostacyclin, forskolin, indomethacin and dypiridamole on human platelets." Thromb Res 42 (1986): 303-11[7] Mulrow C, Lawrence V, Ackermann R, et al. Agency for Healthcare Research and Quality "Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. Evidence Report/Technology Assessment Number 20. AHRQ Publication No. 01-E023 Available from: URL: http://www.ahrq.gov/clinics/garlicsum." ([2000 Oct]):[8] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[9] Evans V "Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use." J Neurosci Nurs 32 (2000): 229-32[10] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[11] German K, Kumar U, Blackford HN "Garlic and the risk of TURP bleeding." Br J Urol 76 (1996): 518[12] Vaes LP, Chyka PA "Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence." Ann Pharmacother 34 (2000): 1478-82[13] Kiesewetter H, Jung F, Jung EM, Mrowietz C, Kosciehlny J, Wenzel E "Effect of garlic on platelet aggregation in patients with increased risk of juvenile ischaemic attack." Eur J Clin Pharmacol 45 (1993): 333-6[14] Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[15] Morris J, Burke V, Mori TA, Vandongen R, Beilin LJ "Effects of garlic extract on platelet aggregation: a randomized placebo-controlled double-blind study." Clin Exp Pharmacol Physiol 22 (1995): 414-7', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190977, 'Garlic', 'Bendroflumethiazide', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191205/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190978, 'Garlic', 'Benzthiazide', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191206/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190979, 'Garlic', 'Bepridil', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191207/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190980, 'Garlic', 'Carteolol', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191208/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190981, 'Garlic', 'Cyclandelate', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191209/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190982, 'Garlic', 'Danaparoid', 'Moderate', 'Garlic may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Garlic has been shown in some studies to have antithrombotic effects and may increase fibrinolysis, decrease platelet aggregation, and increase prothrombin time. Antiplatelet activity is present in garlic powder, aged garlic preparations, garlic oil, and fresh garlic (more so raw than when it is cooked). There have been isolated reports of bleeding complications associated with chronic, high dietary intake of garlic, as well as reports suggesting an interaction between warfarin and garlic resulting in increased INR.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine. In general, consumption of garlic supplements and large amounts of garlic should preferably be avoided during use of coagulation-modifying agents. In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191210/', '[1] Legnani C, Frascaro M, Guazzaloca G, Ludovici S, Cesarano G, Coccheri S "Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects." Arzneimittelforschung 43 (1993): 119-22[2] Steiner M, Lin RS "Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract." J Cardiovasc Pharmacol 31 (1998): 904-8[3] Burnham BE "Garlic as a possible risk for postoperative bleeding." Plast Reconstr Surg 95 (1995): 213[4] Chutani SK, Bordia A "The effect of fried versus raw garlic on fibrinolytic activity in man." Atherosclerosis 38 (1981): 417-21[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] Apitz-Castro R, Escalante J, Vargas R, Jain MK "Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory action of prostacyclin, forskolin, indomethacin and dypiridamole on human platelets." Thromb Res 42 (1986): 303-11[7] Mulrow C, Lawrence V, Ackermann R, et al. Agency for Healthcare Research and Quality "Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. Evidence Report/Technology Assessment Number 20. AHRQ Publication No. 01-E023 Available from: URL: http://www.ahrq.gov/clinics/garlicsum." ([2000 Oct]):[8] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[9] Evans V "Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use." J Neurosci Nurs 32 (2000): 229-32[10] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[11] German K, Kumar U, Blackford HN "Garlic and the risk of TURP bleeding." Br J Urol 76 (1996): 518[12] Vaes LP, Chyka PA "Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence." Ann Pharmacother 34 (2000): 1478-82[13] Kiesewetter H, Jung F, Jung EM, Mrowietz C, Kosciehlny J, Wenzel E "Effect of garlic on platelet aggregation in patients with increased risk of juvenile ischaemic attack." Eur J Clin Pharmacol 45 (1993): 333-6[14] Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[15] Morris J, Burke V, Mori TA, Vandongen R, Beilin LJ "Effects of garlic extract on platelet aggregation: a randomized placebo-controlled double-blind study." Clin Exp Pharmacol Physiol 22 (1995): 414-7', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190983, 'Garlic', 'Deserpidine', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191211/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190984, 'Garlic', 'Dicoumarol', 'Moderate', 'Garlic may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Garlic has been shown in some studies to have antithrombotic effects and may increase fibrinolysis, decrease platelet aggregation, and increase prothrombin time. Antiplatelet activity is present in garlic powder, aged garlic preparations, garlic oil, and fresh garlic (more so raw than when it is cooked). There have been isolated reports of bleeding complications associated with chronic, high dietary intake of garlic, as well as reports suggesting an interaction between warfarin and garlic resulting in increased INR.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine. In general, consumption of garlic supplements and large amounts of garlic should preferably be avoided during use of coagulation-modifying agents. In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191212/', '[1] Legnani C, Frascaro M, Guazzaloca G, Ludovici S, Cesarano G, Coccheri S "Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects." Arzneimittelforschung 43 (1993): 119-22[2] Steiner M, Lin RS "Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract." J Cardiovasc Pharmacol 31 (1998): 904-8[3] Burnham BE "Garlic as a possible risk for postoperative bleeding." Plast Reconstr Surg 95 (1995): 213[4] Chutani SK, Bordia A "The effect of fried versus raw garlic on fibrinolytic activity in man." Atherosclerosis 38 (1981): 417-21[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] Apitz-Castro R, Escalante J, Vargas R, Jain MK "Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory action of prostacyclin, forskolin, indomethacin and dypiridamole on human platelets." Thromb Res 42 (1986): 303-11[7] Mulrow C, Lawrence V, Ackermann R, et al. Agency for Healthcare Research and Quality "Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. Evidence Report/Technology Assessment Number 20. AHRQ Publication No. 01-E023 Available from: URL: http://www.ahrq.gov/clinics/garlicsum." ([2000 Oct]):[8] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[9] Evans V "Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use." J Neurosci Nurs 32 (2000): 229-32[10] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[11] German K, Kumar U, Blackford HN "Garlic and the risk of TURP bleeding." Br J Urol 76 (1996): 518[12] Vaes LP, Chyka PA "Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence." Ann Pharmacother 34 (2000): 1478-82[13] Kiesewetter H, Jung F, Jung EM, Mrowietz C, Kosciehlny J, Wenzel E "Effect of garlic on platelet aggregation in patients with increased risk of juvenile ischaemic attack." Eur J Clin Pharmacol 45 (1993): 333-6[14] Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[15] Morris J, Burke V, Mori TA, Vandongen R, Beilin LJ "Effects of garlic extract on platelet aggregation: a randomized placebo-controlled double-blind study." Clin Exp Pharmacol Physiol 22 (1995): 414-7', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190985, 'Guanabenz', 'Garlic', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191213/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190986, 'Guanadrel', 'Garlic', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191214/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190987, 'Guanethidine', 'Garlic', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191215/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190988, 'Heparin', 'Garlic', 'Moderate', 'Garlic may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Garlic has been shown in some studies to have antithrombotic effects and may increase fibrinolysis, decrease platelet aggregation, and increase prothrombin time. Antiplatelet activity is present in garlic powder, aged garlic preparations, garlic oil, and fresh garlic (more so raw than when it is cooked). There have been isolated reports of bleeding complications associated with chronic, high dietary intake of garlic, as well as reports suggesting an interaction between warfarin and garlic resulting in increased INR.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine. In general, consumption of garlic supplements and large amounts of garlic should preferably be avoided during use of coagulation-modifying agents. In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191216/', '[1] Legnani C, Frascaro M, Guazzaloca G, Ludovici S, Cesarano G, Coccheri S "Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects." Arzneimittelforschung 43 (1993): 119-22[2] Steiner M, Lin RS "Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract." J Cardiovasc Pharmacol 31 (1998): 904-8[3] Burnham BE "Garlic as a possible risk for postoperative bleeding." Plast Reconstr Surg 95 (1995): 213[4] Chutani SK, Bordia A "The effect of fried versus raw garlic on fibrinolytic activity in man." Atherosclerosis 38 (1981): 417-21[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] Apitz-Castro R, Escalante J, Vargas R, Jain MK "Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory action of prostacyclin, forskolin, indomethacin and dypiridamole on human platelets." Thromb Res 42 (1986): 303-11[7] Mulrow C, Lawrence V, Ackermann R, et al. Agency for Healthcare Research and Quality "Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. Evidence Report/Technology Assessment Number 20. AHRQ Publication No. 01-E023 Available from: URL: http://www.ahrq.gov/clinics/garlicsum." ([2000 Oct]):[8] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[9] Evans V "Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use." J Neurosci Nurs 32 (2000): 229-32[10] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[11] German K, Kumar U, Blackford HN "Garlic and the risk of TURP bleeding." Br J Urol 76 (1996): 518[12] Vaes LP, Chyka PA "Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence." Ann Pharmacother 34 (2000): 1478-82[13] Kiesewetter H, Jung F, Jung EM, Mrowietz C, Kosciehlny J, Wenzel E "Effect of garlic on platelet aggregation in patients with increased risk of juvenile ischaemic attack." Eur J Clin Pharmacol 45 (1993): 333-6[14] Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[15] Morris J, Burke V, Mori TA, Vandongen R, Beilin LJ "Effects of garlic extract on platelet aggregation: a randomized placebo-controlled double-blind study." Clin Exp Pharmacol Physiol 22 (1995): 414-7', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190989, 'Hydroflumethiazide', 'Garlic', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191217/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190990, 'Insulin human', 'Garlic', 'Minor', 'Some authors suggest that garlic may potentiate the hypoglycemic effect of insulin and oral antidiabetic agents, although supportive evidence is scarce.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191218/', '[1] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[2] Aslam M, Stockley IH "Interaction between curry ingredient (karela) and drug (chlorpropamide)." Lancet I (1979): 607[3] Semaan N "Integration of complementary disciplines into the oncology clinic - Part III. Herbal medicine - Drug interactions: The role of the pharmacist." Curr Prob Cancer 24 (2000): 213-22[4] Mulrow C, Lawrence V, Ackermann R, et al. Agency for Healthcare Research and Quality "Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. Evidence Report/Technology Assessment Number 20. AHRQ Publication No. 01-E023 Available from: URL: http://www.ahrq.gov/clinics/garlicsum." ([2000 Oct]):[5] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[6] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[7] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[12] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[13] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190991, 'Insulin aspart (aspart protamine)', 'Garlic', 'Minor', 'Some authors suggest that garlic may potentiate the hypoglycemic effect of insulin and oral antidiabetic agents, although supportive evidence is scarce.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191219/', '[1] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[2] Aslam M, Stockley IH "Interaction between curry ingredient (karela) and drug (chlorpropamide)." Lancet I (1979): 607[3] Semaan N "Integration of complementary disciplines into the oncology clinic - Part III. Herbal medicine - Drug interactions: The role of the pharmacist." Curr Prob Cancer 24 (2000): 213-22[4] Mulrow C, Lawrence V, Ackermann R, et al. Agency for Healthcare Research and Quality "Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. Evidence Report/Technology Assessment Number 20. AHRQ Publication No. 01-E023 Available from: URL: http://www.ahrq.gov/clinics/garlicsum." ([2000 Oct]):[5] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[6] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[7] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[12] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[13] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190992, 'Insulin lispro (protamine)', 'Garlic', 'Minor', 'Some authors suggest that garlic may potentiate the hypoglycemic effect of insulin and oral antidiabetic agents, although supportive evidence is scarce.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191220/', '[1] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[2] Aslam M, Stockley IH "Interaction between curry ingredient (karela) and drug (chlorpropamide)." Lancet I (1979): 607[3] Semaan N "Integration of complementary disciplines into the oncology clinic - Part III. Herbal medicine - Drug interactions: The role of the pharmacist." Curr Prob Cancer 24 (2000): 213-22[4] Mulrow C, Lawrence V, Ackermann R, et al. Agency for Healthcare Research and Quality "Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. Evidence Report/Technology Assessment Number 20. AHRQ Publication No. 01-E023 Available from: URL: http://www.ahrq.gov/clinics/garlicsum." ([2000 Oct]):[5] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[6] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[7] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[12] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[13] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190993, 'Insulin human (zinc)', 'Garlic', 'Minor', 'Some authors suggest that garlic may potentiate the hypoglycemic effect of insulin and oral antidiabetic agents, although supportive evidence is scarce.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191221/', '[1] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[2] Aslam M, Stockley IH "Interaction between curry ingredient (karela) and drug (chlorpropamide)." Lancet I (1979): 607[3] Semaan N "Integration of complementary disciplines into the oncology clinic - Part III. Herbal medicine - Drug interactions: The role of the pharmacist." Curr Prob Cancer 24 (2000): 213-22[4] Mulrow C, Lawrence V, Ackermann R, et al. Agency for Healthcare Research and Quality "Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. Evidence Report/Technology Assessment Number 20. AHRQ Publication No. 01-E023 Available from: URL: http://www.ahrq.gov/clinics/garlicsum." ([2000 Oct]):[5] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[6] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[7] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[12] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[13] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190994, 'Insulin human (zinc extended)', 'Garlic', 'Minor', 'Some authors suggest that garlic may potentiate the hypoglycemic effect of insulin and oral antidiabetic agents, although supportive evidence is scarce.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191222/', '[1] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[2] Aslam M, Stockley IH "Interaction between curry ingredient (karela) and drug (chlorpropamide)." Lancet I (1979): 607[3] Semaan N "Integration of complementary disciplines into the oncology clinic - Part III. Herbal medicine - Drug interactions: The role of the pharmacist." Curr Prob Cancer 24 (2000): 213-22[4] Mulrow C, Lawrence V, Ackermann R, et al. Agency for Healthcare Research and Quality "Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. Evidence Report/Technology Assessment Number 20. AHRQ Publication No. 01-E023 Available from: URL: http://www.ahrq.gov/clinics/garlicsum." ([2000 Oct]):[5] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[6] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[7] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[12] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[13] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190995, 'Isosorbide', 'Garlic', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191223/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190996, 'Garlic', 'Lepirudin', 'Moderate', 'Garlic may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Garlic has been shown in some studies to have antithrombotic effects and may increase fibrinolysis, decrease platelet aggregation, and increase prothrombin time. Antiplatelet activity is present in garlic powder, aged garlic preparations, garlic oil, and fresh garlic (more so raw than when it is cooked). There have been isolated reports of bleeding complications associated with chronic, high dietary intake of garlic, as well as reports suggesting an interaction between warfarin and garlic resulting in increased INR.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine. In general, consumption of garlic supplements and large amounts of garlic should preferably be avoided during use of coagulation-modifying agents. In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191224/', '[1] Legnani C, Frascaro M, Guazzaloca G, Ludovici S, Cesarano G, Coccheri S "Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects." Arzneimittelforschung 43 (1993): 119-22[2] Steiner M, Lin RS "Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract." J Cardiovasc Pharmacol 31 (1998): 904-8[3] Burnham BE "Garlic as a possible risk for postoperative bleeding." Plast Reconstr Surg 95 (1995): 213[4] Chutani SK, Bordia A "The effect of fried versus raw garlic on fibrinolytic activity in man." Atherosclerosis 38 (1981): 417-21[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] Apitz-Castro R, Escalante J, Vargas R, Jain MK "Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory action of prostacyclin, forskolin, indomethacin and dypiridamole on human platelets." Thromb Res 42 (1986): 303-11[7] Mulrow C, Lawrence V, Ackermann R, et al. Agency for Healthcare Research and Quality "Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. Evidence Report/Technology Assessment Number 20. AHRQ Publication No. 01-E023 Available from: URL: http://www.ahrq.gov/clinics/garlicsum." ([2000 Oct]):[8] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[9] Evans V "Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use." J Neurosci Nurs 32 (2000): 229-32[10] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[11] German K, Kumar U, Blackford HN "Garlic and the risk of TURP bleeding." Br J Urol 76 (1996): 518[12] Vaes LP, Chyka PA "Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence." Ann Pharmacother 34 (2000): 1478-82[13] Kiesewetter H, Jung F, Jung EM, Mrowietz C, Kosciehlny J, Wenzel E "Effect of garlic on platelet aggregation in patients with increased risk of juvenile ischaemic attack." Eur J Clin Pharmacol 45 (1993): 333-6[14] Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[15] Morris J, Burke V, Mori TA, Vandongen R, Beilin LJ "Effects of garlic extract on platelet aggregation: a randomized placebo-controlled double-blind study." Clin Exp Pharmacol Physiol 22 (1995): 414-7', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190997, 'Garlic', 'Papaverine', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191225/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190998, 'Garlic', 'Penbutolol', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191226/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (190999, 'Garlic', 'Polythiazide', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191227/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767365209);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (191000, 'Garlic', 'Reserpine', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/191228/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767365209);
